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ABSTRACT 
 
Despite over three decades of research in blood-material interactions, the biomaterials 
field has been unsuccessful in developing a truly non-thrombogenic biomaterial. This is 
due to an incomplete understanding of the factors underlying biomaterial-associated 
thrombosis, especially the mechanisms mediating the interactions of platelets with the 
adsorbed plasma protein layer(s) on the implant surface. The work presented here is 
motivated by the primary goal of delineating these mechanisms, and understanding the 
platelet receptors involved, as well as the domains/amino acid sequences they bind to in 
the protein molecules. 
It is critical to differentiate between the amount and the conformation of the adsorbed 
protein, both of which are potential mediators of platelet adhesion, while designing 
hemocompatible biomaterials. We accomplished this by independently varying the 
surface chemistry and protein solution concentration, and illustrated that the platelet 
adhesion correlated strongly with the degree of adsorption-induced fibrinogen (Fg) 
unfolding, as measure by the loss in α-helix measured via circular dichroism (CD) 
spectropolarimetry. Additionally, platelet adhesion to adsorbed albumin (Alb), which is 
conventionally thought to be unable to bind platelets, strongly correlated with Alb 
unfolding beyond a critical level of unfolding (~34% α-helix loss).  
A variety of blocking strategies were employed in order to identify the platelet 
receptors involved in the adhesion process, including soluble peptides, monoclonal 
antibodies, as well as a platelet antagonist drug. Our preliminary results suggested that 
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two platelet receptor sets were potentially mediating the adhesion, as a peptide containing 
the Arginine-Glycine-Aspartic Acid (RGD) sequence, which is a well known cell-binding 
sequence, was found to be a partial inhibitor of platelet adhesion to both adsorbed Fg and 
Alb. We therefore hypothesized that one set was specific to the RGD amino acid 
sequence, and mediated both platelet adhesion and activation. The other set was likely 
non-RGD-specific and mediated adhesion with little/no activation.  
Targeting the GPIb-IX-V complex as the non-RGD-specific receptor set using 
monoclonal antibodies against GPIb, did not inhibit platelet adhesion to adsorbed Fg and 
Alb. However, the use of Aggrastat, a platelet antagonist drug against the RGD-specific 
GPIIb/IIIa platelet receptor, led to a near complete inhibition of platelet adhesion to both 
adsorbed Fg and Alb, clearly illustrating the critical role played by this receptor in 
platelet adhesion.  
Chemical modification of the arginine residues in adsorbed Alb led to a significant 
decrease in platelet adhesion to Alb, thereby provided deeper insight into their role in 
mediating platelet-Alb interactions, while the modification of lysine residues did not 
affect platelet adhesion. Thus, we hypothesize that beyond a critical degree of adsorption-
induced conformational changes in Alb, the arginine and aspartic/glutamic acid residues 
may become spatially oriented such that they form RGD-like motifs which are 
recognized by the GPIIb/IIIa platelet receptors. Additionally, we also showed that an 
irreversibly adsorbed, tightly packed Alb layer undergoes increased unfolding with 
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increasing residence times of up to 6 months, thereby enabling and enhancing platelet 
adhesion.  
Overall, these studies present deeper insights into the molecular mechanisms 
mediating platelet interactions with adsorbed plasma proteins, and how these interactions 
can be controlled to improve the hemocompatibility of cardiovascular biomaterials.  
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CHAPTER 1 
INTRODUCTION  
 
The development of truly hemocompatible biomaterials for cardiovascular 
applications has been hindered by the failure to completely understand the molecular 
mechanisms underlying biomaterial-associated thrombosis, mainly due to the complexity 
of blood-material interactions. The adsorbed layer of plasma proteins on the biomaterial 
surface plays a critical role in the recruitment of platelets from the bloodstream to form 
thrombi, which in adverse cases may lead to thrombotic and thromboembolic 
complications, which are the primary factors mediating the blood incompatibility of 
biomaterials. Chapter 2 of this dissertation presents a critical review of blood-biomaterial 
interactions, focusing on the role of adsorbed proteins, especially fibrinogen (Fg) and 
albumin (Alb), and platelets in mediating the thrombogenicity of biomaterial surfaces.  
The specific aims of this research project in delineating/probing the mechanisms of 
platelets to adsorbed Fg and Alb are listed in Chapter 3. The biomaterials literature has 
remained unclear on whether it is the conformation or the surface coverage of adsorbed 
proteins which influences the platelet response, and our research proposes to examine this 
critical question.  
Studies covered in Chapter 4 involved the combined use of surface chemistry and 
protein solution concentration to independently vary the degree of structural change in 
the proteins from the surface coverage of adsorbed protein, which was examined using 
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circular dichroism (CD) spectropolarimetry. Using these surfaces with differing amounts 
and conformations of adsorbed protein, we were able to definitively delineate the critical 
role played by the adsorbed conformation in mediating the platelet response to adsorbed 
Fg (Chapter 5) and Alb (Chapter 6).  
Both chapters provide deeper insight into the roles of specific platelet receptors and 
specific amino acid residues in the adsorbed protein in the platelet adhesion response, 
which were ascertained using blocking strategies on the platelets, as well as the adsorbed 
protein layer. The results presented in Chapter 6 provide conclusive information on the 
potential of adsorbed Alb to bind platelets, with the mechanisms of platelet adhesion to 
both Fg and Alb being similar in nature, as a function of adsorption-induced unfolding. 
Chapter 7 builds on the results obtained in the previous two chapters, probing the role 
of the GPIIb/IIIa and GPIb-IX-V platelet receptors in mediating adhesion to adsorbed Fg 
and Alb. The role of Asp and Glu residues in the adsorbed Alb layer in mediating platelet 
binding was analyzed using chemical modification studies. Additionally, residence time-
dependent conformational changes in an irreversibly adsorbed, tightly packed layer of 
adsorbed Alb and its potential in enabling and enhancing platelet attachment was 
analyzed in Chapter 8.  
The appendix provides details on the formation and characterization of the SAM 
surfaces, protein adsorption, washed platelet preparation and platelet adhesion. 
Additionally, this section expands on the techniques for the side-chain modification of 
the native/adsorbed proteins, used for delineating the platelet adhesion mechanisms.  
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Overall, the experiments described in this dissertation provide deeper insights into the 
molecular mechanisms mediating platelet adhesion to adsorbed proteins on biomaterial 
surfaces, and hopefully will aid in the development of more blood-compatible 
biomaterials for cardiovascular applications. 
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CHAPTER 2 
BACKGROUND INFORMATION 
2.1 Blood-material interactions  
2.1.1 Overview  
Under normal conditions, blood comes into contact with an anticoagulant and 
antithrombotic endothelium, which represents the inner lining of the entire cardiovascular 
system. However, when a biomaterial is implanted in the body, it represents the 
introduction of a ‘foreign surface’ with non-endothelial properties into the circulation, as 
a result of which a series of complex, interlinked events occur including protein 
adsorption, platelet and leukocyte adhesion and activation, and activation of the 
coagulation and complement cascades [1].  
Upon contact with blood, the implant surface is coated with a layer of plasma proteins 
within seconds to minutes. The cells which arrive at the implant surface after the proteins 
adsorb primarily ‘see’ a protein layer rather than the surface of the implant, and may 
respond to this layer of adsorbed proteins by adhering, spreading, releasing active 
compounds, and also recruiting other cells to the implant surface [2]. The cellular 
response is primarily mediated by the platelets, which are thought to adhere specifically 
to binding motifs/domains exposed in these adsorbed proteins.   
Although they do not bind platelets strongly in their native state in the bloodstream, 
plasma proteins such as fibrinogen (Fg), von Willebrand factor (vWf), fibronectin (Fn) 
and vitronectin (Vn) are strongly adhesive towards platelets in their adsorbed state. This 
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adhesion is primarily mediated by receptors on the platelet membrane, which are 
conventionally thought to bind to the adhesive Arg-Gly-Asp (RGD) amino acid sequence 
present in these proteins, and leads to a complex set of reactions involving the generation 
and release of platelet agonists such as adenosine diphosphate (ADP) and thrombin and 
thromboxanes, which in turn act in concert to recruit other platelets, leading to platelet 
aggregation [3]. The surface of the aggregate serves as a site for rapid thrombin 
formation, the rate of which is higher than that of anticoagulant mechanisms in blood, 
thereby causing further platelet activation and catalyzing the formation of fibrin [3]. The 
formation of a fibrin clot is the final step of a series of proteolytic reactions called the 
coagulation cascade (schematic illustration in Fig. 2.1)  
 
 
2.1.2 Blood coagulation cascade 
In the coagulation cascade (in Fig. 2.1), inactive factors (zymogens) become 
enzymatically active due to surface contact or proteolytic cleavage by other factors, with 
the newly activated enzyme then activating another inactive factor [1].  This cascade is 
initiated either by the surface-mediated route (intrinsic pathway) or due to the cellular 
expression of tissue factor (extrinsic pathway). These two pathways converge into the 
common pathway, leading to the generation of thrombin from prothrombin, resulting in 
the formation of a fibrin clot due to the action of thrombin in catalyzing the conversion of 
fibrinogen to form the clot. The exact mechanisms underlying these pathways, as well as 
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their roles in blood coagulation, however, have remained unclear [1], and may potentially 
be dependent on a combination of synergistic factors.  
 
 
Figure 2.1. The coagulation cascade. (Figure taken from www.sigma-aldrich.com). 
 
The zymogens associated with the initiation of the intrinsic pathway such as high 
molecular weight kininogen (HMWK), prekallikrein and Factor XII (FXII) have been 
conventionally thought to require contact with negatively charged surfaces for activation 
in vitro [4], although recent studies by Chatterjee et al. and Vogler and Siedlecki [5, 6] 
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have suggested that contact activation of FXII is not specific to anionic hydrophilic 
surfaces. Gorbet and Sefton in their review of biomaterial-associated thrombosis [1], 
suggested that the role of the intrinsic pathway in normal blood coagulation has been 
unclear. The fact that patients who have deficiencies in these zymogens do not 
necessarily have bleeding disorders lends credence to the argument that this contact 
activation system may not be relevant in vivo under normal, physiological conditions [4, 
7].   
On the other hand, FXII activation may occur when any artificial surface comes into 
contact with blood, with the surface along with the adsorbed protein layer then 
representing the activating surface [1].  Recent studies [5, 6, 8, 9] have provided strong 
evidence for the role of FXII and the contact activation pathway in mediating blood 
coagulation. However, studies have shown that despite the presence of moderate amounts 
of FXII on biomaterials used for vascular grafts [10] and hemodialyzers [11], it is often 
not present in its activated form (FXIIa) [12]. In vivo studies with hemodialyzer 
membranes have not indicated any significant increase in FXIIa [13], while there was no 
significant correlation between FXIIa and thrombin generation in another study [14]. 
These results potentially suggest that the contact-activation pathway may not play an 
important role in the activation of coagulation cascade by biomaterial surfaces, and 
instead the tissue factor (TF) pathway of blood coagulation is slowly being recognized by 
the biomaterials community [1].   
TF expression by monocytes may result in blood coagulation via the extrinsic 
pathway, when a biomaterial comes into contact with blood. This has been observed in 
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vivo during or after cardiopulmonary bypass [15-17], and thus leukocytes (most likely 
due to TF on monocytes) may play a role in the activation of the coagulation cascade 
[18], suggesting that a TF-dependent pathway of coagulation initiation may occur on 
biomaterial surfaces.  
Since the biomaterials field remains divided over the exact mechanisms of the 
extrinsic and intrinsic coagulation pathways and their roles in the bigger picture of 
biomaterial-associated thrombosis, further research studies investigating these pathways 
are essential in developing a more comprehensive understanding of the coagulation 
cascade.  
 
2.1.3 Additional blood-biomaterial interactions in thrombosis 
Biomaterials-induced thrombosis can also be directly mediated by platelet adhesion 
and activation to adsorbed proteins, thus skipping the initial activating processes of the 
coagulation cascade.  The platelet-mediated thrombotic response to implanted 
biomaterials comprises (i) plasma protein adsorption, (ii) platelet adhesion, and (iii) fibrin 
formation or blood coagulation. Both white (platelet) and red (fibrin) thrombi form on 
valves and other cardiovascular implants, and under adverse conditions, these thrombi 
may get dislodged from the implant surface, leading to thromboembolic complications, 
which may even be fatal in some cases [19].  Virchow attributed the causes of thrombus 
formation and propagation in his triad (see Fig. 2.2) to abnormalities in (i) blood flow 
(circulatory stasis), (ii) vessel wall (vascular wall injury), and (iii) blood components 
(hypercoagulable state). In addition to the relative propensity for thrombus formation, 
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this triad also often predicts the location of thrombotic deposits associated with 
cardiovascular implants [20]. 
 
 
Figure 2.2. Virchow’s triad illustrating the three broad categories of factors (and their 
causes) which contribute to thrombosis.  
 
Thus, the blood compatibility (or hemocompatibility) of biomaterials can be defined 
as that property due to which these materials or devices can function in an environment 
where they come into contact with blood without inducing any adverse reaction, such as 
thrombosis [21].  Despite over three decades of research, no material has been found to 
be truly hemocompatible so far, although many cardiovascular biomaterials/devices have 
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been found to function with minimal or acceptable risks of complications [7]. The 
thrombotic and thromboembolic complications associated with these devices are fairly 
low and can be addressed using anticoagulant therapy, but the bleeding risks associated 
with anticoagulants still remain serious concerns [1].  
The failure to design a completely hemocompatible biomaterial can be attributed to 
the insufficient understanding of the complexities underlying blood-material interactions. 
In addition to platelets and plasma proteins like fibrinogen (Fg) that are associated with 
the coagulation response, other proteins (notably the complement system) and a variety 
of cells (such as leukocytes) that are associated with the inflammatory response also play 
important roles in determining the blood compatibility of biomaterial implants [1].  
The complement system consists of more than 20 plasma proteins which play an 
important role in mediating the body’s defense mechanisms against infection and foreign 
elements [1] by coating the surface of the foreign body with complement fragments (such 
as C3b, C4b and iC3b). This process is known as opsonization [22], and facilitates the 
uptake of the foreign body by phagocytic cells. Biomaterials which activate the 
complement system are generally characterized by the presence of hydroxyl and amine 
surface groups which promote the binding of complement product C3b, leading to the 
formation of C3 and C5 convertase which propagate the complement cascade [23, 24]. 
Although the complement and coagulation cascades are generally treated as separate 
processes, they have been shown to modulate each other’s activities [25]. Overall, 
although some of the consequences of complement activation by biomaterials are well 
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understood, more research needs to be done in order to fully understand the mechanisms 
underlying biomaterial-associated complement activation and how this can be inhibited.   
Leukocytes consist of neutrophils, basophils, eosinophils, monocytes and 
lymphocytes, and play a critical role in the inflammatory response to biomaterials. 
Neutrophils and monocytes become activated on contact with cardiovascular biomaterial 
surfaces, leading to increased leukocyte adhesion on these surfaces [1]. Although the 
exact nature of the mechanisms of leukocyte adhesion to biomaterials remains unclear, 
preliminary results suggest that it is mediated in part by the complement product iC3b 
[26], as in vitro studies showed that inhibition of complement activation led to a decrease 
in leukocyte adhesion [27-29]. Platelets have also been found to associate with 
leukocytes in the presence of cardiovascular devices via P-selectin glycoprotein ligand-1 
(PSGL-1) on the leukocyte membrane which binds to P-selectin on the platelet surface 
[30], but the exact implications of this association remains unclear.  
Although platelets, plasma proteins, complement system and leukocytes all play 
critical roles in blood-biomaterial interactions, it is important to analyze the role of 
individual components prior to looking at the system as a whole while analyzing the 
mechanisms of biomaterial-associated thrombosis. Since the adsorbed plasma proteins 
and the platelets are the critical players in the cellular response to the implant, our studies 
specifically deal with understanding these interactions at the molecular level.  
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2.2 Protein adsorption on surfaces 
2.2.1 Fundamentals of protein adsorption 
As mentioned in Section 2.1, the layer of adsorbed proteins plays a critical role in 
determining the nature of the blood-material interface, with the properties of the protein 
and the surface influencing the interfacial interactions [31]. Surface properties such as 
charge, free energy, roughness, hydrophilicity/hydrophobicity, and functionality are 
important parameters which affect interactions with proteins [32]. Depending on the 
properties of the surfaces, proteins adsorb in differing densities, orientations and 
conformations [33], and a protein (or even a particular region of the protein molecule) 
may have different affinities for different surfaces [31]. Protein molecules have a greater 
affinity for hydrophobic surfaces, as a result of which hydrophobic surfaces exhibit 
greater surface coverage of protein compared to their hydrophilic counterparts [34]. In 
addition to the size and charge of the protein molecules, their structural properties such as 
stability and unfolding rate also affect their interactions with surfaces. Overall, the 
adsorption process is complex, and involves van der Waals, electrostatic, and 
hydrophobic interactions.  
The adsorption process on any surface is driven by a combination of the 
thermodynamics and the kinetics of the system, as a result of which protein molecules 
undergo conformational changes in order to minimize the free energy of the system. The 
degree of conformational change is more prominent on hydrophobic surfaces, leading to 
the exposure of hydrophobic residues in the core of the protein to the adsorbent surface 
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[33, 35]. On the other hand, hydrophilic surfaces exhibit minimal unfolding, indicating 
that the hydrophobic interaction between the protein molecules and the surface is the 
primary driving force for post-adsorptive conformational changes in the protein 
molecules [34]. These adsorption-induced conformational changes may also expose 
integrin binding sites, which mediate subsequent cell adhesion.  
Changes in conformation of adsorbed proteins may be (i) time-dependent and (ii) 
dependent on the bulk protein solution concentration. In the former, as the residence time 
of the protein on the surface increases, it forms more contacts with the surface, and as a 
result of this, the probability of desorption decreases. Fg has been found to bind more 
tightly [36] and undergo conformational changes with increasing residence time on 
surfaces, with evidence suggesting that this may cause the protein to become less 
recognizable by platelets [37, 38].  
On the other hand, the bulk protein solution concentration affects the transport rate of 
protein molecules to the surface. At lower bulk protein solution concentrations, the rate 
of arrival of the protein molecules at the surface is slow, as a result of which they have 
more surface area over which they can spread (and form contacts) before they come into 
contact with neighboring protein molecules [31, 39]. Hence, the conformational changes 
in the adsorbed protein would be more prominent, while the surface coverage would be 
lower, at lower bulk protein concentrations.  
Although much of our understanding of the mechanisms mediating protein adsorption 
on surfaces is from single-component solutions, adsorption from multi-component 
solutions is highly relevant to understanding the interactions at the blood-material 
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interface, since blood contains numerous biomolecules, including more than 150 proteins. 
The affinity (e.g., size, charge and conformational stability) and kinetic factors (e.g., size 
and concentration) associated with the proteins play a role in determining which proteins 
adsorb on the material surface [31]. Considering a diffusion-limited situation at the 
interface, protein molecules with higher concentration and/or higher diffusion 
coefficients (i.e., smaller size) arrive first at the surface. Over time, molecules with higher 
overall affinity for the surface, but slower diffusion rates (due to their larger size and/or 
lower solution concentration) will approach the surface. However, the surface may 
already be covered with a monolayer of protein molecules, in which case the newly 
arriving molecules can attach only if the adsorbed molecules detach. Although simple 
desorption rarely occurs, the protein molecules can exchange with one another, until the 
surface is occupied with molecules having strong interactions with the surface. This 
process of adsorption and subsequent exchange is called the Vroman effect [40]. 
Since the adsorbed protein layer mediates the subsequent cellular response and the 
biocompatibility of the implant, in the past decade, the design of protein-resistant 
surfaces, using techniques such as polyethylene oxide (PEO) immobilization, has been a 
popular approach to achieve biocompatibility. Most protein-resistant surfaces are 
evaluated on the basis of the amount of protein adsorbed under biological conditions over 
a relatively short period of time using a variety of techniques including surface plasmon 
resonance (SPR) spectroscopy [41, 42], ellipsometry [43], radiolabeling [36] and 
enzyme-linked immunosorbent assay (ELISA) [44]. However, these studies may not be 
appropriate for devices for long-term, blood-contacting applications. Additionally, the 
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efficacy of these PEO-coated surfaces in reducing protein adsorption and subsequent 
platelet adhesion has remained questionable with regard to thrombogenicity [1]. Studies 
have shown that surfaces functionalized with polyethylene glycol (PEG) or PEO cause 
increased complement activation compared to non-functionalized control surfaces [45, 
46], and it has been hypothesized that this is due to the hydroxyl groups at the end of the 
PEG chain [45]. Hydroxyl and amino groups on surfaces have been shown to cause 
increased complement activation and increased binding of complement product C3b [24]. 
Thus, although PEG and PEO may be effective in creating relatively protein-resistant 
surfaces, they may be unsuitable from the aspect of hemocompatibility due to their ability 
to activate the complement system.  
Although the elimination of protein adsorption may be desirable from the 
hemocompatibility aspect, the fact remains that under normal physiological conditions 
we have a multitude of proteins in solution in our blood plasma and interstitial fluids, 
which (generally) do not trigger any adverse cellular response in their native/solution 
state, but mediate cell attachment in their adsorbed state. Hence, rather than the presence 
of proteins themselves on the biomaterial surfaces, it is more likely that adsorption-
induced conformational changes lead to the exposure of bioactive domains in the protein 
that are normally ‘hidden’ in its native conformation, which then mediate binding of 
platelets.  
Standard analytical tools which have been used so far for studying protein adsorption 
such as quartz crystal microbalance (QCM)  [47-49], surface plasmon resonance (SPR) 
[47, 48, 50], ellipsometry [48] and atomic force microscopy (AFM) [47, 51-53] provide 
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generalized information on the adsorbed protein, indicating that it undergoes 
conformational changes, but do not provide any quantitative data on the secondary 
structural composition of the adsorbed protein layer. Information on the conformation of 
the surface-bound protein and its role in mediating cell-surface interactions has come into 
prominence only recently using techniques such as circular dichroism (CD) 
spectropolarimetry, and grazing-angle Fourier transform infrared spectroscopy (GA-
FTIR) [33, 54, 55]. 
 
 
2.2.2 Plasma proteins involved in mediating platelet-biomaterial interactions 
Fg (plasma concentration = 3.0 mg/mL) is a 340 kDa glycoprotein, composed of two 
copies each of three distinct polypeptide chains – α, β and γ.  It is essential for platelet-
biomaterial interactions, as it mediates platelet adhesion and aggregation. Removal of Fg 
from plasma reduces platelet adhesion drastically, while removal of other plasma proteins 
such as vWf, Fn or Vn reportedly causes little or no change in platelet adhesion [56, 57], 
illustrating its critical role in platelet adhesion compared to other plasma proteins.  
There are three likely platelet binding sites in the Fg molecule. Two of these are the 
well known RGD sequences, RGDF at α95-98 and RGDS at α572-575, in the Aα chains; 
the other is the C-terminal dodecapeptide (HHLGGAKQAGDV) at γ400-411 [58]. 
Studies have suggested that the γC-terminal dodecapeptide sequence is essential for 
platelet binding to adsorbed Fg [59], while the role of the RGD sequences remains 
unclear. Although this sequence does not contain the classic RGD cell adhesion 
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sequence, structural studies of the γC dodecapeptide complex with the GPIIb/IIIa platelet 
receptor have indicated that the role of Lys-406 in γC is functionally similar to that of 
Arg in RGD, and that the KQAGD sequence in γC occupies the same site as RGD when 
it binds GPIIb/IIIa [60]. 
However, recent studies have pointed to the possibilities that there may be other 
amino acid sequences in Fg which play important roles in platelet binding. A recent study 
by Remijn et al. using recombinant Fg as well as blood from patients with 
dysfibrinogenemia (i.e., congenitally defective Fg which leads to defective clot 
formation) showed that in addition to the γC chain, the γ316-322 sequence (DNDNDKF) 
may play a role in platelet interactions with adsorbed Fg [61]. This sequence is part of the 
fibrin-specific region in Fg, and is buried inside the Fg molecule in its native state, but 
becomes exposed on fibrin polymerization, and also when Fg is adsorbed on material 
surfaces. Another set of studies using recombinant Fg identified a new binding site for 
platelet GPIIb/IIIa receptors in the γC domain of Fg, spanning residues γ365-383 (also 
called P3) [62], which functions as a binding site of GPIIb/IIIa during clot retraction. 
Further studies subsequently narrowed this down to two sequences γ370-375 (ATWKTR) 
and γ376-381 (WYSMKK), which were found to be capable of independently mediating 
αIIbβ3 (synonymous with GPIIb/IIIa) recognition [63].  These residues are not exposed in 
soluble Fg, but become exposed like the γ316-322 sequence, when Fg is adsorbed on 
surfaces or when Fg is converted to fibrin [64].  Thus, it is possible to delineate the role 
of specific domains or amino acid sequences in mediating platelet attachment to Fg using 
recombinant fibrinogen. 
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Although the specific mechanisms underlying platelet adhesion to Fg remain to be 
fully defined, the amount of adsorbed Fg has been widely cited in biomaterials literature 
[65-67] to be the primary determinant of the hemocompatibility of biomaterials. 
However, other studies have shown that the conformation of the adsorbed Fg layer may 
actually be more important than the amount of adsorbed Fg [54, 55]. This is further 
supported by the fact that non-activated platelets are unable to strongly adhere to Fg in its 
native, soluble conformation in the bloodstream, but readily adhere and activate when 
they contact Fg in its adsorbed state on a surface, clearly indicating that adsorption-
induced conformational changes in Fg may expose platelet-binding sites, which 
otherwise remain hidden in the native state. 
Although Fg is the pre-eminent protein involved in platelet-protein interactions and 
subsequent thrombotic response, the initial interactions between the platelets and the 
vessel wall and subsequent platelet deposition at sites of vascular injury is mediated by 
von Willebrand factor (vWf). vWf is present in the Weibel-Palade bodies of endothelial 
cells, in the α-granules of platelets, and in plasma at a concentration of approximately 10 
µg/mL [68]. It is a multimeric protein which binds to the two major platelet receptors 
GPIIb/IIIa and GPIb-IX-V, as well as to collagen [69]. The interaction between the GPIb 
platelet receptor and the A1 domain of vWf is pivotal in mediating the initial adhesion of 
platelets on the subendothelium under conditions of high shear stress [69], while the 
RGD sequence in the C1 domain of vWf serves as a binding motif for both GPIIb/IIIa 
and αVβ3 platelet integrins, which mediates subsequent platelet adhesion and aggregation.  
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Figure 2.3. Schematic illustration of the dual-step mechanism of platelet adhesion to 
immobilized vWf [70].  
 
Under normal conditions, the GPIb-IX-V platelet receptor complex does not interact 
strongly with soluble vWf, but when collagen is exposed at sites of vascular injury, vWf 
becomes immobilized and undergoes conformational changes in its A1 domain, which 
enables platelet binding [69]. As seen in Fig. 2.3, the initial capture of the platelets from 
flowing blood is due to the interactions between the platelet GPIbα receptor and the A1 
domain of vWf. This bond however has a rapid dissociation rate [71] and therefore 
cannot mediate stable platelet adhesion. As a result of this, the platelets detach and 
translocate along the surface in a forward rolling movement due to the torque applied by 
the flowing blood [70]. During this translocation, the GPIb-IX-V receptor complex forms 
bonds with the underlying vWf and collagen, thereby decreasing the velocity of the 
platelets. Although the exact nature of the regulation of the interactions between GPIbα 
and vWf remains unclear, the changes in conformation of the ligand and receptor play 
important roles in these interactions [72]. The GPIb-IX-V receptor complex also 
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functions as a signal transducer, which activates platelet GPIIb/IIIa receptors, leading to 
the arrest and firm adhesion of the platelets on the surface due to the binding of these 
activated GPIIb/IIIa receptors to the RGD sequence in the C1 domain of vWf [73].  
vWf-deficiency in plasma (also known as Bernard-Soulier syndrome) causes severe 
problems in hemostasis and coagulation in humans [74], and also has been shown to 
cause spontaneous bleeding and prolonged bleeding times in mice [75]. However, unlike 
GPIb, vWf is unlikely to be essential for in vivo thrombus formation, as platelet adhesion 
is only delayed, indicating that the GPIb-IX-V receptor complex interacts with some 
other ligand(s) such as Fg, to initiate platelet adhesion, although a study has suggested 
that thrombospondin-1 may also interact with GPIb-IX-V in the absence of vWf [76].   
In addition to Fg, our research is also focused on the possible role of Alb in mediating 
platelet adhesion. Alb is the most abundant plasma protein (35-50 mg/mL in plasma) 
[77], and combined with its moderately low molecular weight (68.3 kDa) [78], is one of 
the first proteins adsorbing on the biomaterial surfaces [79]. Since it lacks any known 
amino acid sequences for binding platelet receptors, it has been considered to be unable 
to support platelet adhesion, and hence is widely used for blocking non-specific platelet-
surface interactions in platelet studies [80], as well as for a blood-compatible coating on 
biomaterial surfaces [81, 82]. However, some studies have suggested that platelets can 
adhere to adsorbed Alb [54, 83, 84], and that the mechanisms underlying this adhesion 
can be attributed to the adsorption-induced conformational changes in Alb [54]. In fact, 
for the same degree of loss of α-helix in the protein, platelet adhesion levels have been 
found in one study to be comparable for both Alb and Fg [54].    
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In addition, other cell types, such as hepatocytes [85], as well as monocytes, 
macrophages and dendritic cells [86-88], have been shown to be able to bind to adsorbed 
Alb. For example, a recent study has shown that macrophages are able to bind to Alb 
adsorbed on perfluorocarbon surfaces, with the adhesion process shown to be primarily 
mediated by the Mac-1 (αMβ2) macrophage integrin [89]. These cell-types may be 
broadly categorized as ‘defensive’ cells, as they play a critical role in the inflammation 
and coagulation cascades [1], and their ability to adhere to Alb may possibly be attributed 
to an inherent ability to recognize and adhere to misfolded proteins, which are often a 
sign of degenerative diseases [90]. Hence, the role of Alb in mediating the blood-
compatibility of implants cannot be ignored.  
 
2.2.3 Protein adsorption studies on SAM surfaces 
Surface properties are critical in controlling the interactions of plasma proteins and 
cells on biomaterial surfaces. Self-assembled monolayers (SAMs) of alkanethiols on gold 
are widely used as model surfaces for analyzing the effect of surface chemistry on protein 
adsorption, since they are easy to prepare, form highly ordered systems, and permit a 
broad range of surface functionalities to be produced [84, 91-93], thereby permitting us to 
clearly delineate the role of specific surface chemistries on protein adsorption [51, 94-
96].  Their structural integrity coupled with the uniform surface chemistries obtained 
enables them to behave successfully like biomimetic surfaces, such as membranes [97]. 
The alkanethiols we use have the structural formula (HS-(CH2)11-R), with the thiol group 
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at one end which binds to gold, while the long alkyl chain orders the alkanethiol on the 
surface.  
Defects in the SAMs (such as vacancies and grain boundaries) may occur and are 
dependent on the surface smoothness and cleanliness, concentration and purity of the 
alkanethiols, temperature and time of deposition, and solvent selection [98].  These 
defects may expose the underlying alkyl chain of the alkanethiols to the proteins that are 
adsorbing on the surface.  Protein-surface interactions are dominated by hydrophobic 
interactions; hence Triton-X-100 (Fig. 2.4) has been used as a blocking agent to cover 
hydrophobic defects from proteins on SAMs with neutral non-methyl terminating groups 
[99].  The Triton-X-100 molecule contains ethylene glycol repeat units, which are known 
to resist protein adsorption and effectively fills defect sites in the SAM structure.    
 
 
Figure 2.4.  Chemical structure of Triton-X-100, which is used as a blocking agent on 
alkanethiol SAMs. (n= 9-10) 
 
Studies have shown that Fg adsorption is higher on CH3-terminated SAMs than on 
the COOH- and OH-functionalized surfaces [34, 100, 101], with a linear decrease in the 
amount of Fg adsorbed as the percentage of hydroxyl groups on the surface increased 
(i.e., increasing hydrophilicity) [84]. Additionally, the differential affinity of different 
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proteins on a given surface is illustrated in studies which showed that Fg exhibited higher 
levels of surface coverage on both hydrophobic and hydrophilic surfaces compared to 
Alb [51]. Alb has also been found to adsorb more firmly on hydrophobic surfaces, like 
CH3-terminated SAMs, whereas adsorption on hydrophilic surfaces, such as OH-
terminated SAMs, was low [50, 102]. In general, hydrophobic surfaces show higher 
amounts of adsorbed plasma proteins [84] due to their tendency to bind protein more 
strongly, thus packing proteins more tightly on the surface at surface saturation. These 
interactions between the protein and surface are also the driving force mediating the 
changes in conformation of the adsorbed protein and its irreversible adsorption on the 
surface [34, 35] that was confirmed in recent studies [33, 34, 101], which showed that 
adsorption-induced conformational changes in proteins are higher on CH3-terminated 
surfaces than on OH-terminated ones.  
Competitive protein adsorption studies with Fg and Alb indicated that the addition of 
Fg led to only modest desorption of Alb on hydrophilic and hydrophobic SAMs, 
suggesting the occurrence of minimal Vroman effects on these SAMs for the adsorption 
conditions used [34]. Thus, this clearly confirms that Alb adsorbs strongly even on 
hydrophilic SAMs, as a result of which the more surface-active protein (i.e., Fg) is unable 
to fully displace a less surface-active protein (i.e., Alb) from the surface. This behavior 
may have serious implications from the aspect of blood-biomaterial interactions, raising 
questions about the ability of Fg and other plasma proteins with high surface affinities to 
displace preadsorbed Alb molecules from a biomaterial surface. 
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2.3 Role of platelets in blood-biomaterial interactions 
2.3.1 Platelets and platelet receptors involved in adhesion  
Platelets are normally anucleate, discoid cells with a diameter of 3-4 µm, and play a 
critical role in hemostasis by maintaining the integrity of the vascular endothelium [1]. 
They accomplish this by (i) forming platelet plugs which stop the bleeding at injury sites, 
and (ii) catalyzing the reactions in the coagulation cascade leading to the formation of 
fibrin which stabilizes these platelet plugs [3], thereby preventing blood loss. As 
mentioned earlier, resting platelets do not bind to plasma proteins like Fg, vWf, Fn, and 
Vn in the bloodstream. However, the GPIIb/IIIa platelet receptor (80,000 copies per 
platelet) undergoes conformational changes upon platelet activation, leading to intra-
platelet signaling, thereby enabling platelet binding to these proteins [3]. Resting platelets 
also have the ability to bind to adsorbed plasma proteins, which is believed to be due to 
the conformational changes in the proteins during the adsorption process.  
Normal (non-activated) platelets are discoid in shape, but undergo a rapid change in 
morphology upon activation, spreading and forming filopodia, ultimately leading to the 
formation of platelet aggregates [103]. Minimal stimulation is required to elicit a platelet 
response, as a result of which they become activated when they contact any thrombogenic 
surface (such as an injured endothelium, subendothelium and synthetic surfaces), and are 
the first cells to adhere to the layer of adsorbed protein on a biomaterial surface [104]. 
The activation process is often associated with the coupling of a ligand to specific platelet 
receptors, leading to intra- and extra-cellular signaling (i.e., ‘inside-out’ and ‘outside-in’ 
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signaling, respectively) [105]. These ligands include plasma proteins such as Fg, vWf and 
thrombin, parts of the vascular endothelium such as collagen, as well as platelet agonist 
molecules such as adenosine diphosphate (ADP) and thromboxane A2 secreted by 
inflammatory cells and activated platelets. Negatively-charged phospholipids (such as P-
selectin) are translocated from the platelet α-granules to the platelet membrane [106] 
upon platelet activation, as a result of which coagulation factors Va and Xa can bind to 
the platelet membrane and form the prothrombinase complex. The thrombin generated by 
the prothrombinase complex stimulates thrombosis, which, in the case of an implant, 
ultimately may lead to its failure or adverse events such as the generation of 
thromboemboli. Thus, platelet activation is clearly linked to the thrombotic complications 
associated with cardiovascular devices. 
Platelet receptors play a key role in mediating the thrombotic response, and hence are 
the main target of anti-thrombotic therapies. The GPIIb/IIIa receptor (also known as the 
αIIbβ3 integrin) is thought to be the main receptor mediating platelet-plasma protein 
interactions. It can bind to several ligands containing the RGD amino acid sequence, such 
as Fg, fibrin, vWf, Fn, Vn and thrombospondin [73].  In resting platelets, this integrin is 
in a highly bent, low-affinity or ‘off’ state, in which the RGD-binding region is believed 
to be hidden [73]. However, when the platelets are activated, the integrin undergoes a 
conformational switch into its high-affinity or ‘on’ state, leading to the exposure of the 
RGD-binding site, as a result of inside-out signaling. Previous studies have also shown 
that the RGDS peptide inhibits platelet attachment to Fg and other plasma proteins [107, 
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108] suggests that further research into the regulation of the RGD-binding domain on 
platelets is essential in understanding the mechanisms of platelet-protein interactions.  
Savage et al. showed that the GPIIb/IIIa receptor was essential for platelet binding to 
adsorbed Fg using a monoclonal antibody LJ-CP3 to block the GPIIb/IIIa receptor [59]. 
At low shear rates (100 s-1 or lower, which are usually seen in the venous circulation) 
[109], non-activated GPIIb/IIIa
 
selectively binds surface-immobilized Fg [59], in addition 
to contributing to platelet aggregation by cross-linking with the GPIIb/IIIa receptors on 
adjacent platelets. However, at high shear rates, the initial stages of platelet-surface 
interactions are mediated by the interactions between the platelet GPIb-IX-V receptor 
complex (about 25,000 copies per platelet) and surface immobilized vWf, independent of 
the activation state of the platelets. These newly adherent platelets are then activated by 
agonists, such as ADP, thrombin or epinephrine, released by other platelets that are 
already adherent and activated, as well as by shear stress [110], resulting in GPIIb/IIIa 
activation and irreversible platelet aggregation, finally leading to thrombus formation.  
Other receptors involved in platelet adhesion include those for collagen (GPVI, α2β1), 
fibronectin (α5β1), and vitronectin (αVβ3). P2Y receptors for ADP, and PAR receptors for 
thrombin also play a subsidiary role in mediating platelet activation [111]. These 
‘secondary’ platelet receptors may act in synergy with the primary platelet receptors 
(GPIIb/IIIa and GPIb-IX-V) in mediating adhesion to adsorbed proteins.  
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2.3.2 Platelet interactions with adsorbed proteins on surfaces 
The platelet adhesion on a surface is typically quantified using a colorimetric LDH 
assay [54], in addition to microscopy techniques like scanning electron microscopy 
(SEM) [84, 97] or glutaraldehyde induced fluorescence technique (GIFT) [84, 112]. The 
activation state and the morphology of the adherent platelets is assessed by techniques 
such as confocal microscopy, total internal reflection fluorescence microscopy (TIR-FM) 
and immunofluorescence microscopy [113, 114], in addition to other conventional 
microscopic techniques such as GIFT and SEM.  
Currently, it is unclear whether the adhesion and activation of platelets on a layer of 
adsorbed proteins is mediated by the conformation or the amount of adsorbed proteins. 
The conventional thought in the biomaterials field has been that the surface coverage of 
the adsorbed protein mediates platelet binding, with the investigation of the role of the 
conformation of the adsorbed layer coming into prominence very recently [54, 55]. 
Platelets exhibit a greater extent of spreading on a given surface coated with low-density 
Fg (0.003 mg/mL bulk solution concentration) compared to high-density Fg (0.1 mg/mL 
bulk solution concentration) [113]. GPIIb/IIIa activation was examined using the PAC-1 
monoclonal antibody (mAb) which selectively recognizes activated GPIIb/IIIa [115], and 
it stained the spread platelets on low-density Fg four times more intensely than on high-
density Fg [113]. The results from this study clearly suggest that the surface coverage of 
Fg affects both platelet adhesion and GPIIb/IIIa-mediated outside-in signaling, resulting 
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in differences in Ca2+ signaling, signal transduction mechanisms, platelet morphology, 
and inside-out signaling.  
However, various groups have hypothesized that the platelet adhesion correlated with 
the amount of Fg that can be recognized by conformation-specific antibodies against Fg, 
rather than the total surface coverage of Fg [80, 116-118]. Thus, in addition to the surface 
coverage of adsorbed Fg, the conformational of this Fg layer also plays a critical role in 
mediating platelet adhesion and subsequent activation [119-121]. 
In a study by Tanaka et al. [55], although poly(2-methoxyethylacrylate) (PMEA) and 
poly(hydroxyethlylmethacrylate) (PHEMA) surfaces adsorbed the same amount of Fg, 
the PHEMA surface showed significantly greater levels of platelet adhesion compared to 
PMEA, which was attributed to the increased level of denaturation of Fg on the PHEMA 
surface. Thus, this suggests rather than the surface coverage of Fg, its adsorbed 
conformation mediates platelet binding. 
Recent investigations [84, 97] have indicated that CH3 SAMs with adsorbed proteins 
showed stronger platelet adhesion compared to OH-terminated SAM surfaces, with  
scanning electron microscopy (SEM) results revealing that the platelets adherent on the 
CH3 SAM exhibited high levels of platelet activation, with the degree of activation and 
adhesion decreasing with increasing hydrophilicity (i.e., increase in percentage of OH 
groups on the surface) [84]. Accounting for the fact that proteins adsorbed on more 
hydrophobic surfaces exhibit a higher degree of adsorption-induced unfolding compared 
to hydrophilic surfaces [33], this seems to suggest that the adsorption-induced 
conformational changes in Fg lead to the exposure of platelet-binding sites which would 
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have normally remained ‘hidden’ in the native/solution state of the protein and thus cause 
increased platelet adhesion and activation. The lower extent of adsorption-induced 
unfolding on hydrophilic surfaces would maintain the structure of protein closer to that in 
its native state and thereby have lesser tendency to expose platelet-binding domains, 
explaining the low platelet adhesion.  
The same explanation may hold true while explaining platelet adhesion observed on 
Alb-coated surfaces [54, 84]. In cases where platelet adhesion has been observed on Alb-
coated surfaces in the past, it has been attributed to non-specific processes [80], such as 
the platelet interactions with exposed surface area of the substrate as opposed to actual 
binding to the adsorbed Alb. However, as mentioned in Section 2.2.3, the fact that Alb 
adsorbs firmly on hydrophilic surfaces, as a result of which Fg has been shown to be 
unable to displace it [34], suggests that the Alb adsorbed on biomaterial surfaces may not 
be easily displaced by more surface-active proteins from blood.  
Two recent studies reported that platelet adhesion to Alb may actually be via specific 
mechanisms, which are linked to the conformational state of the adsorbed Alb [54, 84]. 
However, these studies did not rule out the possibility that the observed response maybe 
have been due to platelet interactions with some other residual protein in the system, 
leaving the question of the exact nature of platelet-Alb interactions still open to debate. 
Hence, it is imperative for us to definitively examine whether non-activated platelets can 
adhere to Alb; and if so, whether this is via a receptor-mediated process that can be 
directly correlated with the degree of adsorption-induced conformational changes in Alb 
on the surfaces. 
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Although the platelet adhesion is higher on more hydrophobic surfaces, it is also 
important to note that surfaces which cause a higher degree of adsorption-induced 
unfolding in proteins also adsorb larger amounts of proteins. Differentiating between 
these two potential mediators of platelet binding is essential, as they lead to two very 
different approaches to the design of hemocompatible biomaterials. If the platelet 
adhesion is mediated by the amount of adsorbed proteins, biomaterial surfaces must be 
designed so as to minimize the surface coverage of adsorbed protein, irrespective of its 
conformation. On the other hand, if the degree of adsorption-induced unfolding of the 
proteins mediates the platelet attachment, then the surfaces should be designed in a 
manner which retains the proteins as close to their native conformation as possible, 
irrespective of the surface coverage of adsorbed protein. 
 
 
2.4 Assessment of adsorption-induced conformational changes in proteins 
One of the primary questions this project aims to address is whether the surface 
coverage or the conformation of the adsorbed protein mediates subsequent platelet 
adhesion.  By using a broad range of surface chemistries and a wide range of protein 
solution concentrations, it is possible to obtain a large set of systems with differing 
amounts and conformations of adsorbed protein. In order to accurately ascertain the 
conformation of the native protein in solution and adsorbed protein on the SAM surfaces, 
it is essential to use a highly sensitive experimental technique. 
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While post-adsorptive conformational changes in protein layers on surfaces have been 
evaluated using nuclear magnetic resonance (NMR) [122] and Fourier transform infra 
red-attenuated total internal reflection (FTIR) spectroscopy [123, 124], both methods 
have inherent disadvantages that limit their usefulness for this application. Although 
NMR provides an extremely powerful technique that can potentially reveal the complete 
three-dimensional structure of a protein on a surface, it requires samples with very high 
surface area density [125], while FTIR requires high protein surface concentrations, 
which may lead to protein aggregation and associated conformational changes [125]. As 
an alternative to these methods, circular dichroism (CD) spectroscopy is relatively simple 
and easy to use, and can be used to analyze samples with relatively low surface area and 
at relatively low degrees of surface coverage.  Because of these advantages, CD has been 
increasingly used in recent studies as a means of examining protein-surface interactions 
at the molecular level [54, 55, 126-128].  
 
2.4.1 Fundamentals of Circular Dichroism (CD) Spectropolarimetry 
When asymmetric molecules interact with light, they absorb left- and right-handed 
circularly polarized light to different extents, and this difference in absorbance is defined 
as CD. On account of this, the plane of the wave of light is rotated such that the addition 
of the vectors representing the electric fields of left-handed (EL) and right-handed (ER) 
circularly polarized light, resulting in a vector which traces an ellipse and the light is said 
to elliptically polarized.  
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The absorbance of a solute at a given wavelength λ, Ai(λ), is given by Beer’s Law, and 
can be written as [129]: 
Ai(λ) = εi(λ) × C × L      (2.1) 
where εi(λ) is the extinction coefficient (in g/cm2) of the chiral solute for a particular 
handedness of polarized light, C is the concentration of the solute (in g/mL), and L is the 
distance that the light travels through the medium containing the solute (in cm). (Note: A 
is unitless). 
Therefore the difference in absorbance of left- and right-handed circularly polarized 
light (i.e., CD) can be defined as: 
CD ≡ ∆A = AL – AR = (εL × C × L) – (εR × C × L)  
= ∆ε × C × L      (2.2) 
Modern spectropolarimeters use a modulation technique that allows for the direct 
measurement of ∆A, which is generally very small [130]. Since the change in absorbance 
can be accurately measured, ∆ε can be easily calculated and used to report CD data. 
However, CD is often reported in terms of ellipticity [131].   
The vector representing the electric field of a circularly polarized light beam rotates in 
the direction of propagation, completing one revolution per wavelength. When the 
electric field vectors of right- and left-handed circularly polarized light are in the same 
direction, the sum of their magnitudes is the major axis of the elliptically polarized light 
and the minor axis of the ellipse is given by their difference when the vectors are in the 
opposite direction. The ellipticity (θ, generally expressed in millidegrees) is the angle of 
which the tangent is the ratio of the minor axis of the ellipse to its major axis [132, 133].  
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Since this angle of ellipticity is very small, the tangent of θ is approximately equal to θ 
in radians, thus the measured ellipticity can be related to the difference in absorbance by 
the following expression [134]. 
θ [rad] ≈ tan θ = (│EL│-│ER│) / (│EL│+│ER│) 
= [exp(-AL/2) - exp(-AR/2)]/[exp(-AL/2) + exp(-AR/2)]   (2.3) 
This expression can be simplified by converting θ to degrees and expanding the 
exponentials, while neglecting the higher terms of order of ∆A in comparison with unity, 
to yield the following expression [134]: 
θ [deg] = 180 × ln 10 × ∆A/4pi = 32.98 ∆A   (2.4) 
Equation 2.4 shows that the ellipticity is directly proportional to the differential 
absorption of right- and left-handed circularly polarized light by the optically active 
medium. For protein analysis, the measured ellipticity is often converted into its 
corresponding molar ellipticity ([θ]) value by the following expression [135]: 
[θ] = (θ × M0) / (10,000 × C × L)    (2.5) 
where [θ] is the molar ellipticity (deg·cm2/dmol) and M0 is the mean amino acid residue 
molecular weight (118 g/mol). 
 
 
2.4.2 Analysis of protein structure 
Proteins are considered to have four levels of structure – primary, secondary, tertiary 
and quarternary [136]. The primary structure of proteins consists of its defined sequence 
34 
 
of amino acids. The secondary structure of proteins refers to the segments of amino acid 
sequences that fold into regular conformations with well-defined, repeated torsion angles 
that are stabilized by hydrogen bonding. The tertiary structure of the protein is 
determined by the folding and binding together of the secondary components of the 
protein, which is mediated by nonbonded interactions between side-chain of the amino 
acid residues and possibly disulfide bond formation, giving the protein its overall three-
dimensional shape. The quarternary structure of proteins contains multiple polypeptide 
chains, each with its own N and C termini, such as dimers and trimers, which are 
arranged in a regular manner [136].  
Helices are the most common type of secondary structural unit occurring in proteins. 
The α-helix, which was first modeled in 1951 by Pauling, Corey, and Branson [137], is 
the most abundant type of helix found in proteins and its coiled structure consists of 3.6 
residues per turn. Two alternative helices that have been found in proteins are 310 helices, 
which have tighter coils consisting of 3.0 residues per turn, and the larger pi helices that 
consist of coils containing 4.1 residues per turn [138]. The second most common type of 
secondary structure are β-sheets that are formed by β-strands, which consist of either 
parallel or anti-parallel stretches of amino acids whose peptide backbone chains are 
nearly in full extension, with hydrogen bonding between adjacent β-strands [139]. Turns 
are the third type of secondary structure that is often found in proteins, resulting due to 
the formation of hydrogen bonds between amino acid residues that are close to one 
another in the primary sequence along a polypeptide chain. For a turn to form, the Cα 
atoms of the amino acids involved must be within 7 Å of each other, with neither of the 
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amino acids being contained within another secondary structural unit. β-turns are the 
most frequent type of turn and are characterized by Cα atoms separated by three residues, 
while γ-, α-, and pi-turns are characterized by Cα atoms separated by two, four, and five 
residues, respectively [140, 141]. The final type of secondary structure is the random 
loop, which consist of unstructured segments of the polypeptide chain that link the other 
types of secondary structural elements with one another. 
As a result of ‘exciton’ interactions, when the chromophores of the amides in the 
polypeptide chain of proteins are aligned in arrays, their optical transitions are either 
shifted or split into multiple transitions [142]. Thus, the different secondary structural 
components in proteins have their own characteristic spectra, and the overall CD 
spectrum contains contributions from all the structural components within the protein.  
This causes the curves for each individual component of the secondary structure (such as 
α-helix and β-sheet) to overlap to give a single spectrum that can be deciphered to 
provide an estimate of the overall secondary structural composition of the protein.  
For example, the CD spectra for α-helical proteins exhibit negative maxima at 222 nm 
and 208 nm, along with a positive maximum at 193 nm [143]. Proteins with well-defined 
β-sheets have negative bands in their spectra at 218 nm and positive bands at 195 nm 
[144], while those with disordered/random structure have very low ellipticity at 
wavelengths greater than 210 nm, and negative bands near 195 nm [145]. This is clearly 
illustrated in Fig 2.5 (below), for different conformations of poly-L-lysine.  
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Figure 2.5. CD Spectra of poly-L-lysine in various conformations: (1) 100% α-helix, (2) 
100% β-sheet, and (3) 100% random chain [144].  
 
While performing CD experiments, it is imperative to take certain key points into 
consideration [132]. The protein used must be at least 95% pure, and the buffer used for 
preparing the protein solutions must be free of any other optically active materials that 
may interfere with the CD signal and complicate the analysis by masking the change in 
the CD signal due to the protein itself. Hence, nanopure water would be the best solvent 
suited for this method. But this does not represent physiological conditions, with the lack 
of salts in the buffer possibly influencing the structure of the protein. Additionally, so as 
37 
 
to obtain accurate data, the total absorbance of the sample (inclusive of the cuvette, 
sample and buffer) in the wavelength range of 190-200 nm must not exceed a critical 
value beyond which the high tension (HT) voltage limits for the instrument are exceeded 
[132]. The CD spectrum obtained within these experimental constraints is then 
deconvoluted using spectral analysis algorithms such as SELCON3 or CONTINLL [146, 
147] to estimate the content of α-helix, 310 helix, β-sheet, β-turn, polyproline type-II helix 
and unordered residues [142, 148]. This method provides a quantification of the 
secondary structural content of the proteins that has been shown to closely reflect the 
actual secondary structural composition of proteins.  
Thus, CD spectropolarimetry is an accurate and sensitive experimental technique to 
quantify the degree of adsorption-induced conformational changes occurring for a given 
protein [54], and can potentially also be used to quantify the surface coverage of the 
adsorbed proteins.  
 
 
2.5 Blockade of platelet receptors 
The role of specific platelet receptors in mediating adhesion to adsorbed proteins such 
as Fg and Alb can be delineated via their blockade using monoclonal antibodies or 
fragment antigen binding (Fab) antibodies. The GPIIb/IIIa
 
platelet integrin is the major 
platelet receptor supporting platelet aggregation and thrombus formation [149], and since 
platelets from patients with Glanzmann’s thrombasthenia, which lack functional 
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GPIIb/IIIa, exhibit diminished binding function [150], the blockade of GPIIb/IIIa
 
has 
been the main focus of anti-thrombotic therapies [151, 152].  
Since GPIIb/IIIa platelet receptors are RGD-specific, RGD-containing peptides were 
among the first candidates to be examined for inhibition of platelet receptor function 
[108, 153, 154]. The RGDS peptide was found to inhibit agonist-induced platelet 
aggregation, as well as Fg-binding to ADP-stimulated platelets [107]. However, it was 
found to be a partial competitive inhibitor of platelet aggregation and Fg-binding, 
suggesting that the platelet receptors for Fg (i.e., GPIIb/IIIa) were likely to still be able to 
interact with Fg in their RGDS-bound low-affinity state. Additionally, studies by Du et 
al. [155] indicated that RGDS peptides function as partial agonists of platelet integrins, in 
addition to being competitive antagonists.  RGDS induces conformational changes in 
both the αIIb and β3 subunits of the GPIIb/IIIa platelet receptors [156, 157], and it is this 
conformational shift in the β3 subunit which mediates GPIIb/IIIa-mediated outside-in 
signaling, leading to the activation of the α2β1 platelet integrin for collagen [158]. These 
results are in agreement with other studies which have reported that the cytoplasmic 
domain of the β3 subunit plays an important role in GPIIb/IIIa-mediated outside-in 
signaling [159-161]. Hence, in analyzing the role of the GPIIb/IIIa platelet receptor in 
platelet adhesion to adsorbed proteins, it is imperative to use an antagonist which inhibits 
the receptor without causing any associated induced platelet signaling. 
The peptide-mimetic GPIIb/IIIa
 
antagonist Aggrastat (or tirofiban, MW = 495.08 
g/mol) has been shown to bind to GPIIb/IIIa on non-activated platelets [157], inhibiting 
their ability to bind Fg, and also preventing overall platelet activation (as measured by P-
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selectin exposure), α2β1 activation and subsequent collagen binding [158]. This is due to 
the fact that it induces a conformational change only in the αIIb but not the β3 subunit, 
which is consistent with other studies [156, 157]. However, the anti-GPIIb/IIIa
 
monoclonal antibody fragment ReoPro (or abciximab, MW = 145,651 g/mol) has been 
found to be more therapeutically potent clinically [162], as it has been shown to inhibit 
the αVβ3 platelet receptor as well as the macrophage Mac-1 integrin, in addition to the 
platelet GPIIb/IIIa
 
receptor [163].  
The GPIb-IX-V platelet receptor complex is the second most abundant platelet 
receptor set with 25,000 copies per platelet, and the interaction between vWf and the 
GPIbα platelet receptor is important for platelet adhesion, especially at high shear stress. 
The inhibition of the GPIb receptor as a highly potent target for anti-thrombotic drug 
development has come into prominence only in the last decade [164]. One of the first 
studies examining the anti-thrombotic effect of blockade of the GPIb-IX-V receptor used 
a novel murine anti-GPIb mAb 6B4 [165]. The results from this study indicated that the 
mAb and its F(ab′)2 and Fab fragments were highly effective in inhibiting GPIb binding 
to vWf under static and flow conditions. Recent studies carried out using murine anti-
GPIbα mAbs 24G10 and 6B4 [166] as well as platelets from patients with Bernard-
Soulier syndrome which display GPIb-deficiency [111] showed complete inhibition of 
platelet adhesion to immobilized vWf. Phage display studies have narrowed the epitope 
for 6B4 to the amino acid sequences 230-242 and 259-262 in GPIb, while the epitope for 
24G10 has been mapped to the amino acid sequence 1-81 in GPIb [166]. Blockade of 
GPIb using these agents led to a moderate decrease of 29% and 26% in the activation of 
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GPIIb/IIIa
 
and platelet integrin α2β1 receptors, respectively [111], suggesting that it 
functions primarily as an adhesive receptor and does not have any major role in platelet 
activation. Inhibition of GPIbα has also been shown to lead to reduced thrombus 
formation when atherosclerotic plaques were exposed to flowing blood [167]. Studies 
involving the blocking of GPIIb/IIIa, GPIbα, or both by monoclonal antibodies has been 
shown to inhibit arterial thrombosis in baboons without increasing the bleeding time 
[168, 169], illustrating the critical roles played by both receptors in thrombosis. Hence, 
the analysis of the interactions of both of these receptor sets with adsorbed Fg and Alb 
form an important part of this doctoral work. 
 
 
2.6 Chemical modification of amino acid residues in proteins 
Site-specific chemical modification of amino acid residues in proteins is potentially a 
quick and highly effective technique for examining the role of specific amino acid 
residues in proteins [170, 171].  It stoichiometrically alters a protein with the covalent 
transformation of a single set of amino acid residues, usually without any change in 
conformation of the protein or altering any other amino acid residues [171]. Hence, this 
technique has the potential to be a powerful tool in determining the role of specific amino 
acid residues in platelet adhesion.  
The site-specific modification reaction depends on the protonation state of the amino 
acid residue of interest [171]. The local microenvironment surrounding this residue 
affects the physical and chemical properties of its functional group, especially for 
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nucleophiles such as amine groups, hydroxyl groups, phenolic hydroxyl groups, and 
sulfhydryl groups. The effective pK of these nucleophilic groups is affected by various 
factors in addition to solvent accessibility including electrostatic interactions with 
neighboring residues, hydrogen bonding with adjacent residues, and steric interference 
[172]. Thus, although the residue of interest may be solvent-accessible, it may not 
undergo chemical modification due to the non-uniform microenvironments surrounding 
all residues within the same protein or the same residue from protein to protein. Reaction 
conditions may be altered to shift the protonation state of these functional groups so that 
the desired modification reaction may occur, but may lead to undesirable conformational 
changes and modify multiple amino acid types in the protein. However, residues carrying 
the same charge (e.g., arginine and lysine) can be preferentially modified by suitable 
selection of reaction conditions (pH, ionic strength, solvent and temperature), illustrating 
the use of the effect of local chemistry on the pK of individual residues [171, 172].  
Although many restrictions may apply regarding the ability to selectively modify specific 
amino acid types in a protein, several analytical procedures have been developed and 
applied over the past few decades to successfully accomplish this for designed types of 
amino acids. 
The Arg-Gly-Asp (RGD) sequence is one of the main cell-binding motifs present in 
proteins, playing a critical role in the binding of platelet receptors [173]. 2, 3-butanedione 
has been used for neutralizing Arg residues under mild reaction conditions (pH 8.0) 
[174], and this Arg modification has been shown to inhibit fibroblast adhesion to plasma 
lipoproteins [175]. The reaction scheme is illustrated in Fig. 2.6.  
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Acetylation of proteins using acetic anhydride is one of the oldest and most widely 
used experimental approaches for the chemical modification of proteins [171]. This 
modification strategy has been shown to lead to extensive modification of amino groups 
[176], and is influenced by the relative accessibility of these residues, which depends on 
the microenvironment around them.  
Overall, based on the information discussed in this chapter, studies were carried out to 
analyze the mechanisms of protein adsorption on varying surface chemistries, and 
delineate the mechanisms of platelet adhesion to adsorbed Fg and Alb.  
 
 
 
Figure 2.6. Reaction scheme for site-specfic modification of arginine residues using 2,3-
butanedione [171].  
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Figure 2.7. Schematic representation for the reaction of acetic anhydride with amino 
groups of proteins [171].  
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CHAPTER 3 
SPECIFIC AIMS AND SIGNIFICANCE 
 
3.1 Hypothesis 
The molecular mechanisms mediating platelet adhesion to adsorbed proteins on 
biomaterial surfaces have not been completely understood by the biomaterials field 
despite over three decades of research into blood-biomaterial interactions [2]. The role of 
Fg in platelet-biomaterial interactions is well known, although it has remained unclear 
whether these are mediated by the surface coverage or the conformation of the adsorbed 
Fg. Additionally, although Alb is the most abundant plasma protein [77] and is the first 
protein to adsorb on biomaterial surfaces [79], the possible role for Alb in blood-
biomaterial interactions has not been critically examined. Recent studies have highlighted 
the potential role of Alb in mediating platelet attachment [54, 84], which is a surprising 
finding given that Alb does not have any known amino acid sequences that mediate 
platelet binding. The mechanisms governing these interactions therefore remain to be 
elucidated. 
Previous studies [54, 55] have focused on the role of the conformation of adsorbed 
proteins in mediating platelet adhesion, but have not put forward a definitive hypothesis 
on whether the conformation or the surface coverage of the adsorbed protein is the main 
parameter involved in platelet adhesion, nor have they determined the mechanisms 
responsible for the apparent ability of platelets to adhere to adsorbed albumin. Hence, our 
research was targeted on definitively delineating the mechanisms mediating platelet 
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adhesion to adsorbed Fg and Alb, with a critical focus on clearly determining whether 
this platelet response is actually driven by the amount of surface-adsorbed protein or the 
degree of the adsorption-induced conformational changes in the protein when it adsorbs 
on the surface. Since platelets do not interact strongly with proteins in their native state in 
the bloodstream, but can readily bind to adsorbed proteins, we hypothesize that 
adsorption-induced conformational changes in blood proteins lead to the exposure 
and/or formation of platelet-binding sites/domains in the protein molecules, which would 
have otherwise remained hidden or not present in their native state. To provide support 
for our hypothesis, we planned and carried out a series of studies that were designed to 
definitively show that platelet adhesion response is directly related to the degree of 
adsorption-induced protein unfolding rather than the amount of protein adsorbed 
(Specific Aims I and II).  We also planned and conducted a series of studies employing a 
variety of blocking strategies on the adsorbed protein as well as on specific platelet 
receptors to provide deeper insight into the exact nature of these platelet-protein 
interactions (Specific Aims III and IV).  Finally, we conducted aging studies of adsorbed 
Alb to begin to investigate how this factor may be expected to influence the structure of 
adsorbed proteins and how this subsequently influences the platelet response (Specific 
Aim V). 
Overall, this research provides deeper and newer perspectives on the molecular 
mechanisms mediating platelet interactions with adsorbed proteins, and how these 
interactions can be controlled to enhance the hemocompatibility of biomaterials used for 
cardiovascular applications.  
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3.2 Specific Aims and Significance 
Specific Aim I.  Analysis of adsorption-induced conformational changes in Fg and Alb 
as a function of protein solution concentration using CD spectropolarimetry 
Since surfaces that tend to adsorb proteins strongly, leading to a large amount of 
protein adsorption on the surface, also tend to cause a greater degree of conformational 
change in the adsorbed protein, it is difficult to differentiate which of these two factors is 
more critical in mediating subsequent platelet adhesion. To address this question, it was 
necessary to design a protein adsorption study to independently vary the amount of 
protein adsorbed and the degree of adsorption-induced unfolding in the adsorbed protein 
layer. To accomplish this, protein adsorption studies were planned and conducted using a 
broad range of surface chemistries using alkanethiol SAM surfaces and a wide range of 
protein solution concentrations (0.1, 1.0, and 10 mg/mL), which permitted us obtain a 
large set of systems with widely differing amounts and conformational states of the 
adsorbed proteins. CD analyses were then conducted to assess the degree of adsorption-
induced conformational change that occurred relative to the protein’s solution-state 
structure, with the surface coverage of the adsorbed protein being obtained from the 
absorbance spectra for the adsorbed protein layer.  
 
Specific Aim II.  Analyze the role of the conformation of the adsorbed protein vs. 
amount of adsorbed protein as a critical determinant of platelet adhesion 
SAM surfaces with varying functionalities were preadsorbed with Fg and Alb at three 
different bulk solution concentrations (as described in Specific Aim I), following which 
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they were incubated with washed human platelets. Platelet adhesion was quantified via a 
colorimetric Lactate Dehydrogenase (LDH) assay, while the morphology of the adherent 
platelets was visualized via scanning electron microscopy (SEM). The changes in 
secondary structure of the adsorbed plasma proteins as well as the amount of adsorbed 
protein (Specific Aim I) were then correlated with the platelet adhesion levels on the 
different surfaces in order to determine which of these two factors plays a more important 
role in mediating platelet binding. 
 
Specific Aim III.  Probing the molecular mechanisms of platelet adhesion to adsorbed 
Fg and Alb 
A variety of blocking strategies were utilized on the adsorbed layer of protein, as well 
as the platelets, in order to examine the mechanisms underlying platelet adhesion to 
adsorbed protein. The analysis of platelet adhesion mechanisms to Alb is an important 
component of our work, as recent studies have suggested that platelets may actually 
adhere to Alb via specific mechanisms [54, 84], and this may be linked to the 
conformation of adsorbed Alb [54].  
The Arg-Gly-Asp-Ser (RGDS) peptide, a potent inhibitor of platelet-plasma protein 
interactions in solution [107, 108], was used to examine the specific mechanisms 
involved in platelet adhesion to both adsorbed Fg and Alb. Additionally, we used 
polyclonal antibodies against Fg (pAb-Fg) and Alb (pAb-Alb) to definitively determine 
whether the platelets were adhering to Fg or Alb, respectively, with polyclonal antibodies 
against the other protein as negative controls. These pAb studies provided further insight 
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into the role of non-specific interactions in mediating platelet adhesion to adsorbed Fg 
and Alb. 
While Fg contains numerous known platelet adhesion sites, Alb does not contain any, 
and thus we were particularly interested in trying to determine which amino acids in the 
Alb were involved in platelet adhesion. Chemical neutralization of Arg [174, 177] and 
Lys [176, 178] residues in Alb, under reaction conditions close to physiological 
conditions, permitted us to examine the role of these residues in mediating platelet 
binding. Control studies conducted to modify these residues in solution were followed up 
with mass spectrometric analysis to confirm that the reactions caused the intended site-
specific modification. CD studies of both the solution and adsorbed structure of Alb were 
also conducted to ensure that these modifications did not significantly alter the secondary 
structure of Alb. 
 
Specific Aim IV.  Examining the role of specific platelet receptors in mediating 
adhesion to adsorbed Fg and Alb 
Our preliminary results pointed to the possibility that there are at least two distinct sets 
of receptors associated with platelet adhesion to adsorbed Fg and Alb; one RGD-specific 
receptor that mediates adhesion along with activation, and another non-RGD specific 
receptor set that mediates adhesion with minimal activation. We specifically targeted the 
the GPIIb/IIIa receptor, which is the pre-eminent platelet receptor [1] and is well known 
to be RGD-specific, as well as the GPIb-IX-V receptor complex which has been found to 
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primarily mediate adhesion and not activation [111]. These studies were performed by 
blocking these receptors using a peptidomimetic GPIIb/IIIa antagonist called Aggrastat 
(or tirofiban), along with GPIbα-specific monoclonal antibodies (mAbs), thereby 
examining their abilities to inhibit platelet adhesion and/or activation. 
 
 
Specific Aim V.  Time-dependent conformational changes in adsorbed Alb and platelet 
adhesion 
As addressed below in Chapter 4, the results from our Aim II studies showed that 
there is a strong correlation between the solution concentration from which Alb is 
adsorbed from and the degree of subsequent adsorption-induced unfolding, with 
adsorption of Alb from more dilute solutions resulting in a greater degree of unfolding.  
Our results also then showed that platelets are able to specifically adhere to adsorbed Alb, 
but only after Alb undergoes a substantial degree of adsorption-induced unfolding (i.e., > 
34% loss in α-helix), with a negligible degree of platelet adhesion occurring otherwise.  
In particular, we found that preadsorption of Alb from a 10.0 mg/mL bulk solution 
concentration on SAM surfaces led to a minimal degree of adsorption-induced unfolding 
and negligible platelet adhesion.  Based on these results, it can therefore be assumed that 
the adsorption of Alb at even higher solution concentrations than 10 mg/mL will result in 
even less unfolding and negligible platelet adhesion to the adsorbed Alb.  Since the 
concentration of Alb in blood plasma is about 40 mg/mL, it can thus be assumed that, in 
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vivo, Alb will largely retain its native state when adsorbed from blood to a biomaterial 
surface, with minimal exposure/formation of platelet binding sites.  Therefore, it could be 
argued that our findings that platelets adhere to adsorbed Alb after it undergoes 
substantial adsorption-induced unfolding is only of academic interest with little relevance 
to clinical applications.  
However, it is important to realize that competitive adsorption studies have indicated 
that Alb adsorbs irreversibly and with only modest displacement by larger proteins such 
as Fg on both hydrophilic and hydrophobic surfaces [34]. This means that once adsorbed 
on a biomaterial surface, Alb will be permanently retained on the surface. This then raises 
the question of whether an irreversibly adsorbed, tightly packed Alb layer on an implant 
surface will permanently retain its native-state conformational structure for the rest of the 
life of the patient, or will this adsorbed layer of protein undergo structural changes, 
including unfolding, over time. If so, the question must be asked whether aging-induced 
unfolding will then result in the exposure/formation of platelet binding sites and 
subsequent platelet adhesion and activation in a manner similar to that which occurs 
when the unfolding of adsorbed Alb is induced by adsorption from dilute solution.  This 
question of the aging behavior of irreversibly adsorbed proteins may also apply to other 
plasma proteins, such as Fg, and may provide important further insight into the nature of 
platelet interactions with adsorbed plasma proteins on implants used in cardiovascular 
applications.  
To address this question, we therefore planned and conducted a set of studies to 
investigate the effect of aging on the structure of an adsorbed layer of Alb and the 
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subsequent influence of aging-induced Alb unfolding on platelet adhesion.  For these 
studies, Alb was adsorbed to a SAM surface from 10 mg/mL, thus inducing a negligible 
amount of initial unfolding in the adsorbed protein, and these adsorbed Alb layers were 
then aged at 37°C for over a six-month time period with periodic CD and platelet 
adhesion studies performed to follow aging-induced unfolding of the adsorbed proteins 
secondary structure and subsequent platelet response. 
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CHAPTER 4 
ASSESSMENT OF CONFORMATION OF ADSORBED PROTEIN LAYER 
USING CIRCULAR DICHROISM SPECTROPOLARIMETRY 
 
4.1 Introduction 
When a biomaterial is implanted in the human body, the adsorption of plasma 
proteins to the surface of the implant is one of the first events to occur, subsequently 
influencing the cellular response to the biomaterial. Understanding the molecular 
mechanisms underlying these protein-surface interactions is important for the design of 
hemocompatible cardiovascular biomaterials, as the adsorption of plasma proteins 
influence the onset of a variety of adverse responses, such as thrombi and emboli 
formation and complement activation on the biomaterial surface [1].  
Protein adsorption is a complex process, and is dependent on a variety of material 
properties, especially surface chemistry [32]. Conventional thinking holds that surfaces 
that adsorb the least amount of plasma proteins support less platelet adhesion and thus 
exhibit lower surface thrombogenicity. However, recent studies have suggested that the 
critical determinant of the hemocompatibility of a surface may actually be the 
conformational state of the adsorbed protein rather than the total amount of adsorbed 
protein on the surface [54, 55].  This likelihood is further supported by the fact that 
proteins do not induce adverse reactions when they are in their native soluble state in the 
blood.  Based on this understanding, we hypothesize that adsorption processes cause the 
exposure and/or the creation of bioactive motifs that are ‘hidden’ or not in a active 
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conformation within the protein in its native conformation, which then stimulate adverse 
cellular responses.  The effect of surface chemistry in inducing post-adsorptive 
conformational changes in proteins may thus be an important consideration for 
biomaterials surface design.  
Alkanethiol SAMs on gold are widely used as model systems for studying the effects 
of surface chemistry on protein adsorption [51, 94-96] since they are easy to prepare, 
form highly ordered systems, and permit a wide variety of surface functionalities to be 
produced [84, 91-93].  While studies using these SAM surfaces have clearly shown that 
both the amount of protein adsorbed on a surface and the level of cellular response to the 
adsorbed protein layer generally increase with increasing surface hydrophobicity, it is 
difficult to clearly determine if the cellular response is actually driven by the amount of 
the protein on the surface or the degree of adsorption-induced refolding of the protein on 
the surface.  This is because it is generally true that surface chemistries that adsorb a 
larger amount of protein (i.e., strong protein-surface interactions) also tend to cause a 
higher degree of conformational change in the proteins when they adsorb.  To investigate 
this issue, a sensitive method is needed that is able to accurately measure the degree of 
structural change that occurs when a protein adsorbs to a surface and experimental 
conditions are needed that are able to vary the degree of conformational change that 
occurs during adsorption in a manner that can be separated from the amount of protein 
that is adsorbed. 
Circular dichroism (CD) spectroscopy can be used to analyze samples with relatively 
low surface area and at relatively low degrees of surface coverage, and information on 
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the conformational state, as well as the surface coverage of the protein is easily obtained 
using this instrument. Because of these advantages, CD has been increasingly used in 
recent studies as a means of examining protein-surface interactions at the molecular level 
[54, 126-128].  
Important considerations that should be taken into account when performing CD 
experiments and subsequent data analysis have been described previously [179]. 
Additionally, in order to obtain accurate data for protein adsorption experiments, the total 
absorbance of the sample (including the cuvette, sample, and buffer) in the 190 nm – 200 
nm wavelength range must not exceed a critical value for a given instrument beyond 
which the high tension (HT) voltage limits of the instrument are exceeded [179].  Once 
conditions are set that allow a CD spectrum to be successfully obtained within these 
designated constraints,  it is then analyzed via curve fitting algorithms [146-148, 180] 
that are used to quantify the fractions of the different secondary structural components 
that it contains.   
In this chapter, we present the refinement of experimental methods for CD 
spectropolarimetry using a cuvette that was specifically designed for protein adsorption 
studies to increase the sensitivity and reproducibility of our measurements by maximizing 
the number of surfaces that can be used in a single sample while minimizing the path-
length through the buffer solution, thereby substantially improving the signal-to-noise 
ratio of the CD spectra.  These methods were then applied to investigate the effects of 
surface chemistry and solution concentration on the secondary structure of adsorbed Fg 
and Alb as a means of separately varying the amount of protein adsorbed and degree of 
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adsorption-induced changes in the protein’s secondary structure [39]. From these studies, 
we show that our refined CD methods provide a very sensitive and reproducible means to 
measure the conformation of adsorbed proteins.  Our results indicate that for these 
surfaces and proteins, an increase in surface hydrophobicity for a given solution 
concentration results in an increase in both the amount of protein adsorbed and the degree 
of adsorption-induced changes in their secondary structure, while an increase in solution 
concentration for a given surface chemistry results in an increase in the amount of protein 
adsorbed but a decrease in the degree of conformational change, with this latter effect 
being more pronounced on the more hydrophobic surfaces. 
 
 
4.2 Materials and methods 
4.2.1 Protein Solutions 
Human fibrinogen (FIB3, plasminogen, von Willebrand factor and fibronectin 
depleted) was purchased from Enzyme Research Laboratories (South Bend, IN) and 
human serum albumin was purchased from Sigma (Catalog No. A 9511). The buffer used 
for all experiments was a 25 mM potassium phosphate buffer, consisting of appropriate 
amounts of monobasic potassium phosphate (Sigma) and dibasic potassium phosphate 
(Sigma) combined as necessary to adjust the solution pH to 7.4. 
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4.2.2 Gold substrates 
Quartz slides (0.375” x 1.625” x 0.0625”, Chemglass) were cleaned at 50°C by 
immersion in a piranha solution (7:3 v/v H2SO4/H2O2) for at least 30 minutes, followed 
by a Radio Corporation of America (RCA) basic wash (1:1:5 v/v NH4OH/H2O2/H2O), 
and this procedure was repeated twice. These slides were then rinsed with 100% ethanol 
(Pharmco-Aaper; Catalog No. 11100200), followed by nanopure water and then dried 
under a stream of nitrogen gas. 
The quartz substrates were then coated with a 30 Å chromium adhesion layer 
followed by 100 Å of gold via a thermal vapor deposition (TVD) evaporator (Model E 12 
E, Edwards High Vacuum Ltd.), prior to SAM formation on these substrates. The 
thicknesses of the gold and chromium layers were verified using a DekTak profilometer 
and a GES5 ellipsometer (Sopra, Inc., Palo Alto, CA).  
 
4.2.3 Formation of self-assembled monolayers (SAMs) of alkanethiols 
The following alkanethiols were used (as received) for our experiments: 
1-Dodecanethiol (SH-(CH2)11CH3; Aldrich; CH3),  
11-(2,2,2-Trifuoroethoxy) undecane-1-thiol) SH-(CH2)11OCH2CF3; Asemblon; CF3), 
11-Amino-1-undecanethiol, hydrochloride (SH-(CH2)11NH2HCl; Prochimia; NH2) 
11-Mercaptoundecanoic acid (SH-(CH2)11COOH; Aldrich; COOH), and 
11-Mercapto-1-undecanol (SH-(CH2)11OH; Aldrich; OH). 
SAM surfaces were prepared as per established protocols.[181, 182] Briefly, pure 
alkanethiol solutions were prepared in 100% ethanol (Pharmco-Aaper; Catalog No. 
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111000200) to yield a final concentration of 1.0 mM. The gold substrates were cleaned 
by dipping them for 1 minute each in a modified piranha wash (4:1 v/v H2SO4/H2O2),  
followed by an RCA basic wash (1:1:5 v/v NH4OH/H2O2/H2O), rinsed copiously with 
ethanol,  and then immersed in the alkanethiol solutions for 24 hours to form the SAM 
surfaces. 
After SAM formation on the gold substrates, the SAM surfaces were cleaned to 
remove any traces of hydrophobic contaminants, prior to surface characterization and 
protein adsorption [99, 172]. The CH3 and CF3 SAM surfaces were sonicated in ethanol, 
hexane and ethanol, and finally rinsed with nanopure water. The NH2, COOH and OH 
SAMs were sonicated in ethanol, prior to incubation in a 25 mM potassium phosphate 
buffer solution containing 0.005 volume % Triton-X-100 (Sigma-Aldrich, Catalog No. T-
9284), to block off any hydrophobic defect sites (e.g., grain boundaries). These SAM 
surfaces were then sonicated in acetone, followed by ethanol, to remove any traces of 
residual/loosely-bound Triton, and finally rinsed with nanopure water. 
 
4.2.4 Surface characterization 
4.2.4.1 Contact angle goniometry 
Advancing contact angle measurements were measured on the SAM surfaces using a 
CAM 200 Optical Contact Angle/Surface Tension Meter (KSV Instruments Ltd) and 
CAM 200 software provided with the instrument. The surfaces were sonicated in ethanol 
for 10 minutes, rinsed with nanopure water and dried with flowing nitrogen gas, and 
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mounted on the sample stage. The advancing water contact angles from six separate 
drops of nanopure water (pH=7.0) were measured on each surface. 
4.2.4.2 X-ray photoelectron spectroscopy  
XPS measurements of each type of SAM surface were conducted at the National 
ESCA and Surface Analysis Center (NESAC/BIO, University of Washington, Seattle, 
WA), using a Surface Science Instrument X-Probe spectrometer (Mountain View, CA) or 
a Kratos-Axis Ultra DLD spectrometer, equipped with a monochromatic Al Kα source 
(KE = 1486.6 eV), a hemispherical analyzer and a multichannel detector. The XPS 
spectra were collected at a nominal photoelectron takeoff angle (with respect to the 
sample surface normal) of 55°, at a pass energy of 80 eV for survey spectra and 20 eV for 
high resolution C1s and S2p spectra. The elemental composition was determined from 
the peak areas in the spectra, using the SSI data analysis software or Kratos Vision 2 
software program.  
4.2.4.3 Ellipsometry 
Ellipsometry measurements were performed using a Sopra GES5 variable angle 
spectroscopic ellipsometer (Sopra Inc., Palo Alto, CA) and the accompanying GESPack 
software package. The substrates used were 18 mm square coverslips (VWR), coated 
with 50Ǻ of chromium and 1000Ǻ of gold via thermal vapor deposition to ensure high 
reflectivity. Ellipsometry was performed on these gold-coated samples before and after 
incubation in alkanethiol, to determine the thickness of the SAM monolayer. Briefly, the 
spectra for five test points on each sample were scanned from 250 nm to 850 nm using an 
incident angle of 70°. The thickness of the SAM monolayer was calculated via the 
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regression method in the Sopra WinElli software package (version 4.07) by setting the n 
and k values for the alkanethiol layer as 1.5 and 0.0, respectively. The results presented 
are the average of five measurements on each surface for each SAM.  
 
4.2.5 Protein adsorption 
Protein stock solutions were prepared by dissolving human Fg and Alb in 25 mM 
phosphate buffer solution (pH 7.4). Each set of cleaned SAM-coated surfaces was 
incubated in the phosphate buffer in a Pyrex petri dish and then a suitable amount of 
protein stock solution was pipetted into the buffer. It is important to ensure that the 
pipette tip was below the air-water interface, to avoid denaturation of the protein at this 
interface. Protein adsorption was conducted under two different protein solution 
concentrations, 0.1 mg/mL and 1.0 mg/mL, in order to investigate the effect of bulk 
protein solution concentration on the adsorption-induced conformational changes. The 
SAMs were incubated in protein for 2 hours, after which the protein solutions over the 
SAM surfaces were infinitely diluted to remove the bulk protein solution and wash away 
any loosely adherent protein prior to removal of the SAMs from the buffer solution.  
Following this infinite dilution step, the SAM surfaces were able to be safely removed 
from the pure buffer solution without dragging the surfaces through the denatured protein 
film that can be expected to be present at the liquid-air interface if the protein solution 
had not been replaced with pure buffer prior to surface removal. 
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4.2.6 Determination of solution structure, adsorbed concentration, and adsorption-
induced conformational changes of proteins using circular dichroism spectroscopy 
The structure of Fg and Alb in solution, the adsorption-induced conformational 
changes in these proteins on the various SAM surfaces, and the amount of protein 
adsorbed on each surface were determined using CD spectropolarimetry. The CD spectra 
(consisting of the ellipticity and absorbance values over wavelengths ranging from 190 
nm to 240 nm) were obtained at room temperature using a Jasco J-810 spectropolarimeter 
(Jasco Inc., Easton, MD).  The solution structure of the proteins was determined using 
special high-transparency quartz cuvettes (Starna Cells Inc., Atascadero, CA) while the 
structure of the adsorbed proteins was determined using cuvettes that we custom-
designed for maximum signal-to-noise ratio (addressed below, see Fig. 4.1). Prior to 
running the instrument, it was calibrated using a 1.0 cm path-length quartz cuvette 
containing a solution of (1S)-(+)-10-camphorsulfonic acid, which has an ellipticity of 
+190.4 millidegrees (mdeg) at a wavelength of 290.5 nm [183].  
4.2.6.1. Solution structure of proteins  
The background spectrum (i.e., buffer only in the cuvette) was measured first, 
followed by that of the protein solution. Each CD spectrum was the average of ten scans 
done at a scan rate of 50 nm/min, using a data pitch of 0.1 nm, in a 0.1 mm path length 
quartz cuvette. The background spectrum was subtracted from the CD spectrum of 
protein solution to yield the spectrum of the protein solution alone. The contribution of 
any protein adsorbed on the walls of the cuvette while measuring the CD spectra for the 
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solution structure of the proteins was found to have negligible influence on the 
determination of the structure of the protein in solution (see Table 4.S.1 and Fig. 4.S.1.)  
The ellipticity value (θ, in mdeg) was converted to molar ellipticity with standard 
units of deg·cm2/dmol (designated as [θ]) using the following equation [135, 179]:  
[θ] = (θ · M0)/(10,000 · Csoln · L)        (4.1) 
where θ is the molar ellipticity in mdeg, L is the path length of the cuvette in cm, Csoln is 
the solution concentration of the protein in g/mL, and M0 is the mean residue molecular 
weight of 118 g/mol. 
Proteins exhibit a peptide absorbance peak at 195 nm (A195), and hence we use the 
height of the absorbance peak at this wavelength to determine Csoln [184]. The 
absorbances of serial dilutions of 2.0 mg/mL stock protein solutions were measured at 
195 nm, with the concentrations of the stock solutions being verified using a 
bicinchoninic acid assay (BCA, Pierce Biotechnology). Calibration plots of A195 vs. Csoln 
were first plotted for both Fg and Alb, with the slope of these plots representing “εprotein · 
L” from Beer’s Law, which is expressed as:  
A195 = εprotein · Csoln · L          (4.2) 
where εprotein is the extinction coefficient of the protein  in mL · g-1 · cm-1 (or cm2/g) and L 
is the path length of the cuvette in cm.  
The data of the molar ellipticity as a function of wavelength that were obtained from 
the CD scans were deconvoluted using the SP-22X algorithm and analyzed using the 
SELCON and CONTIN/LL software packages [142, 148] to yield the percentages of 
secondary structure components (α-helix and β-sheet). These programs analyze the 
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ellipticity values at each wavelength and compare them with a library of proteins with 
known secondary structure in order to estimate the percentages of the various secondary 
structural components. 
4.2.6.2. Adsorbed protein concentration  
It should be noted that the term “Csoln · L” in Eqn. (4.2) has units of g/cm2, which is 
equivalent to the units of surface concentration of adsorbed protein. Assuming that the 
absorbance is dependent only on the total mass of protein per unit area that the light beam 
passes through, irrespective of whether the protein is in solution or adsorbed to a surface, 
the same calibration plots used for the proteins in solution along with Eqn. (4.2) can also 
be used to directly determine the amount of protein adsorbed per unit area on the SAM 
surfaces, Qads, by replacing Csoln · L in Eqn. (4.2) with Qads. The validity of using this 
relationship to measure the amount of protein adsorbed on the SAM surfaces was 
confirmed by the independent measurement of Qads using ellipsometry (see 
supplementary information, Section 4.5, Table 4.S.2). 
4.2.6.3. Adsorbed protein structure 
As noted above, the CD spectra for the analysis of adsorbed protein structure on the 
different SAM surfaces were obtained using a specially modified quartz cuvette that we 
custom-designed to enhance the signal-to-noise ratio for these experiments, by increasing 
the number of surface samples and reducing the path-length of buffer through which the 
beam of light passes (as seen in Figure 4.1). The cuvette was designed to hold four SAM 
surfaces with 1/16” (0.159 cm) as the total path-length of the buffer through which the 
CD beam passes. By reducing this path-length, we were able to keep the total absorbance 
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and HT voltage below their critical values while maximizing the number of surfaces 
being scanned, thereby minimizing the signal-to-noise ratio to obtain a high level of 
sensitivity for the measurement of the CD spectra of the adsorbed protein layers. 
 
Figure 4.1. Top-view of the custom-designed cuvette used for measuring the CD spectra 
of adsorbed protein on the SAM surfaces. 
To evaluate the structure of the adsorbed protein layer on each SAM surface, the 
background spectra for the SAM-coated quartz slides were first obtained prior to protein 
adsorption. After the completion of the protein adsorption process, the modified cuvette 
was filled with 1.0 mL of the 25 mM phosphate buffer and the protein-coated SAM 
surfaces were inserted into the slots provided for the slides, taking care to ensure minimal 
exposure of the protein-coated slides to air, (to avoid any potential drying-induced 
conformational changes).  The spectra for the SAM-coated quartz slides with the 
adsorbed protein layer were then taken.  
The collected spectra were prepared for analysis by subtracting the background 
spectrum taken for each SAM without the adsorbed protein from the corresponding 
Light Beam
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spectrum of the same SAM surface after protein adsorption, with this difference then 
representing the contribution to the overall spectrum from the adsorbed protein layer 
alone. The absorbance of the adsorbed protein layer at 195 nm (A195) was measured and 
the amount of protein adsorbed on the SAM surface was obtained from the calibration 
curve of A195 vs. Qads. The resulting ellipticity values (θ, in mdeg) were then converted to 
molar ellipticity values ([θ], in standard units of deg·cm2/dmol) using the following 
equation [135, 179]:  
[θ] = (θ · M0)/(10,000 · Qads)         (4.3) 
This is the same as Eqn.4.1, with the “Csoln · L” term being replaced by Qads, which 
represents the surface concentration of the adsorbed protein. The molar ellipticity data 
was then analyzed using the SP-22X algorithm and analyzed using the SELCON and 
CONTINLL algorithms to determine the percentage composition of the secondary 
structural components in the adsorbed protein layer. 
 
4.2.7 Statistical analysis 
The results we present are the mean values with 95% confidence interval (CI). The 
statistical significance of differences between mean values for different 
samples/conditions was evaluated using Student’s t-test, with values of p < 0.05 
considered as statistically significant. 
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4.3               Results and Discussion 
4.3.1 Surface characterization 
The contact angle and ellipsometry data for the SAM surfaces is presented in Table 
4.1 and is in excellent agreement with previously reported values for these types of 
surfaces [181, 185].  The contact angle for the OCH2CF3-terminated SAM (CF3) was 
approximately 90°, which was lower than that observed for a CH2-CH2-CF3-terminated 
SAM (estimated to be around 100°), but was consistent with a previous study [79].  It has 
been shown previously that water exerts its influence on atomic layers at a distance of 
approximately 5 Å from the upper surface of the thiol layer, penetrating these layers and 
forming hydrogen bonds [186]. The ether group of the OCH2-CF3 SAM is located at a 
distance of ~3Å from the surface, as a result of which water may be able to form 
hydrogen bonds with the oxygen atoms of the ether groups. This explains the lower 
contact angle observed for the OCH2CF3 SAM, compared to the CH2-CH2-CF3-
terminated SAM. The XPS data for the SAM surfaces is presented in Table 4.2, with 
these data also providing values within the expected range for each type of surface 
chemistry. 
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Table 4.1. Contact angle and ellipsometry data for the SAM surfaces. (Mean ± 95% CI, n 
=7)  
Parameter CH3 OCH2CF3 NH2 COOH OH 
Contact Angle (°) 100.9 ± 1.9 90.2 ± 0.8 47.6 ± 1.8 17.9 ± 1.3 17.6 ± 1.9 
Thickness (Å) 11.5 ± 2.2 22.1 ± 4.9 14.7 ± 2.5 15.8 ± 1.9 12.1 ± 1.4 
 
 
Table 4.2. Atomic composition of Au-alkanethiol SAM surfaces as determined via XPS 
(mean ± 95% C.I., n = 3) 
Surface moiety C (%) S (%) N(%) O (%) F (%) 
CH3 64.9 ± 2.6 2.8 ± 0.9 Negligible Negligible Negligible 
OCH2CF3 44.1 ± 1.8 1.7 ± 0.2 Negligible 6.2 ± 1.0 13.0 ± 0.4 
NH2 54.0 ± 0.8 2.0 ± 0.2 4.0 ± 0.3 3.3 ± 0.3 Negligible 
COOH 47.6 ± 1.6 1.6 ± 0.1 Negligible 7.6 ± 0.3 Negligible 
OH 56.7 ± 3.0 2.8 ± 2.2 Negligible 7.5 ± 0.9 Negligible 
 
 
 
 
 
 4.3.2 Determination of conformational changes using 
The CD spectra for human 
in this figure, both Fg and Alb show a shoulder at 222 nm and a negative minima at 208 
nm, as well as a positive maxima at 193 nm, which are characteristic of 
[55, 179]. The α-helix and β-
CDPro software package, and the results are tabulated in the Table 
agree well with those reported previously in literature
Bank (PDB) files [191, 192]. 
 
Figure 4.2. Representative CD spectra for human fibrinogen (Fg) and human serum 
albumin (Alb) in solution. 
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CD spectroscopy
Fg and Alb in solution are shown in Figure 
α-helical proteins
sheet content for native Fg and Alb was quantified using the 
4.3. These values 
 [187-190], and in the Protein Data 
 
 
4.2.  As seen 
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Table 4.3. Structural composition of human fibrinogen (Fg) and human serum albumin 
(Alb) in solution, as determined by CD spectra. The values for α-helix and β-sheet 
reported in literature (lit) and the Protein Data Bank (PDB) are included for comparison 
(mean ± 95% CI, n = 6).  
Sample  α-helix (%)  β-sheet (%)  
Fg  39.9 ± 1.1  9.5 ± 1.1  
Fg – lit [193] 33.0  Very little  
Fg-PDB [194]
 
 30.0  14.4  
Alb 65.1 ± 1.3  2.6 ± 1.1  
Alb- lit [77] 67.0  0.0  
Alb-PDB [192]
 
 70.0  0.0  
 
The CD data quantifying the secondary structural composition of the adsorbed Fg and 
Alb on the SAM surfaces are shown in Figures 4.3 and 4.4, respectively, and are 
compared with the α-helix and β-sheet content of native Fg and Alb in solution. As 
clearly shown in these plots, the degree of adsorption-induced conformational changes is 
dependent on the SAM surface chemistry, with a prominent decrease in α-helix content 
(p < 0.05) for both Fg and Alb with increasing hydrophobicity of the surfaces (as 
indicated by the water contact angle values presented in Table 4.1).  This is consistent 
with observations made by other groups suggesting that proteins undergo greater 
conformational changes as they adsorb on hydrophobic surfaces [33, 35].  
This appears to be a characteristic response from adsorption-induced protein 
unfolding; or since the β-sheet content increases it may be more appropriate to refer to 
 this as adsorption-induced protein refolding.  We believe that this overall
caused by the thermodynamic driving force of the reduction in free energy of the system, 
which causes the hydrophobically associated secondary structures of the protein to 
separate from each other to form hydrophobic interactions with the non
groups of the SAM surface, thus reducing the overall solvent
hydrophobic functional groups in the system.  This apparently destabilizes the 
structures of the protein, causing them to unravel, with the re
then acting as a template that favors the formation of 
 
Figure 4.3.  Changes in secondary structure of adsorbed human fibrinogen (Fg) adsorbed 
at (A) 0.1 mg/mL and (B) 1.0 mg/mL  on SAM surfac
its native conformation. (n=6, mean ± 95% CI). (
values are significantly different from one another; 
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-polar functional 
-exposed surface area of the 
latively flat SAM surface 
β-sheet structure in their place.  
es, determined by CD compared to 
* denotes not significant, all other 
p < 0.05) 
 behavior is 
α-helix 
 
 
 Figure 4.4.  Changes in secondary structure of adsorbed human serum albu
adsorbed at (A) 0.1 mg/mL and (B)
compared to its native conformation
significant, all other values are significantly different from one another; 
 
Although the OH and COOH SAMs exhibited similar levels of hydrophilicity (
0.05), as inferred from the contact angle data in Table 
difference (p < 0.05) in the way both 
different surfaces, with the COOH SAM surfaces causing both a significantly greater loss 
of α-helix and a significantly greater increase in 
to the OH SAM. As shown in Figures 
(Alb), the structures of the proteins adsorbed on the OH SAM surfaces were closest to 
their native structures, with no statistical difference (
for Fg adsorbed on the OH SAM surface at both protein concentrations. This may be
attributed to the fact that the internal hydrophobic interactions within the proteins 
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 1.0 mg/mL on SAM surfaces, determined by CD 
. (n=6, mean ± 95% CI). Note: *
p < 0.05)
4.1, there was a significant 
Fg and Alb adsorbed and rearranged on these 
β-sheet in the protein structure compared 
4.3A and 4.3B (Fg) and Figures 4.4
p > 0.05) between the α
 
min (Alb) 
 denotes not 
 
p > 
A and 4.4B 
-helix values 
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dominate over their tendency to unfold and form contacts with the polar groups of the 
OH surface, thereby helping in preserving the native structure of fibrinogen and albumin 
[34]. In other words, due to the hydrophilicity of the surfaces (i.e., the lack of a 
hydrophobic driving force to cause protein refolding), the OH groups on the SAM surface 
primarily interact with the proteins by forming hydrogen bonds and van der Waal’s 
interactions with the hydrogen-bondable groups present on the polar and charged amino 
acid residues presented on the outer surface of the protein. As a result of this, the 
thermodynamic stability of the proteins adsorbed on the OH-surfaces is minimally 
perturbed, thereby largely causing it to retain its native structure following adsorption to 
the surface.   
On the other hand, the proteins adsorbed on the COOH SAM surface showed 
significantly greater (p < 0.05) structural rearrangement (i.e., loss of α-helix accompanied 
by gain of β-sheet) compared to their native structures. We attribute this behavior to the 
negatively charged carboxyl groups on the SAM surface (pK = 7.4) [195] interacting with 
positively charged amino acid residues on the protein’s surface, or possibly salt-bridges 
formed by oppositely charged amino acid residue pairs within the core of the protein.  We 
believe that these types of interactions apply new external forces on the proteins, leading 
to a situation where the native states of the Fg and Alb no longer represent the lowest free 
energy states of the protein-SAM-solution complexes, with the proteins then 
subsequently refolding to the new lowest free energy state conformations.   
As also clearly evident from the results presented in Figures 4.3 and 4.4, the NH2 
SAM surface resulted in a significantly greater degree of structural changes in the 
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adsorbed protein (p < 0.05) than the COOH SAM surface.  One explanation for this is 
that Fg (pI = 5.5) [196] and Alb (pI = 4.7) [196] should both have a greater number of 
negatively charged amino acid residues on their surface compared to the number of 
positively charged residues for a buffer solution of pH 7.4.  This should then cause the 
positively charged NH2 SAM surface (surface pK = 8.9) [195] to have a stronger 
electrostatic interaction with these proteins than the COOH SAM (surface pK = 5.0) 
[195].  In addition to these electrostatic effects, the NH2 SAM surface also exhibits a 
much lower degree of attraction to water molecules (as evident by its relatively high 
contact angle, as presented in Table 4.1), with this tending to minimize the free energy 
penalty associated with dehydrating the functional groups on the SAM surface as the 
protein adsorbs.   
These results clearly illustrate that the hydrophobicity of the surface is not the sole 
factor that governs protein adsorption behavior, but that the characteristics of the specific 
functional groups involved also play a significant role.  
Finally, statistical comparisons between the data shown in Figures 4.3A versus 4.3B, 
and 4.4A versus 4.4B, indicates that the amount of loss in α-helix structure and the 
increase in β-sheet structure in both Fg and Alb were significantly greater when these 
proteins were adsorbed from 0.1 mg/mL solution concentration than from the 1.0 mg/mL 
solution concentrations (p < 0.05), with the exception of Fg adsorbed on the OH SAM.  
These results can be explained by kinetic arguments based on the relative kinetics of 
mass transport of the protein to the SAM surfaces compared to the kinetics of the 
refolding of the protein on the SAM surfaces.  When the proteins adsorb from a dilute 
 solution, mass transport to the surface will be substantially slower than from a 
concentrated solution, thus giving the protein molecules more time to unfold, refold, and 
spread out over the surface before the entire surface becomes saturated, which 
further spreading of the protein over the surface
this type of adsorption behavior in the following subsection.
 
4.3.3   Quantification of protein adsorption on the SAM surfaces
Figures 4.5 and 4.6 illustrate the amount of 
SAM surfaces from bulk solutions of 0.1 mg/mL and 1.0 mg/mL solutions.
 
Figure 4.5. Fibrinogen (Fg) adsorption (Q
mg/mL on SAM surfaces. (n=6, mean ± 95% CI).
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 [33, 39]. Further evidence is provided for 
 
 
Fg and Alb, respectively, adsorbed on the 
 
ads) from bulk solutions of 0.1 mg/mL and 1.0 
 
inhibits 
 
 Figure 4.6. Albumin (Alb) adsorption (Q
mg/mL on SAM surfaces. (n=6, mean ± 95% CI). 
other values are significantly different; 
 
Fg has dimensions of about 5.0 x 5.0 x 47.0 nm
2.26 µg/cm2 when it is adsorbed end
side-on adsorption configuration yields a surface coverage of 0.24 µg/cm
adsorbed molecule of Fg) [34]
approximately 4.0 x 4.0 x 14 nm
adsorbed molecule of Alb for end
coverage of 0.72 µg/cm2, and the surface area for side
estimated as 56 nm2, yielding a surface coverage of 0.21 µg/cm
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Note: * denotes not significant, all 
p < 0.05) 
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 [50], yielding a surface coverage of 
-on (25 nm2 per adsorbed molecule of Fg), whereas a 
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. On the basis of the Alb molecule having dimensions of 
3
 [50], it was estimated [34] that the area occupied per 
-on adsorption would be 16 nm2, thereby yielding a 
-on adsorption was similarly 
2
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Our results (shown in Figures 4.5 & 4.6) suggest that our surfaces are saturated with 
protein and these protein molecules are arranged on the surface in a mixture of side-on 
and end-on configurations, as the values for surface coverage, with one exception, lie 
between the theoretical values for side-on and end-on protein adsorption for both of these 
proteins.  
An interesting result from the quantification of protein adsorption is the fact that the 
levels of protein adsorption were much lower for both Fg and Alb on the CF3 SAM 
compared to the CH3 SAM, despite the fact that both of these types of surfaces are 
considered to be strongly hydrophobic.  This can be attributed to the role of water, which 
can be expected to be able to interact with the subsurface ether group of the CF3 SAM via 
hydrogen bonding to a much greater extent than a hydrogen-bondable group from the 
protein because of the much smaller size and increased mobility of a water molecule [39, 
197], thus providing a thermodynamic mechanism to resist the dehydration of this surface 
by an adsorbing protein.  In fact, the CF3 SAM surface even adsorbed a significantly 
lower amount (p < 0.05) of each protein than the NH2 SAM surface, even though the NH2 
SAM is a much more hydrophilic surface. The higher protein adsorption on the NH2 
SAM than OCH2CF3 SAM is attributed to the favorable attractive forces between the 
positively charged SAM surface and the negatively charged proteins combined with the 
ability of the subsurface ether group of the CF3 SAM to preferentially hydrogen bond 
with water compared to an adsorbing protein. 
As clearly shown in Figures 4.5 and 4.6, the amount of protein adsorbed is 
significantly influenced by solution concentration.  At the lower solution concentration 
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(0.1 mg/mL), the rate of arrival of the protein molecules at the surface by diffusion is 
slower than from the solution with higher concentration (1.0 mg/mL). This provides a 
condition where an adsorbed protein has more time to undergo adsorption-induced 
refolding and spreading before it “bumps” into proteins adsorbed to neighboring sites, 
thus enabling each adsorbed protein molecule to occupy a larger amount of surface area 
and subsequently saturate the surface with a lower total amount of adsorbed protein.  As a 
direct result of this phenomenon, and as we observed in this study, surface saturation 
occurred with a lower amount of adsorbed protein per unit area (p < 0.05) for all SAM 
surfaces when the protein was adsorbed from the more dilute solution, with the exception 
of Alb adsorbed on the OH SAM, which exhibited similar levels of surface coverage for 
both 0.1 mg/mL and 1.0 mg/mL solution concentrations. Most importantly for our 
interests, this decrease in the amount of adsorbed protein with decreased solution 
concentration coincides with an increase in the degree of protein refolding, as shown by 
the CD results of the adsorbed protein structure in Figures 4.3 and 4.4.  This then 
provides conditions where the degree of structural change in the proteins following 
adsorption is no longer directly proportional to the amount of protein adsorbed to the 
surface, which will subsequently enable us to investigate which of these two parameters 
most strongly influences platelet adhesion behavior, as is shown in the next chapter.   
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4.4   Conclusions 
This study examined the use of CD spectropolarimetry for measuring the adsorption-
induced conformational changes in Fg and Alb as a function of surface chemistry and 
solution concentration. As an important component of these studies, we developed a 
custom-made sample-holding cuvette that was specifically designed in such a manner to 
minimize the path length of the buffer solution through which the CD beam passes while 
providing multiple surfaces with adsorbed protein.  The use of this new cuvette was 
found to substantially improve the signal-to-noise ratio for these types of measurements 
compared to our previous studies [54].   
Based on the results presented in this section, we conclude that both surface 
chemistry and the concentration of the protein solution play a significant role in 
influencing the amount of protein adsorbed to the surfaces and the degree of 
conformational change that these proteins undergo when they adsorb.  Furthermore, these 
results show that by varying both surface chemistry and solution concentration, we can 
uncouple the relationship between the amount of protein adsorbed and the degree of 
adsorption induced refolding of the protein.  We also conclude that the specific 
characteristics of the functional groups presented by a surface, and not simply their 
relative degrees of hydrophobicity, influence the amount of protein adsorbed and the 
degree of protein refolding that occurs following adsorption.   
Recent studies [54, 55, 84] have shown that the conformation of the adsorbed protein 
layer, and not just the amount of adsorbed protein, is an important determinant of cellular 
response (e.g., platelet response) to biomaterial surfaces.  CD spectropolarimetry 
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provides an excellent means to quantitatively investigate these types of interactions.  
Further studies (presented in Chapter 4) were carried out to correlate cellular response to 
both the amount of protein adsorbed and the degree of adsorption-induced structural 
changes in proteins in order to develop a more comprehensive understanding of how 
protein adsorption influences the biocompatibility of implanted biomaterials; and most 
importantly, to gain further insights into how surfaces can be engineered to control 
protein adsorption behavior and thereby direct biological response.  
 
4.5 Supporting Information 
4.5.S.1  Analysis of contribution of protein adsorbed on the cuvette in the 
determination of secondary structure of proteins in solution 
It is important to examine the contribution of protein adsorbed on the inner surfaces of 
the cuvette, if any, in the CD measurements of the solution structure of the protein. In 
order to accomplish this, we obtained the CD spectrum of phosphate buffer first (buffer 
background, in Fig. 4.S.1) in the 0.1 mm quartz cuvette. The two removable quartz slides 
which form the front and back surfaces of the cuvette were then removed and 
preadsorbed with human fibrinogen (Fg) for a duration equal to the total scanning time 
per sample (i.e., about 20 min) and then infinitely diluted with phosphate buffer to 
remove any weakly adherent protein. The cuvette was then filled with phosphate buffer 
and CD measurements were then carried out to obtain the CD spectrum of the buffer 
along with any contribution from adsorbed Fg (modified background, in Fig. 4.S.1).  
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The cuvette was then cleaned thoroughly, filled with Fg solution, and the CD spectra 
for the Fg solution were obtained as per the procedures mentioned in Section 4.2.6.1. The 
buffer and modified backgrounds were subtracted from the CD spectra for Fg solution, 
and the resultant spectra were deconvoluted and analyzed (as per Section 4.2.6.1) to 
determine the percentages of α-helix and β-sheet in native fibrinogen, which are listed in 
Table 4.S.1.  
 
 
Table 4.S.1. Structural composition of human fibrinogen in solution, as determined by 
CD spectra using different background conditions (mean ± 95% CI, n = 6). 
Background condition α-helix (%) β-sheet (%) 
Buffer background 39.3 ± 0.7 10.5 ± 0.5 
Modified background 39.4 ± 0.6 10.3 ± 0.3 
 
As shown in Table 4.S.1, there was no significant difference (p > 0.05) between the 
values of percentage α-helix and β-sheet for fibrinogen, irrespective of the background 
spectra used. The CD spectra for Fg solution obtained using either background spectrum 
overlapped, as observed in Fig. 4.S.1. Thus, we can conclude that the protein adsorbed on 
the walls of the cuvette during CD measurements of the solution structure of Fg had 
negligible contribution to the overall CD spectrum of the Fg solution. 
  
 Figure 4.S.1. CD spectra of human fibrinogen (Fg) in solution, determ
different background spectra (Average of 6 samples).
 
4.5.S.2  Ellipsometry vs. Absorbance for Measurement of Protein Surface 
Concentration 
To verify the validity of the relationship that we used for quantifying the amount of 
protein adsorbed based on the absorbance measurement at 195 nm (i.e. C
that was used in Section 4.2.6.2 (Adsorbed Protein Concentration), surface concentrations 
were confirmed by ellipsometry.  In these preliminary studies, CH
incubated in 0.1 mg/mL and 1.0 mg/mL fibrinogen and albumin bulk solutions for 2 
hours. The thicknesses of the adsorbed protein layers were  then converted to surface 
coverage (in µg/cm2) using the formula of de Feijter
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Гads =  0.1 df (nf – nb) / (dn/dc)   (4.S.1) 
 
In equation (4.S.1) above, df = film thickness (in nm), nf = refractive index of the 
adsorbed protein film ≈ 1.42 (values lie between 1.36 and 1.50), [102, 199]  nb = 
refractive index of the buffer ≈ 1.33 (measured using a refractometer), and dn/dc = 
increment of refractive index of protein solution versus protein solution concentration ≈ 
0.188 for all proteins. [199] The thickness of the protein layers (in nm) and calculated 
surface coverage for albumin and fibrinogen adsorbed on the CH3 SAM surfaces are 
shown in Table 4.S.2.  
The values for protein adsorption on the CH3 SAM calculated using de Feijter’s 
equation (Гads) are not statistically different (p > 0.05) from those obtained from 
relationship we used for quantifying the amount of protein adsorbed using circular 
dichroism (i.e. Csoln · L =  Qads), thus validating the use of the absorbance method to 
directly measure surface concentration of adsorbed protein.  
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Table 4.S.2. Thickness and adsorbed amounts of the fibrinogen (Fg) and Albumin (Alb) 
layers on a CH3 SAM, adsorbed from 0.1 mg/mL and 1.0 mg/mL bulk solutions, as 
measured by ellipsometry (Гads) and absorbance (Qads).  (n =5, mean ± 95% CI) 
Bulk protein 
concentration 
(mg/mL) 
Thickness of protein 
layer (nm) 
Protein adsorbed, 
Qads (µg/cm2) 
Protein adsorbed, 
Гads (µg/cm2) 
0.1 Fg 32.9 ± 6.0 1.69 ± 0.01 1.57 ± 0.29 
1.0 Fg 44.7 ± 5.0 2.37 ± 0.03 2.13 ± 0.23 
0.1 Alb 11.6 ± 2.0 0.54 ± 0.03 0.55 ± 0.10 
1.0 Alb 12.3 ± 1.8 0.58 ± 0.01 0.59 ± 0.09 
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CHAPTER 5 
PLATELET ADHESION AS A FUNCTION OF ADSORBED CONFORMATION 
VS. SURFACE COVERAGE OF FIBRINOGEN 
 
5.1 Introduction 
While blood contains numerous different types of proteins, any of which may adsorb 
to a biomaterial surface, fibrinogen (Fg) has been identified as one of the most important 
types of adsorbed proteins that induces a platelet adhesion response. Although the 
specific mechanisms mediating platelet adhesion to adsorbed Fg remain to be fully 
defined, it is widely cited in the biomaterials field that the amount of adsorbed Fg is one 
of the most important determinants of the biocompatibility of a given biomaterial [65-67, 
200]. Others, however, have found evidence that the conformational state of adsorbed Fg 
may actually be the more important mediator of platelet adhesion response [54, 55, 116]. 
This belief is further supported by the simple fact that non-activated platelets do not 
strongly interact with Fg when it is in its soluble, native conformation in the blood 
stream, but readily adhere and activate after contacting this same protein when Fg is 
adsorbed on a surface. This implies that adsorption induces some conformational change 
in Fg that exposes and/or creates otherwise hidden or non-active sites that are recognized 
by platelet receptors. 
One of the primary problems in differentiating between these two factors (i.e., 
amount versus conformation of Fg) is that surfaces that tend to strongly adsorb Fg, 
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leading to a large amount of protein on the surface, also tend to induce a large degree of 
conformational unfolding of the protein when it adsorbs. Although commonly coupled in 
this manner, it is very important to differentiate between these two potential mediators of 
platelet adhesion because they lead to two very different approaches for biomaterials 
design to promote blood compatibility. If the amount of adsorbed Fg mediates platelet 
adhesion, then biomaterial surfaces should be designed to minimize the amount of Fg 
adsorbed irrespective of its conformational state.  Alternatively, if platelet adhesion is 
mediated by the degree of adsorption-induced Fg unfolding, then surfaces should be 
designed to adsorb Fg in a manner that maximally retains its native-state structure 
irrespective of the amount of Fg that is adsorbed.   
To address this critical issue, we conducted a set of platelet adhesion studies that were 
specifically designed to uncouple the amount of adsorbed Fg from the degree of 
adsorption-induced Fg unfolding and thereby definitively determine which of these two 
factors is the most important mediator of platelet adhesion response. This was 
accomplished by adsorbing Fg to a broad range of surface chemistries from a wide range 
of solution concentrations to obtain a large set of systems with differing amounts and 
conformational states of adsorbed Fg. The amount of Fg adsorbed and its degree of 
adsorption-induced unfolding was then determined by absorbance and circular dichroism 
(CD) spectropolarimetry, respectively, with a lactate dehydrogenase (LDH) assay and 
scanning electron microscopy (SEM) used to assess the platelet response.  Additional 
studies were conducted using Arg-Gly-Asp-Ser (RGDS) peptides in the platelet 
suspension to block αIIbβ3 platelet integrins, to assess how adsorption-induced unfolding 
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of Fg influences the involvement of this receptor in the overall platelet adhesion 
response. 
 
5.2       Materials and methods 
5.2.1 Gold substrates 
18 mm square cover glasses (VWR Scientific, Catalog No. 48368-040) were used as 
substrates for the platelet adhesion experiments, while quartz slides (0.375” x 1.625” x 
0.0625”, Chemglass) were used for CD experiments. All substrates were cleaned at 50°C 
by immersion in a piranha solution (7:3 v/v H2SO4/H2O2) for at least 30 minutes, 
followed by a Radio Corporation of America (RCA) basic wash (1:1:5 v/v 
NH4OH/H2O2/H2O), and this procedure was repeated twice. These substrates were then 
rinsed with 200-proof ethanol (Pharmco-Aaper; Catalog No. 11100200), followed by 
nanopure water and then dried under a stream of nitrogen gas. 
The cleaned cover glasses were then coated with a 50 Å chromium adhesion layer 
followed by 1000 Å of gold, while the quartz slides for CD were coated with 30 Å of 
chromium and 100 Å of gold, via a thermal vapor deposition (TVD) evaporator (Model E 
12 E, Edwards High Vacuum Ltd.), prior to SAM formation on these substrates. The 
thicknesses of the gold and chromium layers were verified using a DekTak profilometer 
and a GES5 ellipsometer (Sopra, Inc., Palo Alto, CA).  
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5.2.2 Formation of self-assembled monolayers (SAMs) of alkanethiols 
The following alkanethiols were used for creating the SAM surfaces: 
1-Dodecanethiol (SH-(CH2)11CH3; Aldrich; CH3),  
11-(2,2,2-Trifuoroethoxy) undecane-1-thiol) SH-(CH2)11OCH2CF3; Asemblon; CF3), 
11-Amino-1-undecanethiol, hydrochloride (SH-(CH2)11NH2HCl; Prochimia; NH2), 
11-Mercaptoundecanoic acid (SH-(CH2)11COOH; Aldrich; COOH), and 
11-Mercapto-1-undecanol (SH-(CH2)11OH; Aldrich; OH).  
SAM surfaces were prepared as per the established protocols [181, 182] described 
earlier (in Section 4.3). Pure alkanethiol solutions (1.0 mM) were prepared in 100% 
ethanol (Pharmco-Aaper; Catalog No. 111000200). Prior to immersion in the alkanethiol 
solutions for 24 hours, the gold substrates were cleaned by dipping them for 1 minute 
each in a modified piranha wash (4:1 v/v H2SO4/H2O2),  followed by a Radio Corporation 
of America (RCA) basic wash (1:1:5 v/v NH4OH/H2O2/H2O), and then rinsed copiously 
with 100% ethanol. 
All SAM surfaces were cleaned to remove any traces of hydrophobic contaminants on 
their surface prior to surface characterization and protein adsorption [99]. The CH3 and 
CF3 SAMs were cleaned by sonication in ethanol, hexane and ethanol, and then rinsed 
with nanopure water. The NH2, COOH, and OH SAMs were sonicated in ethanol, and 
then incubated in a 25 mM potassium phosphate buffer containing 0.005 volume % 
Triton-X-100 (Sigma; Catalog No. T-9284), in order to block off any hydrophobic defect 
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sites (e.g. grain boundaries), and then rinsed thoroughly with acetone, ethanol and 
nanopure water to remove loosely-bound Triton. 
 
5.2.3 Contact angle measurement 
The advancing contact angle measurements on the SAM surfaces were carried out 
using a CAM 200 Optical Contact Angle/Surface Tension Meter (KSV Instruments Ltd.) 
and the CAM 200 software provided with the instrument. The cleaned SAM surfaces 
were mounted on the stage of the instrument, and the contact angles for six separate drops 
of nanopure water were measured on each surface.  
 
5.2.4 Buffers 
The protein adsorption experiments were carried out using a 25 mM potassium 
phosphate buffer (PBS, pH 7.4), which was prepared by combining appropriate amounts 
of the mono- and dibasic salts (Sigma-Aldrich) to maintain the pH at 7.4. The platelet 
suspension buffer (PSB, pH 7.4) contained 137 mM NaCl, 2.7 mM KCl, 5.5 mM 
Dextrose, 0.4 mM sodium phosphate monobasic, 10 mM HEPES and 0.1 U/mL apyrase 
[201]. 2.5 mM CaCl2 and 1.0 mM MgCl2 was added to the PSB to give a platelet 
suspension buffer with metal ions (PSB+MI). 
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5.2.5 Protein adsorption 
Human Fg (FIB3, plasminogen, von Willebrand factor and fibronectin depleted; 
Enzyme Research Laboratories, South Bend, IN) was dissolved in the 25 mM phosphate 
buffer solution (pH 7.4), to prepare the protein stock solutions, and protein adsorption 
was carried out. Briefly, protein adsorption on the SAM surfaces was carried out at three 
different protein concentrations of 0.1 mg/mL, 1.0 mg/mL, and 10.0 mg/mL, in order to 
obtain adsorbed Fg layers with a wide range of surface conformations and coverages. 
These are essential in delineating the effect of secondary structure and surface coverage 
of the adsorbed Fg layer on the SAM surfaces on platelet adhesion. 
The cleaned SAM surfaces were incubated in phosphate buffer in a six-well-plate 
(Corning Costar, Catalog No. 3506) and then a suitable amount of protein stock solution 
was added to give the desired bulk protein solution concentration, ensuring that the tip of 
the pipette was held below the air-water interface to avoid denaturation of the protein at 
this interface. The SAM surfaces were maintained fully immersed in the protein solution 
for 2 h, after which an infinite dilution step was carried out to wash away the bulk protein 
solution, in addition to any loosely adherent protein prior to removal of the SAMs from 
the buffer solution.  Following this infinite dilution step, the SAM surfaces were able to 
be safely removed from the pure buffer solution without dragging the surfaces through 
the denatured protein film that can be expected to present at the liquid-air interface if the 
protein solution had not been replaced with pure buffer prior to surface removal. 
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The SAM surfaces with preadsorbed protein were then either used for CD studies to 
analyze the structure of the adsorbed protein layer, or incubated with the platelet 
suspension. 
 
5.2.6 CD studies to quantify the adsorption-induced conformational changes and 
total surface coverage of Fg on SAM surfaces  
CD spectropolarimetry was done using a Jasco J-810 spectropolarimeter (Jasco, Inc., 
Easton, MD) to determine the native and adsorbed secondary structures of Fg, as well as 
the surface coverage of adsorbed protein, as described earlier (in Section 4.2.6). Special 
high-transparency quartz cuvettes (Starna Cells, Inc., Atascadero, CA) were used for 
determining the native solution structure, while the adsorbed structure of Fg on the SAM 
surfaces was determined using a cuvette specially custom-designed for maximizing the 
signal-to-noise ratio (see Fig. 4.1). The ellipticity of the samples (θ, in mdeg) was 
converted to molar ellipticity (designated as [θ], with standard units of deg·cm2/dmol) 
using the following equation [132, 135]:  
[θ] = (θ · M0)/(10,000 · Csoln · L)    (5.1) 
where θ is the molar ellipticity in mdeg, L is the path length of the cuvette in cm, Csoln is 
the solution concentration of the protein in g/mL, and M0 is the mean residue molecular 
weight of 118 g/mol. 
Since proteins exhibit an absorbance peak at 195 nm [184], we used the height of this 
absorbance peak (A195) for constructing a calibration curve of A195 vs. Csoln for various 
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known concentrations of Fg, as described in Section 4.2.6. The slope of this plot is 
“εprotein·L” from Beer’s Law, which can be written as: 
A195 = εprotein · Csoln · L          (5.2) 
where εprotein is the extinction coefficient of the protein  in mL · g-1 · cm-1 (or cm2/g) and L 
is the path length of the cuvette.  
The term “Csoln · L” in eq. 5.2 (above) has units of g/cm2, which is equivalent to the 
amount of protein adsorbed per unit area. Assuming that the absorbance is dependent on 
the total amount of protein present per unit area through which the beam of light passes, 
irrespective of whether the protein is in the solution or the adsorbed state, the calibration 
curve of A195 vs. Csoln can also be used for calculating the amount of Fg adsorbed per unit 
area on the SAMs (i.e., Qads). The validity of this method for measuring the surface 
coverage of adsorbed protein has been confirmed by independent measurement of Qads 
from the thickness of the adsorbed protein film obtained by ellipsometry (see Section 
4.S.2) using de Feijter’s formula [198]. 
Hence, while calculating the molar ellipticity for the adsorbed Fg layer on the SAMs, 
the term “Csoln · L” in eq. 5.1 can be replaced by the term Qads to give the following 
equation: 
[θ] = (θ · M0)/(10,000 · Qads),           (5.3) 
The CD spectra (molar ellipticity vs. wavelength) thus obtained were deconvoluted 
using the SP-22X algorithm and analyzed using the SELCON and CONTIN/LL software 
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packages to quantify the percentage of α-helix and β-sheet content of the native/adsorbed 
protein [148]. 
 
5.2.7 Platelet adhesion 
All protocols pertaining to the use of whole blood and platelets were approved by the 
IRB (Institutional Review Board) and IBC (Institutional Biosafety Committee) at 
Clemson University. The blood (25 mL) was collected via venipuncture from healthy, 
aspirin-free human volunteers at the Redfern Health Center at Clemson University in BD 
Vacutainer tubes (Catalog No. 364606, Becton-Dickinson, Franklin Lakes, NJ) 
containing an acid-citrated dextrose (ACD) anticoagulant. It is important to note that the 
first few mL of blood was discarded, as it is rich in clotting factors, and then the 
remaining 25 mL was collected. 
Platelet rich plasma (PRP) was generated by centrifuging the ACD-anticoagulated 
blood (225 g, 15 min, 25°C) using a Beckman Coulter Allegra 6R centrifuge (Beckman 
Coulter, Fullerton, CA) . Platelets were separated from the PRP via a gel separation 
method [201]. A liquid chromatography column (Sigma-Aldrich, Catalog No. C4169) 
was filled Sepharose 2B (Sigma, Catalog No. 2B-300) and the column was allowed to 
equilibrate with PSB.  The PRP was then carefully pipetted onto the column and then 
allowed to pass into the column. PSB was added to top of the column from a reservoir, 
while the setup was kept running. Fractions were collected from the outlet of the column, 
with the platelet-rich fractions being identified by their increased turbidity. The platelet-
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rich fractions that had maximum turbidity were pooled, and then the platelet 
concentration was measured using a Beckman Coulter Z2 Coulter Particle Count and Size 
Analyzer (Beckman Coulter, Fullerton, CA). The platelet concentration was adjusted to 
108 platelets/mL with PSB, and CaCl2 and MgCl2 were added to yield 2.5 mM and 1.0 
mM final concentrations of these salts in the platelet suspension, respectively. The 
platelet suspension was allowed to rest for 30 min at 37°C, and then added to the protein-
coated SAM surfaces and allowed to adhere for 1 h at 37°C.  
At the end of the platelet adhesion step, the suspension was aspirated from each well, 
and the non-adherent platelets were rinsed away by filling and aspirating the wells five 
times with PBS. The samples were then removed to a fresh well-plate and the platelet 
adhesion levels were quantified using a lactate dehydrogenase (LDH) assay, while the 
morphology of the adherent platelets was visualized using scanning electron microscopy 
(SEM).  
A control platelet adhesion study was also performed with the PSB being 
supplemented with 4 mg/mL bovine serum albumin (BSA; Sigma-Aldrich), which is 
conventionally used as a blocking agent for non-specific interactions, in order to examine 
its effect on the adhesion of the washed platelets to the adsorbed Fg on the SAM surfaces.  
The results from this study showed that the addition of BSA had no significant effect on 
platelet adhesion (see Figure 5.S.1 of the Supporting Information, Section 5.6, provided 
after the conclusions section of this chapter). 
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5.2.8 SDS-PAGE analysis of platelet suspension 
It is essential to ensure that the platelet suspension was free of any plasma proteins, 
which may have been retained in the platelet suspension from blood plasma or released 
from the platelets due to platelet activation during the separation process. The platelet 
suspensions obtained from two separate gel separation runs were centrifuged at 1200 
rpm, 1500 rpm, and 1800 rpm, and the supernatant was aspirated and analyzed via 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) for any traces of 
residual plasma proteins. Silver staining was done using a Silver SNAP Stain Kit II 
(Pierce, Rockford, IL), which provides a rapid and highly sensitive detection system for 
sub-nanogram levels of proteins in polyacrylamide gels. 
 
5.2.9 Measurement of platelet adhesion using lactate dehydrogenase (LDH) assay 
Platelet adhesion was quantified by measuring the lactate dehydrogenase (LDH) 
released when the adherent platelets were lysed with a Triton-PSB buffer (2 % v/v 
Triton-X-100 in PSB), using a CytoTox96® Non-Radioactive Cytotoxicity Assay 
(Promega Corporation, Madison, WI). This is a modification of the methods used 
previously [202, 203]. A calibration curve was constructed using a known number of 
platelets, counted using a Beckman Coulter Z2 Coulter Particle Count and Size Analyzer 
(Beckman Coulter, Fullerton, CA), and the platelet adhesion on the SAM surfaces was 
determined from this calibration curve. 
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5.2.10 Scanning electron microscopy (SEM) 
The samples for SEM were fixed for 30 min at room temperature using a special 
fixing buffer (3% glutaraldehyde, 0.1 M sodium cacodylate, pH 7.4), after which they 
were  rinsed with PBS thrice. To dehydrate the adherent platelets, the samples were 
incubating in ascending ethanol:water mixtures (50%, 60%, 70%, 80%, 90% and 99% 
ethanol) for 10 min. The samples were finally treated with 0.02 mL of 
hexamethyldisilazane (Sigma) and allowed to dry overnight.  The morphology of the 
adherent platelets was examined using a FESEM-Hitachi S4800 scanning electron 
microscope (Electron Microscopy Facility, Advanced Materials Research Laboratory, 
Clemson University, Pendleton, SC). 
 
5.2.11 Inhibition of platelet-protein interactions using Arg-Gly-Asp (RGD)-containing 
peptides 
In order to inhibit interactions between RGD-binding platelet receptors and Fg, the 
platelet suspension was incubated for 30 min at room temperature with 300 µM of an 
Arg-Gly-Asp-Ser (RGDS) peptide (Calbiochem, La Jolla, CA), which has been shown to 
be sufficient to inhibit platelet aggregation [107].  These platelets were then allowed to 
adhere on the CH3 and OH SAMs preadsorbed with 0.1 mg/mL protein solution, after 
which the platelet adhesion was quantified using an LDH assay and the morphology of 
the adherent platelets was examined using SEM. 
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As a control, platelets incubated with 300 µM of an Arg-Gly-Glu-Ser (RGES) peptide 
(American Peptide Company, Sunnyvale, CA) were allowed to adhere on the SAM 
surfaces preadsorbed with Fg, and the adhesion characteristics were analyzed. 
 
5.2.12 Study using polyclonal antibodies against Fg and Alb 
Polyclonal antibodies against human Fg and Alb (Anti-Fg/Alb Rabbit pAb; 
Calbiochem, La Jolla, CA) at a concentration of 4 µg/mL were incubated for 30 min at 
room temperature, on the Fg coated surfaces in order to examine the role of any non-
specific platelet binding to the adsorbed Fg layer. Platelet adhesion was characterized 
using an LDH assay. 
 
5.2.13 Statistical analysis 
The results we present are the mean values with 95% confidence intervals (CI). 
Statistical significance of differences between mean values for different samples and 
conditions was evaluated using a Student’s t-test, with p ≤ 0.05 considered as statistically 
significant. 
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5.3      Results and Discussion 
5.3.1 Amount of Fg adsorbed on SAM surfaces 
The amount of Fg adsorbed on alkanethiol self-assembled monolayer (SAM) surfaces 
on gold functionalized with OH, COOH, NH2, CF3, and CH3 function groups under 
solution concentration conditions of 0.1, 1.0, and 10 mg/mL of Fg was measured 
spectroscopically by absorbance at 195 nm (as described in Section 4.2.6.1).  The results 
presented in Figure 5.1 show that the amount of Fg generally increased with increased 
surface hydrophobicity (see Table 5.1), and indicate that the amount of Fg adsorbed was 
dependent on the solution concentration from which it was adsorbed, with significantly 
greater amounts of Fg being adsorbed on a given SAM surface for each increasingly 
higher solution concentration. This can be explained by the fact that at a high solution 
concentration, the rate of diffusion of protein molecules to the surface is higher than that 
from a more dilute solution [31], and has been shown to be independent of the surface 
chemistry by Wertz et al. [34]. Therefore, an adsorbed protein molecule has less time to 
unfold and spread out over the surface before other protein molecules adsorb next to it, 
blocking further spreading on the surface [31, 39], leading to higher surface coverages of 
adsorbed Fg.   
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Table 5.1. Contact angle data for the SAM surfaces. (mean ± 95% CI, n =7). 
 OH COOH NH2 CF3 CH3 
Contact 
Angle (°) 17.6 ± 1.9 17.9 ± 1.3 47.6 ± 1.8 90.2 ± 0.8 100.9 ± 1.9 
 
The minimum amount of Fg adsorbed under any our conditions was 0.8 µg/cm2, as 
shown in Figure 5.1. Given that the Fg molecule has dimensions of about 5.0 x 5.0 x 47.0 
nm3 [50], which yields a theoretical surface coverage at saturation between 0.24 µg/cm2 
and 2.26 µg/cm2 for side-on versus end-on adsorption [34], respectively, the amounts of 
Fg adsorbed on the SAM surfaces from each bulk solution condition clearly show that 
our surfaces were saturated with the adsorbed protein. The values of surface coverage 
obtained for preadsorption with 0.1 and 1.0 mg/mL Fg lie between the theoretical 
maxima for side-on and end-on adsorption of Fg, suggesting a tight monolayer coverage. 
Adsorption from the 10.0 mg/mL Fg solution concentration led to surface coverage 
values well beyond the theoretical maximum for monolayer coverage of Fg, indicating 
multilayer adsorption.  
We expect the Fg molecules to adsorb on the SAMs in a wide range of orientations, 
which would play a role in the platelet adhesion response. Unfortunately, CD 
spectropolarimetry does not provide information on the orientation of the adsorbed Fg 
layer. Overall, our results indicate that the Fg molecules preadsorbed from 0.1 mg/mL 
and 1.0 mg/mL bulk solution concentrations are arranged in a mixture of side-on and 
end-on orientations, since the surface coverage lies between the theoretical maxima for 
 these two orientations. A recent study of Fg adsorption showed that the majority of Fg 
molecules are adsorbed end
concentrations greater than 0.2 mg/mL 
concentration for preadsorption increases, the fraction of Fg molecules adsorbed in an 
end-on orientation will increase, thereby increasing the surface coverage at higher Fg 
solution concentrations. 
 
Figure 5.1. Fg adsorption from bulk solutions of 0.1 mg/mL, 1.0 mg/mL and 10.0 
mg/mL on SAM surfaces functionalized with OH, COOH, NH
groups (n=6, mean ± 95% CI).
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5.3.2 Conformation of adsorbed Fg on SAM surfaces 
The secondary structural composition (percentage α-helix and β-sheet content) of Fg 
adsorbed on the SAM surfaces, which was determined by adsorbed-state CD 
spectropolarimetry is presented in Figure 5.2, with the native/solution structure included 
for comparison. As shown, the combined variation of surface chemistry and protein 
solution concentration provided a wide range of average conformational states of the 
adsorbed Fg on the SAM surfaces. As the surfaces became more hydrophobic (see Table 
5.1), Fg underwent a higher degree of adsorption-induced conformational change (i.e., 
loss of α-helix, accompanied by increase in β-sheet), which is consistent with 
observations made by other groups [33, 35]. This effect can be understood based on the 
increasingly strong thermodynamic driving force to induce protein unfolding on a surface 
to reduce the overall solvent accessible surface area of the system as a surface becomes 
increasingly hydrophobic. Similarly, the degree of adsorption-induced loss of α-helix was 
more prominent when the protein was absorbed from lower solution concentrations. This 
effect is particularly evident when Fg was adsorbed from the 10.0 mg/mL Fg solutions 
(Figure 5.2C), in which case the Fg adsorbed so rapidly that it had little time to unfold 
before the surface became saturated, resulting in minimal conformational changes such 
that the secondary structure of the adsorbed protein was much closer to the native 
solution structure of Fg.  
 
 100
 
 
 
Figure 5.2.  Changes in secondary structure of adsorbed human fibrinogen (Fg) adsorbed at (A) 0.1 mg/mL, (B) 1.0 mg/mL, 
and (C) 10.0 mg/mL on SAM surfaces determined by CD compared to its native conformation. (n=6, mean ± 95% CI). * 
denotes not significant, all other values are significantly different from one another; 
 
p < 0.05. 
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As with the amount of Fg adsorbed, this concentration effect can be understood to be 
due to the relationship between the kinetics of transport of the protein to the surface by 
diffusion compared to its rate of unfolding on the surface after it adsorbs. At lower 
protein solution concentrations, the transport of protein molecules to the surface has been 
shown to be much slower [34], thus providing adsorbed protein molecules with more 
time to unfold and spread out on the surface before they come in contact with 
neighboring adsorbed protein molecules, which inhibits further spreading [31, 39].  
Although it would be ideal to know the full structural composition of the adsorbed 
protein layers in each of these cases, this information cannot be obtained using CD 
studies. Results obtained via CD represent the single average secondary structural content 
of the adsorbed Fg, and CD studies cannot distinguish between discrete sub-populations 
of states and a uniform distribution of a single population. Hence, we cannot rule out the 
possibility that the multilayer observed for preadsorption with 10.0 mg/mL Fg solution 
may be composed of more than one population, with varying degrees of unfolding.  
 
5.3.3 Platelet adhesion to adsorbed Fg on SAM surfaces 
Prior to conducting platelet adhesion experiments, SDS-PAGE analysis was carried 
out to test for traces of residual proteins in the platelet suspension which may either have 
entered the platelet suspension from the platelet-rich plasma (PRP) or released due to 
platelet activation during the separation process from whole blood. These could 
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complicate our study by potentially displacing the preadsorbed Fg through Vroman 
effects [39, 204].  
 
 
Figure 5.3. SDS-PAGE results for analysis of residual protein content in supernatant of 
platelet suspension. (Lanes 1, 6, 10: Blank, Lane 2: Protein ladder, Lanes 3 & 7: Platelet 
suspension centrifuged at 1200 rpm, Lanes 4 & 8:  Platelet suspension centrifuged at 
1500 rpm, Lanes 5 & 9: Platelet suspension centrifuged at 1800 rpm).  Staining was done 
using a SilverSNAP® Stain Kit II. 
 
The platelet suspension obtained from two different gel chromatographic separation 
processes was centrifuged at three different speeds and then examined for traces of 
residual plasma proteins via SDS-PAGE analysis. The SilverSNAP® Stain Kit II used for 
staining is highly sensitive and can detect sub-nanogram levels of proteins. As seen in 
Figure 5.3, only the platelet suspension sample centrifuged at 1800 rpm showed traces of 
 plasma proteins, suggesting that platelet lysis occurred at this high speed, releasing 
intracellular proteins into the supernatant. This suggests that 
in the platelet suspension were below detectable limits, thus providing confidence that the 
measured platelet adhesion response was directly mediated by the preadsorbed
Fg. 
Figure 5.4. Platelet adhesion on SAM surfaces preadsorbed with Fg, assessed by LDH 
assay (n=6, mean ± 95% CI).  * denotes no statistically significant difference, 
 
Figure 5.4 shows the platelet adhesion levels to preadsorbed Fg on each of the five 
SAM surfaces at each of the three different Fg solution concentrations. 
adhesion value represents the mean of a set of six independent measurements (n = 6), 
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with each measurement being conducted using a different blood sample. As is clearly 
evident, the platelet adhesion levels observed were strongly influenced by both the 
surface chemistry as well as the solution concentration from which the protein was 
adsorbed. The platelet adhesion response increased with increasing surface 
hydrophobicity for each solution concentration and decreased with increased solution 
concentration for each surface chemistry, except for the OH SAM surface, where solution 
concentration did not significantly influence the platelet adhesion response.  
To investigate whether platelet adhesion was more strongly mediated by the amount of 
adsorbed Fg or the conformation of adsorbed Fg, the data presented in Figures 5.1, 5.2 
and 5.4 were re-plotted to show the platelet adhesion response versus the amount of 
adsorbed Fg (Figure 5.5A) and versus the degree of adsorption-induced Fg unfolding as 
represented by the percent loss in α-helix content of the protein (Figure 5.5B). As shown 
in Figure 5.5A, platelet adhesion appears to correlate fairly strongly with the amount of 
Fg adsorbed when the protein is adsorbed from a given solution concentration.  However, 
when the universal data set is considered, the correlation between platelet adhesion and 
the amount of adsorbed Fg is essentially zero (r2 = 0.04). In distinct contrast to this, the 
platelet adhesion response correlates very strongly with the adsorption-induced loss in α-
helix (r2 = 0.96), as seen in Figure 5.5B, when the results for all surfaces and Fg solution 
conditions are combined. These results strongly indicate that under these experimental 
conditions platelet adhesion is actually not in response to the amount of Fg adsorbed, but 
rather it is controlled by the conformational state of the protein on the surface, and 
provide an explanation for why many previous studies have reported results that imply 
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that platelet adhesion is in response to the amount of adsorbed Fg. Referring to the data 
presented in Figure 5.5A, platelet response does correlate with the amount of adsorbed Fg 
for a given solution concentration. However, close evaluation for each of the three 
individual data sets shown in Figure 5.5A for each solution concentration in comparison 
with Figure 5.5B reveals that within a given solution concentration, the change in the 
conformation of the adsorbed protein also tracks very closely with the adsorbed amount 
of Fg.  It is only when the results are presented as a universal data set combining the 
results from each different solution concentration that these two effects are clearly 
separated, which then reveals that platelet adhesion is actually responding to the change 
in adsorbed structure of the Fg with little influence from the amount of Fg adsorbed.  
This situation is particularly demonstrated by comparing the platelet response to the 
COOH and OH SAMs with Fg preadsorbed from the 10.0 mg/mL Fg solution in 
comparison to the platelet response to the CH3 SAM with Fg preadsorbed from the 1.0 
mg/mL Fg solution (see associated data points in Fig. 5.5A).  In each of these cases, the 
amount of adsorbed Fg was nearly the same while the degree of change in conformation 
of the adsorbed Fg on the CH3 SAM was much greater than on either the COOH or the 
OH SAMs (see associated data points in Fig. 5.5B).  If platelet adhesion was primarily 
governed by the amount of adsorbed Fg, then the platelet response would be expected to 
be nearly the same for each of these conditions.  However, the platelet response on the 
CH3 SAM (with the much greater degree of structural change in the adsorbed Fg) is 
nearly four times greater than on the COOH and OH SAMs.  This clearly illustrates that 
the platelets are responding to something other than simply the amount of Fg adsorbed on 
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the surface.  The strong correlation shown in Fig. 5.5B indicates that the degree of 
structural unfolding of the adsorbed Fg is the much greater determinant of the platelet 
response than the amount of Fg adsorbed.     
Additionally, it is also important to keep in mind that this study was focused on 
comparing the role of the conformation verses the amount of adsorbed Fg in mediating 
the platelet response. Other factors, such as the orientation, packing arrangement, and 
structural heterogeneity of the adsorbed Fg layer can be expected to also influence the 
overall bioactive state of the adsorbed layer of protein, and in turn the platelet adhesion 
response.  However, the results from these present studies indicate that these other 
variables, which were not controlled or measured in this study, do not obscure the effect 
of the adsorbed conformation of Fg on platelet adhesion, as indicated by the strong 
correlation between these two factors as shown in Fig. 5.5B.  
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Figure 5.5. Platelet adhesion to Fg adsorbed on SAM surfaces as a function of (A) the amount of adsorbed Fg, and (B) the loss 
of α-helix. (Each point represents the mean of six values for each SAM surface.) 
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5.3.4 The role of RGD-specific receptors in mediating platelet adhesion to adsorbed 
Fg 
Previous studies have shown that αIIbβ3 platelet integrins are involved in platelet 
adhesion to adsorbed Fg, with this receptor being effectively blocked by Arg-Gly-Asp-
Ser (RGDS) peptide [107, 108]. In order to probe the extent of the involvement of this 
platelet receptor as a mediator of the platelet adhesion response as a function of the 
degree of adsorption-induced Fg unfolding, we conducted additional studies for Fg 
adsorbed from the most dilute solution concentration (0.1 mg/mL) on the two SAM 
surfaces representing the extremes in hydrophobicity (OH and CH3 SAMs).  The platelet 
suspensions were treated with an RGDS peptide (300 µM solution concentration) prior to 
exposure to the SAM surfaces preadsorbed with Fg to determine the extent that platelet 
adhesion is mediated by RGD-specific receptors (e.g., αIIbβ3 and αVβ3 platelet integrins) 
[173], with an Arg-Gly-Glu-Ser (RGES) peptide used as a non-bioactive control.  The 
results of these studies are shown in Figure 5.6. 
As presented in Figure 5.6, treatment of the platelets with the RGDS peptide resulted 
in a substantial decrease in platelet binding to adsorbed Fg on both of the SAM surfaces, 
while the RGES peptide had no significant effect (p > 0.05) on platelet adhesion to Fg for 
either surface. RGDS-treatment of the platelets led to a similar extent of inhibition of 
platelet adhesion to adsorbed Fg on both the CH3 and OH SAMs (58.3% on CH3, 45.7% 
on OH SAM) compared to the normal (unblocked) platelet control. These results indicate 
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that RGD-specific platelet receptors play a key role in mediating the interactions with 
adsorbed proteins, but only account for about half of the total platelet adhesion response.  
This not surprising, considering the fact that the RGDS peptide has been shown to be 
a partial inhibitor of platelet-Fg interactions in a previous study [107], leading to a 
hypothesis that RGDS-bound platelet receptors can still interact with Fg but with lower 
affinity compared to their unbound state. Additionally, RGDS peptides have been shown 
to ‘activate’ the GPIIb/IIIa platelet receptors [155], and a recent study indicated that 
RGDS-treatment of washed platelets led to powerful activation of the α2β1 platelet 
integrin without overall platelet activation [158]. This suggests that the role of GPIIb/IIIa 
in its RGDS-bound low-affinity state, as well as other platelet receptors cannot be ruled 
out in mediating the adhesion to RGDS-treated platelets to adsorbed Fg.  
The fact that the RGDS peptide was unable to completely inhibit platelet interactions 
with adsorbed Fg suggests that the remaining level of platelet adhesion was either due to 
(i) non-specific platelet adhesion to exposed areas of the SAM surfaces and/or (ii) a 
specific receptor mediated process by non-RGD-specific platelet receptors to the 
adsorbed Fg.   
 Figure 5.6. Platelet adhesion on OH
0.1 mg/mL solutions under various blocking treatments. The blocking treatments 
included RGDS and RGES peptides and polyclonal antibo
(pAb - Fg) and human albu
significant difference, p > 0.05.
 
To address this issue, we treated the adsorbed Fg with polyclonal antibodies against 
Fg (pAb-Fg), with polyclonal antibodies against Alb (pAb
seen in Figure 5.6, the pAb
entirely, while the pAb-Alb had no significant effect on platelet adhesion. These results 
thus clearly indicate that the adhesion of RGDS
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due to a non-specific platelet adhesion mechanism, but rather suggests that nearly 50% of 
the platelet adhesion response on both SAM surface may be mediated by non-RGD-
specific platelet receptors. Alternatively, these data may also indicate that RGDS is only 
a partial inhibitor of the GPIIb/IIIa receptor, with this receptor still able to competitively 
bind to adsorbed Fg even in the presence of RGDS peptide.  Future studies are planned to 
elucidate what these non-RGD-specific receptors may be and what the motifs are that 
they are binding to in the adsorbed, unfolded Fg.  One method to investigate whether this 
behavior is due to a competitive binding mechanism would be to investigate the effect of 
RGDS solution concentration on the degree of inhibition of platelet binding.   
 
5.3.5 SEM analysis of platelet adhesion to adsorbed Fg  
Scanning electron microscopy (SEM) was carried out to assess the morphology of the 
adherent platelets to Fg on the CH3 and OH SAMs, as well as to analyze the effect of 
platelet-receptor blocking with RGDS-peptides on the adherent platelet morphology.  
The platelets adherent to both the CH3 SAM (Figure 5.7A) and the OH SAM (Figure 
5.7C) preadsorbed with 0.1 mg/mL Fg were considerably spread, with the expression of 
extensive filopodia (thus showing that our platelets were sensitive to activating surface 
conditions), with the primary difference between these two surfaces only being the 
number of adherent platelets per unit area as opposed to their morphology.  In distinct 
contrast to this, the RGDS-treated platelets adherent to Fg adsorbed on both the CH3 
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SAM surface (Figure 5.7B) and the OH SAM surface (Figure 5.7D) did not exhibit any 
filopodial extensions and were only moderately spread with prominent granulomeres.  
 
 
Figure 5.7. Platelet adhesion to the CH3 (top row) and OH SAMs (bottom row) 
preadsorbed with 0.1 mg/mL Fg, under different blocking conditions: (A,C) unblocked 
Fg, (B,D) platelets treated with RGDS. 
 
The difference in morphology of the RGDS-treated platelets compared to untreated 
platelets also strongly suggests that there may be at least two distinct set of receptors 
associated with platelet adhesion to adsorbed Fg. The RGD-specific receptor set is shown 
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to mediate adhesion along with a high degree of activation (i.e., spreading, accompanied 
by extension of filopodia), while the non-RGD-specific receptor set mediates platelet 
adhesion with minimal activation (i.e., minimal spreading, with no expression of 
filopodia).  Alternatively, the decrease in the degree in platelet activation with RGDS in 
solution may indicate that platelet response is related to the number of receptors per unit 
area of the platelet that are activated upon binding, with the partial inhibition of platelet 
receptors leading to a decrease in the severity of platelet activation. 
 
 
5.4 Conclusions 
The results from these studies indicate that the platelet response correlates strongly 
with the adsorption-induced conformational changes in Fg, as measured by the loss of α-
helix. Adsorption-induced conformational changes apparently lead to the exposure and/or 
creation of platelet binding motifs in Fg that are otherwise not accessible to platelet 
receptors in the native/solution state of this protein. The facts that the RGDS peptides 
only partially inhibited platelet adhesion to adsorbed Fg while pAb vs. Fg nearly totally 
blocked platelet adhesion suggests that either non-RGD-binding platelet receptor(s) are 
also substantially involved in mediating platelet adhesion to adsorbed Fg or that RGDS 
only serves as to partially block RGD-binding receptors, with these receptors then being 
still able to bind to sites in the adsorbed Fg in a competitive manner. Further studies are 
planned to elucidate the specific platelet receptors and their recognition sites in Fg that 
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mediate platelet adhesion responses to adsorbed Fg as a function of adsorption-induced 
unfolding. 
These results call for a re-evaluation in the biomaterials field of our understanding of 
how Fg adsorption influences platelet response and our approach to design surfaces for 
improved hemocompatibility. Based on these results, studies that use adsorbed Fg as a 
measure of blood compatibility of biomaterials surfaces should be based on the ability of 
surfaces to maximally retain the native state of adsorbed Fg as opposed to focusing 
merely on the amount of Fg that is adsorbed. While the determination of adsorbed 
conformation of a protein is more difficult to assess than the adsorbed amount, this factor 
should correlate much more strongly with platelet response, and thus serve as a much 
more sensitive indicator of the tendency of a surface to resist a platelet-induced 
thrombotic response.  
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5.5 Supporting information  
5.5.S.1  Effect of BSA on the adhesion of washed platelets to adsorbed Fg 
In most platelet adhesion studies reported in the literature, the platelet suspension 
buffer generally contains 4 mg/mL BSA [201], which functions as an agent for blocking 
non-specific platelet adhesion interactions to exposed areas of the surface. Platelet 
adhesion to Fg preadsorbed on the CH3 and OH SAMs from 0.1 mg/mL Fg bulk solutions 
was carried using a platelet suspension supplemented with 4 mg/mL BSA. The addition 
of BSA had no significant effect (p > 0.05) on the platelet adhesion levels, which concurs 
with our results using polyclonal antibodies (Figure 5.6), confirming that the contribution 
of non-specific interactions in platelet adhesion to adsorbed Fg was minimal. 
 
Figure 5.S.1. Adhesion of platelet suspensions supplemented with 4 mg/mL BSA (grey 
bars) and without 4 mg/mL BSA (white bars) to CH3 and OH SAMs preadsorbed with 
0.1 mg/mL Fg, assessed by LDH assay (n=6, mean ± 95% CI).  * denotes no statistically 
significant difference, p > 0.05. 
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CHAPTER 6 
RECEPTOR-MEDIATED RECOGNITION OF BINDING SITES EXPOSED BY 
ADSORPTION-INDUCED UNFOLDING UNDERLIES PLATELET ADHESION 
TO ADSORBED ALBUMIN 
 
6.1      Introduction 
Human albumin (Alb), with a plasma concentration of 40 mg/mL [77], is the most 
abundant protein in blood. Its high concentration, combined with a moderately low 
molecular weight (68.3 kDa) [78] causes it to be one of the first proteins to adsorb on the 
surface of implanted biomaterials [79]. Since Alb lacks any known amino acid sequences 
for binding platelet receptors, this protein has been considered to be unable to support 
platelet adhesion and hence is widely used for blocking non-specific platelet-surface 
interactions in platelet adhesion studies [80] as well as for a hemocompatible coating for 
biomaterial surfaces [81, 82]. In cases where platelet adhesion has been observed to occur 
on Alb-coated surfaces, it has generally been attributed to some non-specific process 
[80], such as the interaction between the platelets and exposed surface area of the 
substrate, as opposed to actually representing an interaction with Alb itself.  
Two recent studies, however, have suggested that platelets may actually have specific 
mechanisms to adhere to adsorbed Alb [54, 84], and that these mechanisms may be 
linked to the conformational state of the protein [54]. Unfortunately, these studies did not 
rule out the possibility that these responses may have been due to platelet interactions 
with some other residual protein in the system, thus leaving this question still open to 
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debate. To clarify this issue, we conducted studies to definitively determine whether non-
activated platelets can adhere to adsorbed Alb; and if so, whether the adhesion response 
is due to receptor-mediated processes that can be directly correlated with the degree of 
adsorption-induced unfolding of the protein, which we measured by adsorbed-state 
circular dichroism (CD) spectropolarimetry. 
CD spectropolarimetry was first used by McMillin et al. [128] to examine the 
adsorbed conformation of fibrinogen and factor XII on quartz substrates. Subsequent CD 
studies by Norde and Favier [205] showed that proteins tend to undergo a loss in α-
helical content upon adsorption, with this effect being diminished with increasing protein 
solution concentration, which translated to higher protein surface coverage. As seen in 
Chapter 3, our investigations into the role of surface chemistry and protein solution 
concentration on the adsorbed conformation of fibrinogen (Fg) and Alb, showed that both 
these proteins underwent a greater degree of unfolding with increasing surface 
hydrophobicity and decreasing solution concentration, which is in agreement with the 
results obtained by Norde and Favier, as well other groups via grazing-angle infrared 
spectroscopy [33] and total internal reflectance fluorescence (TIRF) [34]. These studies 
have thus demonstrated that CD spectropolarimetry is a powerful technique for 
examining post-adsorptive conformational changes in proteins on biomaterial surfaces.  
The role of the adsorbed conformation of the protein in mediating platelet interactions 
has come into prominence relatively recently [54, 55, 121], whereas previously the 
amount of adsorbed protein has generally been considered to be the primary determinant 
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of the hemocompatibility of biomaterials [65, 67]. Tanaka et al. [55] indicated that 
although poly(2-methoxyethylacrylate) (PMEA) and poly(2-hydroxyethylmethacrylate) 
(PHEMA) adsorbed similar amounts of Fg, the PHEMA surface exhibited higher platelet 
adhesion compared to PMEA, which was believed to be due to a higher degree of 
conformational change in the adsorbed Fg (as measured by the loss in α-helix using CD) 
on PHEMA. In support of the findings by Tanaka et al., a recent study by Hylton et al. 
[54] also showed a strong correlation between platelet adhesion and the adsorption-
induced loss in percentage α-helix in adsorbed proteins, providing further evidence that 
conformation is a critical determinant of the ability of an adsorbed protein layer to 
mediate platelet adhesion. The fact that non-activated platelets do not become activated 
when they interact with proteins in their native state in the bloodstream, but readily bind 
and become activated when they interact with adsorbed proteins such as fibrinogen, 
vitronectin, and fibronectin [103], also strongly suggests that the adsorption process 
causes structural changes in the protein leading to the exposure, or possibly even the 
formation of platelet-binding sites which would otherwise have remained in a non-active 
form in their native state.  
In order to further investigate the role of adsorption-induced conformational changes 
in mediating platelet adhesion and whether Alb itself can support platelet adhesion by 
specific mechanisms, we established test conditions to provide a broad range of 
conformational states of adsorbed Alb following which platelet adhesion studies were 
carried out, including the use of several different blocking agents to verify whether or not 
the platelet responses were indeed being mediated by specific interactions with the 
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adsorbed Alb. A broad range of conformational states of the adsorbed protein was 
obtained by using (i) a wide range of surface chemistries and (ii) varying the Alb solution 
concentrations to influence the degree of adsorption-induced protein unfolding. For our 
surfaces, we used alkanethiol self-assembled monolayers (SAMs) on gold-coated 
substrates functionalized with OH, COOH, NH2, OCH2CF3, and CH3 head-groups to 
provide a broad range of surface hydrophobicity. These types of surfaces have been 
widely used in previous studies dealing with both plasma protein adsorption [51, 94, 95] 
and platelet adhesion [84, 97]. Alb was adsorbed to each of these surfaces from three 
different solution concentrations (0.1, 1.0, and 10 mg/mL) to vary the rate of protein 
adsorption, following which the conformation of the adsorbed Alb was assessed by 
adsorbed-state CD spectropolarimetry. Platelet adhesion studies were then conducted and 
correlated with the degree of adsorption induce Alb unfolding, with the platelet adhesion 
response assessed by a lactate dehydrogenase (LDH) assay and scanning electron 
spectroscopy (SEM). Platelet blocking studies were performed using a set of antibody, 
soluble peptide, and protein side-chain modification studies.  
 
6.2       Materials and Methods 
6.2.1 Gold substrates 
Quartz slides (0.375” x 1.625” x 0.0625”, Chemglass) were used for CD experiments, 
while 18 mm square cover glasses (VWR Scientific, Catalog No. 48368-040) were used 
as substrates for the platelet adhesion experiments. These substrates were cleaned as 
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previously described in Chapter 3, prior to the deposition of chromium and gold films via 
thermal vapor deposition. Briefly, the substrates were immersed in a piranha solution (7:3 
v/v H2SO4:H2O2) at 50°C for 30 min, followed by an RCA basic wash (1:1:5 v/v 
NH4OH:H2O2:H2O), and this cleaning procedure was repeated twice. The cleaned 
substrates were then rinsed copiously with 100% ethanol (Pharmco-Aaper; Catalog No. 
111000200) and nanopure water, and finally dried using a stream of nitrogen gas.   
The cleaned cover glasses were coated with a 50 Å chromium adhesion layer and 1000 
Å of gold, while the quartz slides for CD were coated with 30 Å of chromium and 100 Å 
of gold. The thicknesses of the gold and chromium layers were verified using a DekTak 
profilometer and a GES5 ellipsometry (Sopra, Inc., Palo Alto, CA).  
 
6.2.2 Formation of self-assembled monolayers (SAMs) of alkanethiols 
The following alkanethiols were prepared in 100% ethanol, and used for creating the 
SAM surfaces, as described previously in Chapters 4 and 5: 
1-Dodecanethiol (SH-(CH2)11CH3; Aldrich; CH3),  
11-(2,2,2-Trifuoroethoxy) undecane-1-thiol (SH-(CH2)11OCH2CF3; Asemblon; CF3) 
11-Amino-1-undecanethiol, hydrochloride (SH-(CH2)11NH2HCl; Prochimia; NH2) 
11-Mercaptoundecanoic acid (SH-(CH2)11COOH; Aldrich; COOH), and 
11-Mercapto-1-undecanol (SH-(CH2)11OH; Aldrich; OH). 
The gold-coated substrates were cleaned by dipping them in a modified piranha wash 
(4:1 v/v H2SO4:H2O2), followed by an RCA basic wash, for 1 minute each and then 
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rinsed copiously with 100% ethanol, prior to incubating them in 1.0 mM alkanethiol 
solutions for 24 h, as per the established protocols [181, 182].  
After SAM formation on the gold substrates, the SAM surfaces were cleaned to 
remove any traces of hydrophobic contaminants on their surface prior to surface 
characterization and protein adsorption [99]. The CH3 and OCH2CF3 SAMs were cleaned 
by sonication in ethanol, hexane and ethanol, and then rinsed with nanopure water. The 
NH2, COOH, and OH SAMs were sonicated in ethanol, and then incubated in a 25 mM 
potassium phosphate buffer containing 0.005 volume % Triton-X-100 (Sigma; Catalog 
No. T-9284), order to block off any hydrophobic defect sites (e.g. grain boundaries), and 
then rinsed thoroughly with acetone, ethanol and nanopure water to remove loosely-
bound Triton. 
 
6.2.3 Contact angle goniometry 
Advancing contact angle measurements on the SAM surfaces were carried out using a 
CAM 200 Optical Contact Angle/Surface Tension Meter (KSV Instruments Ltd.) and the 
CAM 200 software, as described previously in Chapter 4, with the results presented in 
Table 4.1. 
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6.2.4 Buffers 
Protein adsorption experiments were carried out using a 25 mM potassium phosphate 
buffer (pH 7.4), which was prepared by combining appropriate amounts of the mono- and 
dibasic salts (Sigma-Aldrich) to maintain the pH at 7.4. This buffer is recommended for 
protein structural determination by CD experiments [79, 132, 193] as it permits 
measurement of CD spectra with minimal noise below 200 nm, especially the positive 
CD peaks at 193 and 195 nm, which are critical in determining the α-helix and β-sheet 
content of the proteins, respectively. 
The platelet suspension buffer (PSB, pH 7.4) contained 137 mM NaCl, 2.7 mM KCl, 
5.5 mM Dextrose, 0.4 mM sodium phosphate monobasic, 10 mM HEPES and 0.1U/mL 
apyrase [201]. 2.5 mM CaCl2 and 1.0 mM MgCl2 was added to the PSB to give a platelet 
suspension buffer with metal ions (PSB+MI).  It should be noted that bovine serum Alb 
(BSA) was not added to the platelet suspension buffer as a blocking agent, as is 
commonly used in platelet adhesion studies.  Preliminary studies were also conducted, 
however, with 4 mg/mL BSA added to this buffer to assess the influence of this blocking 
agent on the platelet adhesion response, with the use of BSA not resulting in any 
significantly differences (see Supporting Information, Section 6.5). 
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6.2.5 Protein adsorption 
Human Alb (Sigma, Catalog No. A9511) was dissolved in 25 mM phosphate buffer 
solution (pH 7.4), to prepare the protein stock solutions, and protein adsorption was 
carried out as described previously in Chapters 4 and 5, at three different protein 
concentrations of 0.1 mg/mL, 1.0 mg/mL, and 10.0 mg/mL, so as to obtain a broad range 
of conformations and surface coverages of adsorbed Alb.  
The cleaned SAM surfaces were then incubated in 25 mM potassium phosphate 
buffer (pH 7.4) in a six-well-plate (Corning Costar, Catalog No. 3506), and a suitable 
amount of protein stock solution was added to give the desired bulk protein solution 
concentration, taking care to ensure that the tip of the pipette was held below the air-
water interface to avoid denaturation of the protein at this interface. The SAM surfaces 
were incubated in the protein solution for 2 h, after which an infinite dilution step was 
carried out to wash away the bulk protein solution in addition to any loosely adherent 
protein.  Following this infinite dilution step, the SAM surfaces were safely removed 
from the pure buffer solution without dragging the surfaces through the denatured protein 
film that can be expected to present at the liquid-air interface if the protein solution had 
not been replaced with pure buffer prior to surface removal. 
At the end of the protein incubation step, the surfaces with preadsorbed protein were 
either used for CD studies to analyze the structure of the adsorbed layer, or the surfaces 
were incubated with the platelet suspension. 
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6.2.6 CD studies to quantify the conformational changes and total surface coverage 
of Alb on SAM surfaces  
The native and adsorbed secondary structures of Alb, as well as the surface coverage 
of adsorbed Alb, was determined using a Jasco J-810 spectropolarimeter (Jasco, Inc., 
Easton, MD), as described earlier in as described earlier (in Section 4.2.6). Special high-
transparency quartz cuvettes (Starna Cells, Inc., Atascadero, CA) were used for 
determining the native solution structure of Alb, while the adsorbed structure of Alb on 
the SAM surfaces was determined using a special custom-designed cuvette, which 
maximizes the signal-to-noise ratio (as seen in Fig. 4.1). The ellipticity of the samples (θ, 
in mdeg) was converted to molar ellipticity (designated as [θ], with standard units of 
deg·cm2/dmol) using the following equation [132, 135]:  
[θ] = (θ · M0)/(10,000 · Csoln · L),           (6.1) 
where θ is the molar ellipticity in mdeg, L is the path length of the cuvette in cm, Csoln is 
the solution concentration of the protein in g/mL, and M0 is the mean residue molecular 
weight of 118 g/mol. 
Since proteins exhibit an absorbance peak at 195 nm [184], we used the height of this 
absorbance peak (A195) for constructing a calibration curve of A195 vs. Csoln for various 
known concentrations of Alb, as described in Section 4.2.6. The slope of this plot is 
“εprotein·L” from Beer’s Law, which can be written as: 
A195 = εprotein · Csoln · L           (6.2) 
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where εprotein is the extinction coefficient of the protein  in mL · g-1 · cm-1 (or cm2/g) and L 
is the path length of the cuvette.  
The term “Csoln · L” in eq. 6.2 (above) has units of g/cm2, which is equivalent to the 
amount of protein adsorbed per unit area. Assuming that the absorbance is dependent on 
the total amount of protein present per unit area through which the beam of light passes, 
irrespective of whether the protein is in the solution or the adsorbed state, the calibration 
curve of A195 vs. Csoln can also be used for calculating the amount of Fg adsorbed per unit 
area on the SAMs (i.e., Qads). The validity of this method for measuring the surface 
coverage of adsorbed protein has been confirmed by independent measurement of Qads 
from the thickness of the adsorbed protein film obtained by ellipsometry (see Section 
4.5.S.2) using de Feijter’s formula [198]. 
Hence, while calculating the molar ellipticity for the adsorbed Fg layer on the SAMs, 
the term “Csoln · L” in eq. 6.1 can be replaced by the term Qads to give the following 
equation: 
[θ] = (θ · M0)/(10,000 · Qads),            (6.3) 
The CD spectra (molar ellipticity vs. wavelength) thus obtained were deconvoluted 
using the SP-22X algorithm and analyzed using the SELCON and CONTIN/LL software 
packages to quantify the percentage of α-helix and β-sheet content of the native/adsorbed 
protein [148]. 
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6.2.7 Platelet adhesion 
Platelet adhesion was carried out, using a suspension of washed platelets from human 
blood. Briefly, 25.0 mL of blood was collected from volunteers as per protocols approved 
by the Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) at 
Clemson University, in BD Vacutainer tubes (Becton-Dickinson, Catalog No. 364606) 
containing an acid-citrated dextrose (ACD) anti-coagulant. The first few mL of blood 
was discarded, as it is rich in clotting factors and then the 25 mL of blood was collected. 
The ACD-anticoagulated blood was centrifuged (225g, 15 min, 25°C) to generate 
platelet rich plasma (PRP), and platelets were separated from PRP via a gel separation 
method [201], using a liquid chromatography column (Sigma-Aldrich, Catalog No. 
C4169) containing Sepharose 2B (Sigma-Aldrich, Catalog No. 2B-300). The Sepharose 
column was allowed to equilibrate with PSB, after which the PRP was carefully pipetted 
on to the column and allowed to pass into the column. PSB was then added to the column 
from a reservoir, while keeping the column running. Fractions were collected from the 
bottom of the column, with the platelets being identified by their increased turbidity. The 
platelet-rich fractions were pooled, and platelet concentration was measured using a 
Beckman Coulter Z2 Coulter Particle Count and Size Analyzer (Beckman Coulter, 
Fullerton, CA). The platelet count was adjusted to 108 platelets/mL with PSB, and CaCl2 
and MgCl2 were added to give 2.5 mM and 1.0 mM concentrations of these salts, 
respectively. Platelet suspension was allowed to rest for 30 min, and the platelet adhesion 
step was carried out on the protein-coated SAMs for 1 h at 37°C.  
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The platelet suspension was then aspirated from each well at the end of the platelet 
adhesion step, and the non-adherent platelets were rinsed away by filling and aspirating 
the wells five times with PBS. The substrates were then removed to a fresh well-plate, for 
carrying out the lactate dehydrogenase (LDH) assay to quantify the platelet adhesion 
levels. Additionally, the morphology of the adherent platelets was visualized using 
scanning electron microscopy (SEM).  
 
6.2.8 SDS-PAGE analysis of platelet suspension 
The platelet suspensions obtained from two separate gel separation runs were 
centrifuged at 1200 rpm, 1500 rpm, and 1800 rpm, and the supernatant was aspirated and 
analyzed via sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) for 
any traces of residual plasma proteins. Silver staining was done using a Silver SNAP 
Stain Kit II (Pierce, Rockford, IL), which provides a highly sensitive detection system for 
sub-nanogram levels of proteins. This is essential in ensuring that the platelet suspension 
was free of any residual plasma proteins, which may potentially complicate our analysis 
by displacing the preadsorbed protein and then binding platelets. 
 
6.2.9 Quantification of platelet adhesion using lactate dehydrogenase (LDH) assay 
The platelet adhesion levels on the Alb-coated SAMs was quantified by measuring the 
lactate dehydrogenase (LDH) released when the adherent platelets were lysed with a 
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Triton-PSB buffer, (2% v/v Triton-X-100 in PSB) using a CytoTox96® Non-Radioactive 
Cytotoxicity Assay (Promega Corporation, Madison, WI), as indicated in Section 4.2.8. 
A calibration curve was constructed using a known number of platelets, counted using a 
Beckman Coulter Z2 Coulter Particle Count and Size Analyzer (Beckman Coulter, 
Fullerton, CA), and the platelet adhesion on the SAM surfaces was determined from this 
calibration curve. 
 
6.2.10 Morphological analysis of adherent platelets using scanning electron 
microscopy (SEM) 
The samples for SEM were fixed, as described in section 4.2.10. Briefly, the samples 
were immersed in a special fixing buffer (3% glutaraldehyde, 0.1 M sodium cacodylate, 
pH 7.4), for 30 min at room temperature, after which they were rinsed with PBS thrice. 
The fixed samples were then incubated in ascending ethanol:water mixtures (50%, 60%, 
70%, 80%, 90% and 99% ethanol) for 10 min to dehydrate them. These samples were 
finally treated with 0.02 mL of hexamethyldisilazane (Sigma) and allowed to dry 
overnight. The morphology of the adherent platelets was examined using a FESEM-
Hitachi S4800 scanning electron microscope (Electron Microscopy Facility, Advanced 
Materials Research Laboratory, Clemson University, Pendleton, SC). 
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6.2.11 Study using polyclonal antibodies against Alb 
Polyclonal antibodies against human Alb (Anti-Alb Rabbit pAb; Calbiochem, La 
Jolla, CA) at a concentration of 4 µg/mL were incubated for 30 min at room temperature, 
on the Alb surfaces in order to inhibit Alb recognition by the platelet receptors. As a 
control, SAM surfaces coated with Fg (FIB 3; plasminogen, von Willebrand factor, and 
fibronectin depleted; Enzyme Research Laboratories, South Bend, IN) were incubated 
with 4 µg/mL of the anti-Alb polyclonal antibodies, and platelet adhesion was quantified 
using an LDH assay. 
 
6.2.12 Study using polyclonal antibodies against Fg 
Polyclonal antibodies against human Fg (Anti-fibrinogen Rabbit pAb; Calbiochem, La 
Jolla, CA) at a concentration of 4 µg/mL were incubated for 30 min at room temperature, 
on the Alb coated surfaces in order to verify whether the inhibition of platelet-Alb 
interactions was due to the effects of the anti-Alb polyclonal antibodies or the adsorption 
of these antibodies on bare surface exposed between the adsorbed Alb molecules. Platelet 
adhesion was characterized as described above. 
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6.2.13 Inhibition of platelet-protein interactions using Arg-Gly-Asp (RGD)-containing 
peptides 
The platelet suspension was incubated with 300 µM of an Arg-Gly-Asp-Ser (RGDS) 
peptide (Calbiochem, La Jolla, CA) for 30 min at room temperature, in order to inhibit 
interactions between RGD-binding platelet receptors and Alb.  These RGDS-treated 
platelets were then allowed to adhere on the Alb-coated SAM surfaces for 1h at 37°C, 
after which the platelet adhesion was quantified using an LDH assay and the morphology 
of the adherent platelets was examined using SEM. 
Platelets incubated with 300 µM of a control Arg-Gly-Glu-Ser (RGES) peptide 
(American Peptide Company, Sunnyvale, CA) were allowed to adhere on the SAM 
surfaces preadsorbed with Alb.  
 
6.2.14 Modification of Arg residues in Alb using 2,3-butanedione 
Site-specific modification of R residues in Alb was carried out using 2,3-butanedione 
(Fluka), as described previously [177]. Briefly, an Alb solution was modified by addition 
of suitable amount of 2, 3-butanedione to borate buffer to give a final concentration of 50 
mM of the modifying agent. The modified protein samples were dialyzed for 12 h against 
25 mM phosphate buffer, and then analyzed for Arg modification via a protocol 
described previously [99], using electrospray ionization mass spectrometry (ESI-MS) 
performed at the Clemson University Genomics Institute. Additionally, we used CD 
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spectropolarimetry to analyze the secondary structure of the modified Alb in solution and 
compared it with that of unmodified Alb. 
 
6.2.15 Platelet adhesion to SAM surfaces coated with Alb with modified arginine 
residues 
Alb adsorption was carried out, after which the arginine residues exposed in the 
adsorbed Alb layer were neutralized by 2, 3-butanedione, using the protocol described 
above. After washing away the excess butanedione, the surfaces were incubated with 
platelets, and the platelet adhesion levels were quantified using an LDH assay, with the 
morphology of the being observed using SEM. 
 
6.2.16 Statistical analysis 
The results we present are the mean values with 95% confidence intervals (CI). 
Statistical significance of differences between mean values for different samples and 
conditions was evaluated using a Student’s t-test, with p ≤ 0.05 considered as statistically 
significant. 
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6.3       Results and Discussion 
6.3.1 Circular dichroism studies on native and adsorbed Alb  
The secondary structural content of native and adsorbed Alb on the SAM surfaces as 
a function of surface chemistry and solution concentration, determined via CD 
spectropolarimetry, are presented in Figure 6.1.  These results clearly illustrate the higher 
degree of adsorption-induced conformational changes (i.e., loss of α-helix accompanied 
by increased β-sheet) as the surfaces became more hydrophobic and when the protein was 
absorbed from a lower solution concentration, with the combined variation of both 
surface chemistry and solution concentration effectively providing a wide range of 
conformational states of the adsorbed Alb.  
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Figure 6.1. Secondary structure of adsorbed Alb on SAM surfaces at (A) 0.1 mg/mL, (B) 1.0 mg/mL and (C) 10.0 mg/mL 
bulk solution concentrations (n= 6, mean ± 95% CI). * denotes difference not statistically significant, 
 
p > 0.05.
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The surface coverage of albumin adsorbed on the SAMs from the three different bulk 
concentrations was calculated using the height of the absorbance peak at 195 nm (A195), 
and is shown in Table 6.1. The surface coverage at 0.1 and 1.0 mg/mL bulk Alb solution 
concentration lie between the theoretical monolayer surface coverage values of 0.72 
µg/cm2 for end-on adsorption and 0.21 µg/cm2 for side-on adsorption [34], assuming that 
the Alb molecule has dimensions of 4.0 x 4.0 x 14 nm3 [50]. The surface coverage at 10.0 
mg/mL Alb solution concentration was well beyond the theoretical values for monolayer 
surface coverage, indicating multilayer adsorption. These results clearly indicate that the 
surfaces are saturated with Alb, and the amount of Alb adsorbed increases with 
increasing hydrophobicity of the SAM surfaces. Significantly greater Alb adsorption also 
occurred on a given SAM surface with increasing Alb solution concentration. This can be 
explained by the fact that the rate of transport of the protein molecules to the surface 
increases as solution concentration increases, as a result of which the molecules that 
adsorb from higher concentration have less time to unfold and spread before the surface 
becomes saturated with protein [31, 34, 39]. 
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Table 6.1. Amounts of Alb adsorbed on SAM surfaces from 0.1, 1.0 and 10.0 mg/mL 
bulk solution concentrations (n= 6, mean ± 95% CI). 
Albumin 
concentration 
[mg/mL] 
OH 
[µg/cm2] 
COOH 
[µg/cm2] 
NH2 
[µg/cm2] 
CF3 
[µg/cm2] 
CH3 
[µg/cm2] 
0.1 mg/mL 0.25 ± 0.01 0.28 ± 0.01 0.46 ± 0.03 0.40 ± 0.02 0.54 ± 0.03 
1.0 mg/mL 0.26 ± 0.01 0.29 ± 0.01 0.49 ± 0.02 0.44 ± 0.01 0.58 ± 0.01 
10.0 mg/mL 1.77 ± 0.05 2.23 ± 0.09 2.26 ± 0.19 2.55 ± 0.24 2.71 ± 0.18 
 
6.3.2 Platelet adhesion to adsorbed Alb 
A suspension of washed platelets was used for the platelet adhesion runs. Prior to 
carrying out the platelet adhesion experiments, it was essential to check for traces of 
residual proteins that could potentially adsorb onto and/or displace the preadsorbed Alb 
from the SAM surfaces through the Vroman effect [204]. As was shown in Chapter 5 in 
Fig. 5.3, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
analysis performed on supernatant fluid from centrifugation of the platelet suspensions 
showed no detectable levels of proteins in the suspensions centrifuged at 1200 rpm and 
1500 rpm. Since activated platelets are likely to release proteins from their granules into 
the suspension, this also indicates that the platelets in suspension were not activated 
during the gel separation process through the Sepharose column, or during any handling 
prior to the platelet adhesion step.  
Platelet adhesion levels on the SAM surfaces preadsorbed with Alb are shown in 
Figure 6.2. It is clearly evident that platelet adhesion did occur on these surfaces, with 
 platelet adhesion being strongly influenced by both surface chemistry and the solution 
concentration from which the Alb was adsorbed. Platelet adhesion levels followed the 
same general trends observed for the adsorption
(Figure 6.1); i.e., increasing with increasing hydrophobicity of the surfaces and 
decreasing Alb solution concentration. 
 
Figure 6.2. Platelet adhesion on SAM surfaces preadsorbed with Alb fr
of 0.1 mg/mL, 1.0 mg/mL and 10.0 mg/mL 
statistically significant difference, 
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-induced conformational changes in Alb 
 
om bulk solutions 
(n=6, mean ± 95% CI).  * denotes no 
p > 0.05.  
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To investigate the relationship between platelet adhesion and the degree of adsorption-
induced protein unfolding, the platelet adhesion levels (Figure 6.2) were plotted as a 
function of the extent of loss of α-helix in Alb measured on these surfaces, as presented 
in Figure 6.3A. As is clearly shown in this figure, the platelet adhesion response 
correlated strongly (r2 = 0.92) with the degree of conformational change in adsorbed Alb 
when the percentage of α-helix loss was greater than about 34%. For levels of unfolding 
less than this threshold value, platelet adhesion was negligible, with the slope of the 
regression line for this region of the plot not being significantly different than zero (p = 
0.60). Thus, below this critical level of unfolding, the layer of adsorbed Alb can be 
considered to be ‘passive’ in terms of its ability to adhere platelets, which supports the 
conventional understanding that Alb functions as a blocking agent for non-specific 
interactions [80]. However, once this critical level of unfolding was exceeded, platelets 
readily adhered to the adsorbed Alb, with the adhesion response increasing linearly as the 
degree of unfolding increased. Hence, this suggests that platelet binding domains in Alb 
are being exposed and/or formed beyond this critical level of unfolding, thereby inducing 
the platelet adhesion response. 
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Figure 6.3. Platelet adhesion to (A) Alb and (B) Fg on the SAM surfaces as a function of the degree of loss in α-helix (Each 
point represents the mean of six values for each SAM surface).  Fg data is provided for comparison to the Alb results and is 
reproduced from Fig. 5.5B. 
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A particularly intriguing result from this study is that, as seen in Figure 6.3, beyond 
this critical level of unfolding, the increase in platelet adhesion as a function of continued 
unfolding of the Alb (Fig. 6.3A) occurred in a manner very similar to Fg (Fig. 6.3B), 
which we measured in a related set of experiments listed in Chapter 5. This finding 
suggests that, beyond this critical level, platelet adhesion to both of these proteins as a 
function of the degree of adsorption-induced unfolding may be due to similar 
mechanisms. Given the fact that there are no known platelet binding sites in albumin, this 
similarity actually suggests that the platelet binding response to adsorbed Fg as it unfolds 
may be mediated by processes that are not associated with currently known platelet 
binding motifs in Fg, but rather are being driven by the exposure and/or formation of new 
platelet receptor recognition sites similar to the process that is occurring in Alb. 
 
6.3.3 Delineating the role of RGD-specific receptors in platelet-Alb interactions 
To probe the molecular mechanisms underlying the observed platelet adhesion 
response, four independent blocking studies were conducted for Alb adsorbed from the 
most dilute Alb solution (0.1 mg/mL) on the two SAM surfaces representing the extremes 
in hydrophobicity (OH and CH3 SAMs). 
First, in order to confirm that platelets were actually adhering to the adsorbed Alb and 
not to residual proteins that may have adsorbed from the platelet suspension during the 
platelet adhesion process (e.g., proteins released from the platelets granules), the 
adsorbed Alb layer was treated with polyclonal antibodies against human Alb (pAb-Alb) 
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prior to performing the platelet adhesion studies. These pAb-Alb were then also used to 
treat adsorbed Fg as a negative control.  Secondly, to ensure that the effect of the pAb-
Alb was due to their specificity towards Alb, and not due to minimization of interactions 
between platelets and bare SAMs as a result of the adhesion of these antibodies on the 
surface of the SAMs (i.e., in the gaps possibly present between adjacent adsorbed Alb 
molecules), the Alb-coated SAMs were treated with anti-Fg polyclonal antibodies (pAb-
Fg) before exposure to the platelet suspension. Thirdly, the platelet suspensions were 
treated with RGDS peptides prior to exposure to the Alb-coated SAM surfaces, with 
RGES used as a control, to determine whether platelet adhesion was being mediated by 
RGD-specific receptors. Finally, the solvent-accessible arginine (R) residues in 
preadsorbed Alb were chemically modified using 2,3-butanedione [174, 175] prior to 
conducting the platelet adhesion studies, to determine if they were involved in the platelet 
binding motifs that were being exposed or formed as a function of the adsorption-induced 
Alb unfolding. Control studies were conducted by using 2,3-butanedione to modify the R 
residues in Alb in solution, followed by analysis via electrospray ionization mass 
spectrometry (ESI-MS) to confirm that the modification procedures actually caused the 
intended site-specific modification of the R residues. In addition, CD studies were 
conducted to determine the effect of this chemical modification process on the 
conformation of Alb in both its soluble and adsorbed states. The results of these four 
studies are shown in Figure 6.4. 
As seen in Figure 6.4, the pAb-Alb nearly completely inhibited platelet adhesion to 
preadsorbed Alb on both the CH3 and OH SAMs, while not significantly affecting 
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platelet adhesion to either the CH3 or OH SAMs preadsorbed with Fg. Also, the pAb-Fg 
did not inhibit platelet adhesion to adsorbed Alb, providing further proof that the pAb-
Alb were effective in blocking platelet adhesion to adsorbed Alb due to their specificity 
towards Alb and not due to their adsorption on bare surface exposed between the 
adsorbed Alb molecules on the SAMs.  
Treatment of the platelets with the RGDS peptides resulted in a substantial decrease 
in platelet binding, with 60.2% and 48.0% reductions in platelet adhesion to the adsorbed 
Alb on the CH3 and OH SAM surfaces, respectively; while the RGES peptides had no 
significant effect. These results indicate that non-RGD specific platelet receptors, which 
account for nearly 50% of the platelet response on both SAM surfaces, mediate the 
adhesion of RGDS-treated platelets to adsorbed Alb. When these results were compared 
with those obtained from our previous related study for RGDS-based inhibition of 
platelet adhesion to Fg (see Chapter 5, Section 5.3.4), it was surprising to find that for a 
given SAM surface, the levels of inhibition observed were nearly identical for both Alb 
and Fg (58.3% for Fg adsorbed on a CH3 SAM, and 45.7% for Fg adsorbed on the OH 
SAM). These results further support the possibility of platelet adhesion to Fg and Alb as a 
function of their unfolded state is mediated by similar specific mechanisms.  
 
 
 Figure 6.4. Platelet adhesion on SAM surfaces preadsorbed with Alb and Fg from 0.1 
mg/mL solutions under various blocking conditions. The blocking treatments included 
RGDS and RGES peptides, as well as polyclonal antibodies against Alb (pAb vs. Alb) 
and Fg (pAb vs. Fg) (n=6, mean ± 95% CI).  * denotes no statistically significant 
difference, p > 0.05. Fg data is provided for comparison to the Alb results and is 
reproduced from Fig. 5.6.  
 
Chemical modification of R residues of the preadsorbed Alb also signif
reduced platelet adhesion, with the reduction on the OH SAMs not being significantly 
different (p = 0.18) than the response from the RGDS peptides, while the reduction on the 
CH3 SAMs was significantly greater (
142 
p < 0.05) than the reduction from tre
 
icantly 
atment with 
 RGDS.  This may be due to the fact that R
the RGDS peptide by the platelet receptors represents a reversible, competitive binding 
situation, with some level of RGD
occur in the presence of the RGDS peptide. The ESI
chemical modification was specific to only the R residues, with all R residues in the Alb 
in its solution state being modified under the applied condit
results from the CD analyses of Alb before and after R
this chemical treatment had minimal influence on the secondary structure of the Alb in 
either its solution or its adsorbed condition. CD s
modified Alb in solution are 
Figure 6.5. Representative CD spectra for solution structure of normal native Alb and 
Alb with modified arginine residues.
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-MS results confirmed that the 
ions. Table 6.2 presents the 
-modification, which confirms that 
pectra comparing the unmodified and R
presented in Figure 6.5. 
 
-
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Table 6.2. Comparison of secondary structural composition of unmodified Alb and Alb 
with arginine residues modified using 2, 3-butanedione, in solution and after adsorption 
on the CH3 and OH SAMs (n= 6, mean ± 95% CI).  
Sample α-helix (%) β-sheet (%) 
In solution 
  
Human Alb unmodified 66.5 ± 1.5 1.5 ± 0.7 
Human Alb with R-modification  65.8 ± 0.9 0.9 ± 0.3 
After adsorption 
  
CH3, 0.1 mg/mL Alb-unmodified 14.4 ± 0.7 28.3 ± 0.7 
CH3, 0.1 mg/mL Alb-modified 15.7 ± 1.3 28.6 ± 1.5 
OH, 0.1 mg/mL Alb-unmodified 43.1 ± 2.1 13.4 ± 1.1 
OH, 0.1 mg/mL Alb-modified 42.6 ± 1.4 12.3 ± 0.5 
 
 
Overall, these results indicate that platelets are able to adhere to adsorbed Alb and 
that adhesion is strongly correlated with the adsorption-induced loss of α-helix in Alb 
(Figure 6.4A). The adhesion is substantially due to a specific binding mechanism 
involving RGD-specific receptors on non-activated platelets that are able to recognize 
motifs involving R residues that are either exposed and/or formed in Alb after it 
undergoes a critical degree of adsorption-induced unfolding. 
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Figure 6.6. Molecular structure of human serum Alb (PDB ID: 1E7H) [78] with charged 
residues displayed in spacefill mode and all other residues displayed in wireframe.  
Arginine (blue), lysine (green), aspartic acid (red), and glutamic acid (yellow). Figure 
was generated using RASMOL. 
The prominent role played by RGD-binding platelet receptors and the R residues of 
Alb in mediating platelet adhesion to adsorbed Alb is intriguing, considering the 
conventional view that Alb does not support platelet adhesion through specific binding 
mechanisms. As shown in Figure 6.6, Alb contains a large number of charged amino 
acids (24 arginine, 59 lysine, 35 aspartic acid, and 62 glutamic acid residues). We 
hypothesize that in its native state, these residues are not structured in a manner to be 
recognized by platelet receptors, but after undergoing a critical level of adsorption-
induced unfolding, oppositely charged pairs of residues within this protein become 
spatially positioned such that they become recognizable to RGD-specific receptors in the 
platelets similar to an RGD motif. We further hypothesize that the incidence of this 
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increases with increased degree of conformational rearrangement, thus resulting in the 
linear relationship between platelet adhesion and the percent loss in α-helix, observed in 
Figure 6.4A. 
Scanning electron microscopy (SEM) analyses were conducted to assess the effect of 
RGDS peptides and the R modification of adsorbed Alb on the morphology of adherent 
platelets on the OH and CH3 SAMs with preadsorbed Alb. Figures 6.7A and 6.7D, show 
that the platelets adherent on the CH3 and OH SAMs preadsorbed with Alb underwent a 
similar moderate degree of spreading and extension of filopodia on both surfaces, even 
though platelet adhesion on the CH3 SAM was more than six times higher than on the OH 
SAM. These results indicate that the adhesion mechanisms were similar and induced a 
moderate level of platelet activation on both surfaces. However, when the platelets were 
treated with an RGDS peptide prior to the platelet adhesion (Figures 6.7B and 6.7E), 
which resulted in about 50-60% reduction in adhesion, they exhibited a distinctly 
different morphology, with much less spreading and minimal extension of filopodia. 
These results suggest that the mechanism of adhesion to RGDS-treated platelets was 
different from that of untreated platelets. As shown in Figures 6.7C and 6.7F, platelets 
adherent on the adsorbed Alb with R modification exhibited morphologies similar to the 
RGDS-treated platelets. This supports a hypothesis that R modification of adsorbed Alb 
results in blocking the same platelet receptors as those blocked by the RGDS peptides. 
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Figure 6.7. Platelet adhesion to the CH3 (top row) and OH SAMs (bottom row) 
preadsorbed with 0.1 mg/mL Alb, under different blocking conditions: (A,D) unblocked 
Alb, (B,E) platelets treated with RGDS, and (C,F) adsorbed Alb layer treated with 2,3-
butanedione to neutralize Arg.  
 
The morphology of RGDS-treated platelets adherent to adsorbed Alb on the CH3 and 
OH SAMs was strikingly similar to those observed to be adherent to Fg in the presence of 
RGDS on the same SAMs (see Section 5.3.5), as seen in Figure 6.8. This provides further 
evidence that similar adhesion mechanisms are involved in platelet adhesion to both Alb 
and Fg as a function of their degree of adsorption-induced unfolding on a surface. 
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Figure 6.8. Morphology of RGDS-treated platelets adherent to CH3 (top row) and OH 
SAMs (bottom row), preadsorbed with Fg (A,C) and Alb (B,D).  Fg data is provided for 
comparison to the Alb results and is reproduced from Fig. 5.6.  
 
Taken altogether, the SEM results strongly suggest that there are at least two distinct 
sets of receptors associated with platelet adhesion to sites in adsorbed Alb that are 
exposed and/or formed following adsorption-induced unfolding beyond a critical degree; 
one RGD-specific receptor that recognizes a protein motif involving R that mediates both 
adhesion along with a moderate degree of activation, and another that induces platelet 
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adhesion with minimal activation.  We plan to attempt to identify these receptors and to 
further examine the mechanisms underlying their interactions with adsorbed Alb in future 
investigations. 
 
6.4       Conclusions 
The results from these studies conclusively demonstrate that platelets adhesion to 
adsorbed Alb is substantially mediated by interactions between RGD-specific platelet 
receptors and R residues in the adsorbed Alb, beyond a critical level of adsorption-
induced protein unfolding. Additionally, we provide evidence that the mechanisms 
underlying platelet adhesion to Fg and Alb as a function of the degree of adsorption-
induced unfolding are similar in nature, with platelet adhesion increasing as a function of 
the degree in adsorption-induced unfolding for both proteins (beyond a critical degree of 
unfolding of the Alb) and RGDS-treatment induced similar levels of inhibition of platelet 
adhesion to both proteins, with similar morphology of the adherent RGDS-treated 
platelets.  Overall, these results suggest that platelet adhesion to adsorbed fibrinogen, and 
possibly many other adsorbed proteins, involves mechanisms that may be quite different 
than currently understood. Thus, there is still much to learn about the molecular 
mechanisms that mediate the interactions of platelets with adsorbed proteins and how to 
control these interactions to improve the blood compatibility of biomaterials used in 
cardiovascular applications. 
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6.5 Supporting Information 
6.5.S.1 Platelet adhesion with bovine serum albumin (BSA) added to the platelet 
suspension buffer 
Platelet adhesion was carried out on the CH3 and OH SAMs preadsorbed with Alb 
from 0.1 mg/mL bulk solutions, using a platelet suspension supplemented with 4.0 
mg/mL BSA.  As seen in Figure 6.5.S.1, there was no significant change (p > 0.05) in the 
platelet adhesion levels, which concurred with the results obtained using polyclonal 
antibodies (Figure 6.4), confirming that non-specific interactions had minimal role in 
mediating platelet adhesion to Alb. 
 
Figure 6.S.1. Adhesion of platelet suspensions supplemented with 4.0 mg/mL BSA (grey 
bars) and without BSA (white bars) to CH3 and OH SAMs preadsorbed with 0.1 mg/mL 
Alb, assessed by LDH assay (n=6, mean ± 95% CI).  * denotes no statistically significant 
difference,  p > 0.05. 
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CHAPTER 7 
DELINEATING THE ROLES OF THE αIIbβ3 AND GPIb-IX-V PLATELET 
RECEPTORS IN MEDIATING ADHESION TO ADSORBED FIBRINOGEN AND 
ALBUMIN 
  
7.1 Introduction 
Platelets respond to minimal stimuli, and adhere and activate upon contact with 
thrombogenic surfaces such as the exposed endothelium/subendothelium at vascular 
injury sites, as well as on synthetic surfaces [1]. These interactions involve the binding of 
platelet agonists to receptors on the surface of the platelet plasma membrane [206]. 
Agonists include plasma proteins (e.g., thrombin, fibrinogen and von Willebrand factor), 
components of the vascular wall (such as collagen), as well as molecules released by 
inflammatory cells and platelets (such as ADP and serotonin). In order to understand the 
factors underlying platelet interactions with adsorbed proteins, it is imperative to examine 
the role of the principal platelet receptors involved in adhesion and signaling. These 
receptors function in positive and negative feedback loops, playing critical roles in 
platelet function, thereby providing deeper insights into the mechanisms mediating the 
platelet response [207].  
The αIIbβ3 integrin, which is also known as the GPIIb/IIIa receptor, is the most 
abundant platelet receptor with 60,000-80,000 copies per platelet [73], in addition to an 
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intracellular pool which becomes exposed on the platelet surface upon activation [208]. 
αIIbβ3  mediates the adhesion, aggregation and spreading of platelets at vascular injury 
sites upon activation, as well as during pathological thrombus formation [208, 209], as a 
result of which it is considered to be the main platelet receptor involved in regulating 
thrombosis and hemostasis [60]. Glanzmann’s thrombasthenia is a blood disorder 
associated with impaired platelet adhesion and aggregation as a result of the lack or 
dysfunction of the αIIbβ3  platelet integrin [210], illustrating its critical role in mediating 
the platelet response.   
αIIbβ3 binds several ligands, such as fibrin(ogen) (Fg), von Willebrand factor (vWf), 
fibronectin (Fn) and vitronectin (Vn), which contain the arginine-glycine-aspartic acid 
(RGD) amino acid sequence. In their resting, non-activated state, the αIIbβ3 receptor is in 
a ‘low-affinity’ state with its RGD-binding site hidden. Upon agonist-induced platelet 
activation, the receptor changes to its ‘high-affinity’ state as a result of ‘inside-out’ 
signaling events, leading to conformational changes in the platelet receptor which causes 
the unmasking of the RGD-binding site, thereby mediating platelet adhesion [73]. 
The GPIb-IX-V receptor complex (25,000 copies per platelet) mediates the initial 
adhesion of platelets to the vessel wall under conditions of high shear via interactions 
with the A1 domain of vWf in the exposed extracellular matrix at vascular injury sites 
[69, 71]. However, this interaction is insufficient for stable adhesion of the platelets and 
is characterized by its rapid dissociation rate, as a result of which they cause platelets to 
roll or translocate along the vessel wall under normal flow conditions [70]. Therefore, the 
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primary role of this receptor is to reduce the velocity of platelets in flowing blood and 
recruit them to vascular injury sites, thereby facilitating their interactions with the 
thrombogenic surface via other platelet receptors, notably αIIbβ3.  
Although the exact nature of GPIb-vWf interactions remain to be completely 
elucidated, the process has been shown to involve conformational changes in the GPIb-
IX-V receptor complex, as well as the vWf [72]. A recent study by Lecut et al. [111] 
showed that the GPIb-IX-V receptor complex does not have a role in platelet integrin 
activation, although it is critical for platelet adhesion to collagen, thereby illustrating its 
essential role as an adhesive, non-activation receptor. Studies using inhibitory antibodies 
have narrowed down the vWf binding epitopes on GPIb to amino acids 1-81 and 201-268 
[165, 166]. Vanhoorelbeke et al. [211] recently reviewed the potential of GPIb-IX-V as 
an antithrombotic target, highlighting its role in binding other ligands such as α-thrombin, 
factor XII (FXII), factor XI (FXI), high molecular weight kininogen (HMWK), 
macrophage integrin Mac-1 and P-selectin. This suggests that GPIb-IX-V receptors may 
play a more important role in mediating platelet interactions than has been previously 
thought.  
Our results (illustrated in Chapters 5 and 6) indicate that the platelet adhesion 
mechanisms to adsorbed Fg and more importantly albumin (Alb) are mediated by specific 
mechanisms involving RGD- and non-RGD-specific receptor sets. Using chemical 
modification of Arg residues in the adsorbed Alb layer, we have shown that the RGD-
specific receptors interact with Arg residues, confirming the specific mode of platelet-Alb 
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interactions. This led us to hypothesize that since Alb contains a large number of charged 
residues (59 Lys, 24 Arg, 35 Asp and 62 Glu) [192], beyond a critical degree of 
adsorption-induced unfolding, oppositely-charged residues may become spatially 
oriented such that they form an RGD-like motif, which then becomes recognizable to the 
RGD-specific platelet receptors.  We further hypothesized that the RGD-specific receptor 
set mediates the adhesion and activation of platelets, while the non-RGD-specific 
receptor set mediates adhesion with little/no platelet activation. The strong correlation 
between the platelet adhesion levels and the degree of protein unfolding as measured by 
the loss of α-helix (Fig. 6.3) also raised the question as to whether the platelet adhesion 
response as a function of post-adsorptive unfolding was mediated by the same adhesion 
mechanisms and/or platelet receptors. 
Since the αIIbβ3 platelet receptor binds to ligands such as Fg, vWf, Fn and Vn, which 
contain the RGD sequence, we hypothesized that it likely plays the role of the RGD-
specific receptor set. The GPIb-IX-V receptor complex was likely the non-RGD-specific 
set, since it has been shown to mediate platelet adhesion without activation [111]. 
Aggrastat (trade name for tirofiban) is a peptidomimetic αIIbβ3 antagonist which has been 
shown to inhibit platelet binding to collagen, as well as platelet activation as measured by 
P-selectin exposure [157]. Studies using monoclonal antibodies 24G10 (targeting 
residues 1-81 of GPIb) and 6B4 (targeting residues residues 201-268 of GPIb) have 
shown that these antibodies are effective in inhibiting GPIb-vWf interactions [166].  A 
recent study that examined the joint inhibition of the αIIbβ3 platelet integrin and the GPIb-
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IX-V receptor complex showed that this strategy was effective in preventing arterial 
thrombosis [169].  
 
Figure 7.1. Chemical structure of Aggrastat. [212] 
 
Hence, in order to analyze the potential roles of these two receptor sets in mediating 
platelet interactions with adsorbed Fg and Alb, we pretreated the washed platelet 
suspension with the different platelet antagonists (Aggrastat against αIIbβ3, and mAbs 
6B4/24G10 against GPIb) prior to adhesion to the Fg- and Alb-coated SAM surfaces. 
Additionally, to delineate any potential role for GPIb as the non-RGD-specific receptor 
set involved in mediating the adhesion of RGDS-treated platelets, we treated the platelet 
suspension with RGDS followed by 6B4/24G10 anti-GPIb antibodies prior to the platelet 
adhesion step. Finally, in order to modify both Lys and Arg in Alb and thereby neutralize 
the positively charged residues in the adsorbed layer, we carried out the acetylation of 
these residues using acetic anhydride, which has been shown to be a potent strategy for 
chemical modification of the amino groups in proteins [171].   
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7.2  Materials and Methods 
7.2.1 Gold substrates 
1.0 cm x 1.0 cm silicon wafers (Silicon Quest, Inc.) were used as substrates for the 
platelet adhesion experiments, while quartz slides (0.375” x 1.625” x 0.0625”, 
Chemglass) were used for CD experiments. These substrates were cleaned by immersing 
them in a piranha solution (7:3 v/v H2SO4:H2O2) at 50°C for 30 min, followed by an 
RCA basic wash (1:1:5 v/v NH4OH:H2O2:H2O), and this cleaning procedure was 
repeated twice, as described previously in Chapter 3. The cleaned substrates were rinsed 
with 100% ethanol (Pharmco-Aaper; Catalog No. 111000200) and nanopure water, and 
then dried using a stream of nitrogen gas.   
The cleaned silicon wafers were coated with a 50 Å chromium adhesion layer and 
1,000 Å of gold, while the quartz slides for CD were coated with 30 Å of chromium and 
100 Å of gold, via a thermal vapor deposition process. The thicknesses of the gold and 
chromium layers were verified using a DekTak profilometer and a GES5 ellipsometer 
(Sopra, Inc., Palo Alto, CA).  
 
7.2.2 Formation of self-assembled monolayers (SAMs) of alkanethiols 
The gold-coated substrates were cleaned by dipping them in a modified piranha wash 
(4:1 v/v H2SO4:H2O2), followed by an RCA basic wash, for 1 minute each and then 
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rinsed with 100% ethanol, prior to incubation in 1.0 mM alkanethiol solutions for 24 h, as 
per the standard  protocols [181, 182].  
The following alkanethiols were used for creating the SAM surfaces, and were 
prepared in 100% ethanol, as described previously in Chapter 4: 
1-Dodecanethiol (SH-(CH2)11CH3; Aldrich; CH3), and 
11-Mercapto-1-undecanol (SH-(CH2)11OH; Aldrich; OH). 
The SAM surfaces were cleaned to remove any traces of hydrophobic contaminants 
on their surface prior to surface characterization and protein adsorption [99]. The CH3 
SAM surfaces were cleaned by sonication in ethanol, hexane and ethanol, and then rinsed 
with nanopure water. The OH SAMs were sonicated in ethanol, and then incubated in a 
25 mM potassium phosphate buffer containing 0.005 volume % Triton-X-100 (Sigma; 
Catalog No. T-9284), in order to block off any hydrophobic defect sites (e.g. grain 
boundaries), and then rinsed thoroughly with acetone, ethanol and nanopure water to 
remove loosely-bound Triton. 
 
7.2.3 Surface characterization of SAM surfaces 
The SAM surfaces were characterized using contact angle goniometry, ellipsometry 
and XPS, and the results are listed in Chapter 4. 
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7.2.4 Buffers 
Protein adsorption was carried out in a 25 mM potassium phosphate buffer (pH 7.4), 
which was made by combining suitable amounts of the mono- and dibasic salts (Sigma-
Aldrich), in order to maintain the pH at 7.4. This buffer is recommended for CD 
experiments for determining the structure of native/adsorbed proteins [79, 132, 193] as it 
permits measurement of CD spectra with minimal noise below 200 nm, especially the 
positive CD peaks at 193 and 195 nm, which are critical in determining the α-helix and β-
sheet content of the proteins, respectively. 
The platelet suspension buffer (PSB, pH 7.4) contained 137 mM NaCl, 2.7 mM KCl, 
5.5 mM Dextrose, 0.4 mM sodium phosphate monobasic, 10 mM HEPES and 0.1U/mL 
apyrase [201]. 2.5 mM CaCl2 and 1.0 mM MgCl2 was added to the PSB to give a platelet 
suspension buffer with metal ions (PSB+MI).  It should be noted that bovine serum Alb 
(BSA) was not added to the platelet suspension buffer as a blocking agent, as is 
commonly used in platelet adhesion studies.   
 
7.2.5 Protein adsorption 
Human Fg (FIB3, plasminogen, von Willebrand factor and fibronectin depleted, 
Enzyme Research Laboratories) and Alb (Sigma, Catalog No. A9511) was dissolved in 
25 mM phosphate buffer solution (pH 7.4), to prepare the protein stock solutions, and 
159 
 
protein adsorption was carried out as described previously in Chapters  5 and 6, at a 
protein concentration of 0.1 mg/mL.  
The cleaned SAM surfaces were incubated in 25 mM potassium phosphate buffer (pH 
7.4) in a Pyrex petridish, and a suitable amount of protein stock solution was added to 
give the 0.1 mg/mL bulk protein solution concentration, taking care to ensure that the tip 
of the pipette was held below the air-water interface to avoid denaturation of the protein 
at this interface. The protein adsorption step lasted 2 h, after which an infinite dilution 
step was carried out to wash away the bulk protein solution in addition to any loosely 
adherent protein on the SAM surfaces. The SAM surfaces with preadsorbed protein were 
then incubated with the platelet suspension in a well-plate. 
 
7.2.6 Preparation of washed platelet suspension 
Platelet adhesion was carried out, using a suspension of washed platelets from human 
blood, as described in Chapters 5 and 6, in a well plate (Corning Costar, Catalog No. 
3527). 25.0 mL of blood was collected from healthy volunteers as per research protocols 
approved by the Institutional Review Board (IRB) and Institutional Biosafety Committee 
(IBC) at Clemson University. The first few mL of blood was discarded, as it is rich in 
clotting factors, and then 25 mL of blood was collected in BD Vacutainer tubes (Becton-
Dickinson, Catalog No. 364606) containing an acid-citrated dextrose (ACD) anti-
coagulant. 
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The ACD-anticoagulated blood was centrifuged (225g, 15 min, 25°C) to generate 
platelet rich plasma (PRP), and platelets were separated from PRP via a gel separation 
method [201], using a liquid chromatography column (Sigma-Aldrich, Catalog No. 
C4169) containing Sepharose 2B (Sigma-Aldrich, Catalog No. 2B-300). The Sepharose 
column was first equilibrated with PSB, after which the PRP was carefully pipetted on to 
the column and allowed to pass into the column. PSB was then added to the column from 
a reservoir, while keeping the column running. Fractions were collected from the bottom 
of the column, with the platelet-rich fractions being identified by their increased turbidity. 
These fractions were pooled, and platelet concentration was measured using a Beckman 
Coulter Z2 Coulter Particle Count and Size Analyzer (Beckman Coulter, Fullerton, CA). 
The platelet count was adjusted to the desired concentration with PSB, and CaCl2 and 
MgCl2 were added to give 2.5 mM and 1.0 mM concentrations of these salts, 
respectively. Platelet suspension was allowed to rest for 30 min, and the platelet adhesion 
step was carried out on the protein-coated SAMs for 1 h at 37°C.  
At the end of the platelet adhesion step, the platelet suspension was aspirated from 
each well, and the non-adherent platelets were rinsed away by filling and aspirating the 
wells five times with PBS. The substrates were transferred to a fresh well-plate, and the 
adhesion levels were quantified using a lactate dehydrogenase (LDH) assay.  
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7.2.7 Measurement of platelet adhesion using lactate dehydrogenase (LDH) assay 
The platelets adherent on the Fg- and Alb-coated SAMs were lysed with a Triton-PSB 
buffer, (2% v/v Triton-X-100 in PSB), and the platelet adhesion levels on the SAMs was 
quantified by measuring the lactate dehydrogenase (LDH) released from these lysed 
adherent platelets using a CytoTox96® Non-Radioactive Cytotoxicity Assay (Promega 
Corporation, Madison, WI), as indicated in Section 5.2.8. A calibration curve was 
constructed using a known number of platelets, counted using a Beckman Coulter Z2 
Coulter Particle Count and Size Analyzer, and the platelet adhesion on the SAM surfaces 
was determined from this calibration curve. 
 
7.2.8 Inhibition of platelet-protein interactions using anti-GPIb antibodies 6B4 and 
24G10 
Monoclonal antibodies 6B4 and 24G10 against the GPIb platelet receptor were 
generously provided by Dr. Hans Deckmyn (Laboratory for Thrombosis Research, 
Katholieke Universiteit, Leuven, Belgium). The platelet suspension was incubated first 
with 300 µM of an Arg-Gly-Asp-Ser (RGDS) peptide (Calbiochem, La Jolla, CA) for 30 
min at room temperature, in order to inhibit interactions between RGD-binding platelet 
receptors and adsorbed protein, followed by a similar incubation with 5 µg/mL of the 
anti-GPIb antibody for 30 min at room temperature, in order to inhibit any potential 
interactions between the GPIb platelet receptors and the adsorbed Fg/Alb.  These 
platelets were then allowed to adhere on the Fg- and Alb-coated SAM surfaces for 1h at 
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37°C, after which the platelet adhesion was quantified using an LDH assay and the 
morphology of the adherent platelets was examined using SEM. 
Control experiments were also carried out with a washed platelet suspension without 
blocking with RGDS prior to treatment with the anti-GPIb antibodies. 
 
7.2.9 Aggrastat treatment of platelets 
Aggrastat, which is a trade-name for the generic drug called tirofiban, is a potent αIIbβ3 
antagonist, and has been shown to inhibit platelet adhesion and activation on collagen 
[158]. The washed platelet suspension was treated with 5 µg/mL of Aggrastat (Baxter 
Healthcare, Product Code 2J1400) for 30 min at room temperature prior to the platelet 
adhesion step. The Aggrastat-treated platelets were then allowed to adhere to the Fg- and 
Alb-coated SAMs for 1h at 37°C, with the platelet adhesion levels being quantified using 
the LDH assay, and the adherent morphology of the platelets being examined via SEM. A 
platelet suspension without Aggrastat pre-treatment was used as a control in the platelet 
adhesion experiments. 
 
7.2.10 Acetylation of Arg and Lys residues in Alb using acetic anhydride 
Acetylation of proteins using acetic anhydride is one of the oldest and most 
extensively used methods for chemical modification of proteins [171]. Acetylation of Arg 
and Lys residues in Alb was carried out using acetic anhydride (Sigma-Aldrich), as 
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described previously [176, 178]. Briefly, an Alb solution was modified by the addition of 
10% acetic anhydride. The modification step lasted 2 h, after which modified protein 
samples were dialyzed for 12 h against 25 mM phosphate buffer, and then analyzed for 
Arg  and Lys modification via a protocol described previously [99] using electrospray 
ionization mass spectrometry (ESI-MS) performed at the Clemson University Genomics 
Institute, to confirm that the chemical reaction caused the modification of Arg and Lys 
residues. Additionally, acetylation of Alb on the CH3 and OH SAMs preadsorbed from 
0.1 mg/mL bulk solution concentration was carried out, as described above. 
 
7.2.11 CD studies to quantify the adsorption-induced conformational changes and 
total surface coverage of Alb on SAM surfaces  
The secondary structures of acetylated Alb in the solution and adsorbed states, along 
with the surface coverage of adsorbed Alb, was determined using a Jasco J-810 
spectropolarimeter (Jasco, Inc., Easton, MD), as described earlier (in Section 4.2.6). The 
solution structure was determined using a special high-transparency quartz cuvette 
(Starna Cells, Inc., Atascadero, CA), while the adsorbed structure of Alb on the SAM 
surfaces was determined using a special custom-designed cuvette, which maximizes the 
signal-to-noise ratio (as seen in Fig. 4.1). The ellipticity of the samples (θ, in mdeg) was 
converted to molar ellipticity (designated as [θ], with standard units of deg·cm2/dmol) 
using the following equation [132, 135]:  
[θ] = (θ · M0)/(10,000 · Csoln · L),          (7.1) 
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where θ is the ellipticity in mdeg, L is the path length of the cuvette in cm, Csoln is the 
solution concentration of the protein in g/mL, and M0 is the mean residue molecular 
weight of 118 g/mol. 
Since proteins exhibit an absorbance peak at 195 nm [184], we used the height of this 
absorbance peak (A195) for constructing a calibration curve of A195 vs. Csoln for various 
known concentrations of Alb, as described in Section 4.2.6. The slope of this plot is 
“εprotein·L” from Beer’s Law, which can be written as: 
A195 = εprotein · Csoln · L           (7.2) 
where εprotein is the extinction coefficient of the protein  in mL · g-1 · cm-1 (or cm2/g) and L 
is the path length of the cuvette.  
The term “Csoln · L” in eq. 7.2 (above) has units of g/cm2, which is equivalent to the 
amount of protein adsorbed per unit area. Assuming that the absorbance is dependent on 
the total amount of protein present per unit area through which the beam of light passes, 
irrespective of whether the protein is in the solution or the adsorbed state, the calibration 
curve of A195 vs. Csoln can also be used for calculating the amount of Alb adsorbed per 
unit area on the SAMs (i.e., Qads). The validity of this method for measuring the surface 
coverage of adsorbed protein has been confirmed by independent measurement of Qads 
from the thickness of the adsorbed protein film obtained by ellipsometry (see Section 4.5) 
using de Feijter’s formula [198]. 
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Hence, while calculating the molar ellipticity for the adsorbed Alb layer on the SAMs, 
the term “Csoln · L” in eq. 7.1 can be replaced by the term Qads to give the following 
equation: 
[θ] = (θ · M0)/(10,000 · Qads),     (7.3) 
The CD spectra (molar ellipticity vs. wavelength) thus obtained were deconvoluted 
using the SP-22X algorithm and analyzed using the CONTIN/LL software package to 
quantify the percentage of α-helix and β-sheet content of the Alb in the solution and 
adsorbed states [148]. 
 
7.2.12 Effect of acetylation of the adsorbed Alb layer on platelet adhesion 
The CH3 and OH SAM surfaces were preadsorbed with Alb at 0.1 mg/mL bulk 
solution concentration, and acetylation of the adsorbed Alb was carried out, using the 
protocol described in Section 7.2.11. After washing away the excess acetic anhydride, the 
surfaces were incubated with platelets, and the platelet adhesion levels were quantified 
using an LDH assay, with the morphology of the being observed using SEM. 
 
7.2.13 Statistical analysis 
The results we present are the mean values with 95% confidence intervals (CI). 
Statistical significance of differences between mean values for different samples and 
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conditions was evaluated using a Student’s t-test, with p ≤ 0.05 considered as statistically 
significant. 
 
7.3 Results and Discussion 
7.3.1 Effect of anti-GPIb antibodies on platelet adhesion to adsorbed Fg and Alb 
Our platelet adhesion results (shown in Chapters 5 and 6) indicated that platelet 
adhesion to adsorbed Fg and Alb was potentially mediated by a non-RGD-specific 
receptor set, in addition to an RGD-specific receptor set. As seen in the adherent 
morphology of the RGDS-treated platelets in Fig. 6.8, the platelets were moderately 
spread with little or no filopodia, suggesting that this non-RGD-specific receptor set 
mediated adhesion without activation. Since the GPIb-IX-V receptor complex is the 
second most abundant receptor complex on platelets [73], and has been shown to mediate 
adhesion without activation on collagen [111], we examined its role as the non-RGD-
specific platelet receptor set mediating adhesion to adsorbed Fg and Alb. Since studies 
[165, 166] have implicated two vWf-binding domains in platelet GPIbα spanning amino 
acid residues 1-81 and 201-268, we used monoclonal antibodies 24G10 and 6B4 against 
these domains, respectively, in delineating the interactions of this receptor complex with 
adsorbed Fg and Alb.  
 
 Figure 7.2. Platelet adhesion on SAM surfaces preadsorbed with Alb and Fg from 0.1 
mg/mL solutions under various blocking conditions. The blocking treatments 
platelet suspension included the anti
platelets with an RGDS peptide prior to incubation with 24G10 
denotes no statistically significant difference, 
 
As shown in Fig. 7.2, the addition of 24G10 did not lead to 
platelet adhesion levels on the CH
Although we cannot explain the statistically significant higher adhesion levels for 
(RGDS+24G10)-treated platelets compared to the RGDS
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SAM preadsorbed with Alb in Fig. 7.2, this result indicates that the addition of 24G10 did 
not cause any additional inhibition of the adhesion of the RGDS-treated platelets on this 
surface. Similarly, on the CH3 SAM preadsorbed with Fg, the addition of the 24G10 anti-
GPIb antibody did not lead to a decrease in platelet adhesion levels compared to the 
corresponding unblocked control. These results suggest that the amino acid residues 1-81 
in GPIbα do not mediate platelet attachment to adsorbed Fg and Alb, as seen by the 
inability of 24G10 to inhibit the adhesion of untreated and RGDS-treated platelets to the 
adsorbed proteins. 
Further analysis of the adhesion data for platelet adhesion to adsorbed Fg and Alb on 
these SAMs yielded the observation that although the extent of Fg and Alb unfolding was 
vastly different on the OH and CH3 SAMs (~0% Fg unfolding on OH and 72% Fg 
unfolding on CH3; ~34% Alb unfolding on OH and 77% Alb unfolding on CH3), the 
extents of RGDS inhibition were similar (~50%). This suggests that the process of 
adsorption-induced unfolding does not change the basic mechanism that is mediating 
platelet adhesion to the adsorbed Fg and Alb.  
The addition of 6B4, like 24G10, did not lead to an increased inhibition of platelet 
adhesion to adsorbed Fg or Alb, as seen in Fig. 7.3. There was no statistically significant 
difference between the platelet adhesion levels of untreated and 24G10-treated platelets 
on the CH3 and OH SAMs preadsorbed with Fg and Alb. The increased adhesion of the 
(RGDS+6B4)-treated platelets compared to RGDS-treated platelets on the CH3 SAM 
 preadsorbed with Alb confirms that the addition of 6B4 did not cause any further 
inhibition of the adhesion of these RGDS
These combined results for 24G10 and 6B4 indicate that the GPIb
not play a role in mediating platelet adhesion to adsorbed Fg and Alb as the non
specific receptor set.   
Figure 7.3. Platelet adhesion on SAM surfaces preadsorbed with Al
mg/mL solutions under various blocking conditions. The blocking treatments 
platelet suspension included 
platelets with an RGDS peptide prior to incubation with 6B4 
denotes no statistically significant difference, 
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7.3.2 Effect of Aggrastat-pretreatment on platelet adhesion to adsorbed Fg and Alb 
Platelet adhesion and activation on collagen has been shown to be inhibited by the 
αIIbβ3 antagonist Aggrastat [158]. This is a potent, small molecule RGD-mimetic drug, 
which utilizes the separation distance between the Arg and Asp residues as a key 
determinant of its potency [212]. We therefore examined the ability of Aggrastat to 
inhibit interactions with adsorbed Fg and Alb, which, based on literature reports, should 
occur by blocking the αIIbβ3 platelet receptor. 
The addition of Aggrastat to the washed platelet suspension prior to the platelet 
adhesion step led to a strong inhibition of platelet adhesion to adsorbed Fg and Alb, 
compared to the untreated and RGDS-treated platelet suspensions, as indicated in Fig. 
7.4. The CH3 SAM surfaces preadsorbed with Fg and Alb still exhibited low levels of 
platelet adhesion despite Aggrastat-pretreatment, and this could potentially be attributed 
to the inability of Aggrastat to inhibit the αVβ3 integrin [213], which belongs to the β3 
family of integrins like αIIbβ3, and is present on platelets with several hundred copies per 
platelet [207]. Thus, Aggrastat is clearly a more potent inhibitor of platelet interactions 
with the adsorbed proteins than the RGDS peptide.  
 
 Figure 7.4. Adhesion of Aggrastat
Alb and Fg from 0.1 mg/mL solutions
platelets. (n=6, mean ± 95% CI).  * denotes no statistically significant difference, 
0.05.  
 
The results obtained in Chapters 5 and 6 with RGDS
platelet suspension suggested that the remaining adhesion observed for RGDS
platelets may either be mediated by the 
state, or potentially by another receptor set which may become active upon addition of 
RGDS, as RGD-containing peptides have been shown to activate 
171 
-treated platelets on SAM surfaces preadsorbed with 
, compared to untreated and RGDS
-pretreatment of the washed 
αIIbβ3 receptor in its RGD-bound ‘low
αIIbβ3 and other platelet 
 
-treated 
p > 
-treated 
-affinity’ 
172 
 
receptors [155, 158]. However, the ability of Aggrastat to function as a near-complete 
inhibitor of platelet adhesion to adsorbed Fg and Alb (as seen in Fig. 7.4), clearly 
illustrates the critical role played by the αIIbβ3 receptor in accounting for approximately 
90% of the platelet adhesion response.  
Studies have shown that the activation of αIIbβ3 due to inside-out platelet signaling or 
ligand binding (Fg, Fn, vWf, Vn) leads to conformational alterations in αIIbβ3 [105, 208]. 
These changes induce outside-in platelet signaling, leading to intraplatelet cytoplasmic 
changes including increased tyrosine kinase activity, cytoskeletal changes and platelet 
spreading [214].  Changes in the cytoplasmic domain of the β3 sub-unit of αIIbβ3 have 
been shown to be a critical determinant of αIIbβ3-mediated outside-in signaling [160, 161, 
215]. RGDS binding induces changes in both the αIIb and β3 sub-units of the αIIbβ3 
platelet integrin, leading to outside-in platelet signaling which causes platelet adhesion 
and activation, thereby explaining the ability of RGDS-treated platelets to adhere to 
adsorbed Fg and Alb. Aggrastat, on the other hand, induces conformational changes only 
in the αIIb sub-unit but not the β3 sub-unit of αIIbβ3 [156, 157], which does not induce 
outside-in signaling, thus explaining the strong inhibitory effect that we observed on 
platelet interactions with adsorbed Fg and Alb.  
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7.3.3 Effect of acetylation of Arg and Lys residues in adsorbed Alb on platelet 
adhesion 
Our preliminary results (listed in Chapter 6) showed that the site-specific chemical 
modification of Arg residues led to a significant decrease in platelet adhesion, indicating 
that these residues play a critical role in the adhesion process. However, platelet adhesion 
to Fg has also been shown to be mediated by Lys residues in certain domains, such as in 
the dodecapeptide sequence (HHLGGAKQAGDV) in the C-terminus of the γ-chain 
segment of Fg.  Since the Alb molecule contains 59 Lys residues, as compared to 24 Arg 
residues, we also examined chemical modification of both Lys and Arg residues in the 
adsorbed Alb layer as a potential strategy to determine if Lys residues also play a role in 
platelet attachment to the adsorption-induced unfolded state of Alb.  
The ESI-MS results confirmed that all 24 Arg residues were modified, while 52 out of 
58 Lys residues were modified, under the applied conditions, thus confirming that the 
applied treatment modified these residues with high efficiency.  It is assumed that the Lys 
residues that were not modified were not solvent accessible.  The acetylation process had 
minimal effect on the secondary structural content of Alb in its solution and adsorbed 
state, as seen in Table 7.1 and in Fig 7.5.  
 
 
 
 Table 7.1. Comparison of secondary structural composition of unmodified Alb and Alb 
with Arg and Lys residues 
adsorption on the CH3 and OH SAMs (n= 6, mean ± 95% CI). 
Sample
In solution 
Human Alb unmodified
Human Alb-acetylated
After adsorption 
CH3, 0.1 mg/mL Alb-
CH3, 0.1 mg/mL Alb-
OH, 0.1 mg/mL Alb-unmodified
OH, 0.1 mg/mL Alb-acetylated
 
Figure 7.5. Representative CD spectra for solution structure of normal native Alb and 
acetylated Alb with modified 
174 
acetylated using acetic anhydride, in solution and after 
 
 α-helix (%) β-sheet (%)
  
 
68.8 ± 2.3 0.1 ± 
 
66.4 ± 0.7 0.8 ± 0.4
  
unmodified 14.4 ± 0.7 28.3 ± 0.7
acetylated 15.0 ± 2.2 27.4 ± 1.8
 
43.1 ± 2.1 13.4 ± 1.1
 
41.1 ± 2.4 13.4 
Arg and Lys residues. 
 
0.1 
 
 
 
 
± 2.0 
 
 Figure 7.6. Platelet adhesion to SAM surfaces preadsorbed with Alb from 0.1 mg/mL 
solution, for unblocked and acetylated (R+K modified) conditions. Data for R
Alb is reproduced for comparison from Chapter 6. 
statistically significant difference, 
 
The acetylation of adsorbed Alb led to a significant decrease in platelet adhesion, as 
observed in Fig. 7.6. However, the reduction in adhesion levels was not significantly 
different (p = 0.12 for CH3, 
modification of the Arg residues in adsorbed Alb via butanedione treatment. These 
results suggest that the Lys residues in adsorbed Alb likely do not play a role in 
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mediating platelet binding, and that the Arg residues in Alb are the only positive charged 
amino acid residues which are involved in platelet binding.  
Coupled with the results obtained from the pretreatment of platelets with Aggrastat 
(Fig. 7.4), which suggest that the platelet adhesion to Alb is mediated by the RGD-
specific αIIbβ3 receptor, this confirms the critical role played by the Arg residues in 
adsorbed Alb in mediating platelet adhesion. These combined results indicate that the 
residual platelet adhesion that occurred on acetylated Alb must be attributed to amino 
acid residues in Alb other than Arg or Lys, with further studies being necessary to 
determine which other amino acid residues are involved. 
 
7.4 Conclusions 
These studies were primarily aimed at delineating the roles of the GPIb-IX-V and 
αIIbβ3 platelet receptors in mediating platelet adhesion to adsorbed Fg and Alb. Although 
we had initially hypothesized that the former receptor set likely mediated adhesion with 
little/no activation as the non-RGD-specific receptor, our studies showed that anti-GPIb 
antibodies 6B4 and 24G10 were unable to inhibit the adhesion of untreated as well as 
RGDS-treated platelets to the adsorbed Fg and Alb layers. Furthermore, the fact that the 
anti-αIIbβ3 platelet antagonist drug Aggrastat nearly completely inhibited platelet adhesion 
indicates that the αIIbβ3 platelet integrin is the primary receptor involved in about 90% of 
the platelet binding to adsorbed Fg and Alb.  
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Chemical modification studies of amino acid residues provide information on the role 
of specific amino acids in mediating platelet attachment. Platelet adhesion studies to 
acetylated Alb yielded results that indicated that the Arg residues play a critical role in 
platelet binding to Alb, while the Lys residues likely had no role in this process. Further 
chemical modification studies are necessary to determine which other amino acid 
residues are involved in mediating platelet adhesion to Alb other than Arg.  
Overall, these studies provide new insights into the molecular-level mechanisms 
mediating the interactions of platelets with adsorbed plasma proteins. This level of 
understanding is needed by biomaterials field to support its efforts to develop potent 
strategies to inhibit platelet adhesion to adsorbed proteins for the design of more 
hemocompatible biomaterials for cardiovascular applications. 
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CHAPTER 8 
TIME-DEPENDENT CONFORMATIONAL CHANGES IN ADSORBED 
ALBUMIN, AND ITS SUBSEQUENT EFFECT ON PLATELET ADHESION  
 
8.1 Introduction 
The layer of adsorbed proteins on a material surface is a critical determinant of the 
bioactivity of the tissue-biomaterial interface [1, 31], affecting blood coagulation, 
complement activation and subsequent cell adhesion. It is a well known fact that proteins 
undergo some degree of structural changes when they come into contact with solid 
substrates. Conformational changes in the adsorbed protein molecules leads to stronger 
protein-surface interactions, which can lead to greater surface activity [31]. Additionally, 
hydrophobic regions which are generally located in the interior of the protein may 
become exposed upon protein unfolding.  
The adsorption-induced conformational changes in the protein layer have been shown 
to mediate the subsequent cellular response to the biomaterial [1, 33]. Additionally, these 
structural alterations in adsorbed plasma proteins play a critical role in the ability of non-
activated platelets to bind to the adsorbed protein layer [54, 55, 116] and mediate the 
thrombotic response, as shown in our experiments with adsorbed fibrinogen (Fg) and 
albumin (Alb), in Chapters 5 and 6, respectively. 
According to Dee et al. [31], proteins can undergo conformational changes in two 
ways. One mode results from changes in the bulk protein solution concentration, while 
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the other involves time-dependent protein unfolding. In the former, the bulk solution 
concentration of the protein influences the rate of transport of protein molecules to the 
surface. Thus, at lower bulk protein solution concentrations, the protein molecules arrive 
at the surface at a slower rate compared to higher bulk concentrations, as a result of 
which they have more surface area over which they can spread (and form contacts), 
before they come into contact with neighboring protein molecules [31, 39]. Hence, the 
adsorption-induced conformational changes in proteins would be expected to be more 
pronounced, while the surface coverage would be lower, when the protein is adsorbed 
from lower bulk protein solution concentrations. This effect was clearly shown in our 
preliminary results in Chapter 4. On the other hand, as the residence time (i.e., the time 
the protein molecule resides on the surface) increases, the protein may unfold and expose 
functional residues in its interior which can potentially interact with the surface, as well 
as alter the bioactivity of the protein.  
Fibrinogen (Fg) has been shown to undergo increased conformational changes with 
increasing residence time, which render it potentially less recognizable by platelets [37, 
38]. However, these results represent the ability of anti-Fg antibodies to recognize Fg and 
may not accurately represent Fg recognition by platelets. Studies done by 
Balasubramanian et al. [36] on the effect of residence time on Fg adsorption and platelet 
adhesion to polytetrafluoroethylene (PTFE), polyethylene (PE) and silicone rubber (SR) 
showed that there was a very minimal decrease in platelet adhesion levels with increasing 
Fg residence time, which was not statistically significant. Additionally, the binding of the 
monoclonal antibody (mAb) 4A5 against the γC terminal dodecapeptide sequence (γ400-
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411) of Fg, which is considered to be the primary platelet binding sequence in Fg [58], 
has been shown to be independent of the residence time of Fg for time periods up to 2 h 
following adsorption [36, 216]. mAb binding against the RGDF sequence (α95-98) was 
shown to be low initially, but increased with residence time [216], which may suggest 
that this amino acid sequence may become exposed as the adsorbed Fg unfolds with time. 
More recent studies [217, 218] have examined time-dependent conformational changes in 
Fg via atomic force microscopy (AFM), and its subsequent effect on platelet adhesion 
[218]. Platelet adhesion to adsorbed Fg was found to correlate well with the functional 
activity of the adsorbed Fg, peaking at 45 min of residence time and gradually decreasing 
with further increase in residence time [218].  
These studies [36-38, 216-218] were done using low bulk Fg solution concentrations 
for short adsorption times (less than 15 min), after which the protein-coated substrates 
were rinsed and immersed in PBS for relatively short residence times of up to 2 h. The 
biomaterials field has yet to examine the potential conformational changes in an 
irreversibly adsorbed, tightly packed layer of plasma protein(s) on material surfaces over 
long residence times (of the order of weeks to months), and its effect (if any) on 
subsequent platelet adhesion and the blood compatibility of the biomaterial.  
Alb is the most abundant plasma protein [77], and has been shown to be one of the 
first proteins to adsorb on implant surfaces [79].  Studies have shown minimal desorption 
of adsorbed Alb by other more surface-active proteins such as IgG and Fg [34, 219] on 
hydrophilic and hydrophobic surfaces, suggesting that adsorbed Alb may be a major 
component of the protein layer adsorbed on biomaterial implants. Additionally, the 
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inability of Fg to displace adsorbed Alb was found to be more prominent for longer Alb 
aging times on hydrophobic surfaces [34].  
Our results listed in Chapter 6 indicated that platelet adhesion can occur on adsorbed 
Alb, but only if the adsorbed Alb underwent structural unfolding beyond a critical degree 
(i.e., unfolding resulting in about 34% loss in its α-helical structure). When Alb was 
preadsorbed from 10.0 mg/mL bulk solution concentration on SAM surfaces, minimal 
loss in the protein’s structure was found to occur. This effect was attributed to the Alb not 
having sufficient time following adsorption to undergo surface-induced unfolding before 
neighboring proteins adsorbed and inhibited its ability to spread out on the surface. 
Therefore, when Alb is adsorbed from a solution concentration of 10.0 mg/mL or higher, 
it is expected that it will adsorb as an irreversibly bound, tightly packed layer that largely 
retains its native-state structure, thus being unable to mediate platelet adhesion. Because 
Alb is present at even higher concentrations in blood plasma (about 40 mg/mL), these 
results suggest that under clinical conditions, Alb will adsorb to an implant’s surface with 
a minimal degree of unfolding, with negligible subsequent ability to support platelet 
adhesion. If this is the case, then our previous findings regarding platelet adhesion to 
unfolded Alb, while academically interesting, is of little clinical significance. However, 
the findings that Alb mediates platelet adhesion beyond a critical degree of unfolding (as 
shown in Fig. 6.3A) and generally adsorbs in an irreversible manner to surfaces, raise the 
question whether Alb that retains its native-state structure after adsorbing on an implant 
surface will undergo structural changes over time, and if so, whether this will lead to 
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platelet adhesion if the adsorbed Alb unfolds beyond our previously determined critical 
level.  
The objectives of the studies presented in this chapter were to investigate if time-
dependent conformational changes occur in an irreversibly adsorbed, tightly packed Alb 
layer that initially retains its native-state  structure, and if this aging-induced unfolding 
process causes the adsorbed Alb to begin to support platelet adhesion if unfolding occurs 
beyond  the previously determined critical degree of unfolding.  In these studies, we used 
circular dichroism (CD) spectropolarimetry to monitor the structural state of adsorbed 
Alb that was preadsorbed from 10.0 mg/mL bulk solution concentration on CH3 and OH 
SAMs and aged over a six month period of time, with the platelet adhesion response to 
this adsorbed Alb layer quantified at selected time points via a lactate dehydrogenase 
(LDH) assay.  
 
 
8.2 Materials and Methods 
8.2.1 Gold substrates 
Quartz slides (0.375” x 1.625” x 0.0625”, Chemglass) were used for CD experiments, 
while 18 mm square cover glasses (VWR Scientific, Catalog No. 48368-040) were used 
as substrates for the platelet adhesion experiments. These substrates were cleaned as 
described in Chapter 3. The substrates were incubated in a piranha solution (7:3 v/v 
H2SO4:H2O2) at 50°C for 30 min, followed by an RCA basic wash (1:1:5 v/v 
NH4OH:H2O2:H2O), and this cleaning procedure was repeated twice. These cleaned 
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substrates were then rinsed copiously with 100% ethanol (Pharmco-Aaper; Catalog No. 
111000200) and nanopure water, and finally dried using a stream of nitrogen gas.   
The cleaned substrates were coated with a chromium adhesion layer followed by a 
gold layer via a thermal vapor deposition method. A 50 Å chromium adhesion layer and 
1,000 Å of gold were deposited on the cover glasses, while the quartz slides for CD were 
coated with 30 Å of chromium and 100 Å of gold. The thicknesses of the gold and 
chromium layers were also verified using a DekTak profilometer and a GES5 
ellipsometer (Sopra, Inc., Palo Alto, CA).  
 
8.2.2 Formation of self-assembled monolayers (SAMs) of alkanethiols 
1-Dodecanethiol (SH-(CH2)11CH3; Aldrich; CH3) and 11-Mercapto-1-undecanol (SH-
(CH2)11OH; Aldrich; OH) in 100% ethanol were used as the alkanethiols for creating the 
SAM surfaces, as described previously in Chapter 4.  
The gold-coated substrates were dipped in a modified piranha wash (4:1 v/v 
H2SO4:H2O2), followed by an RCA basic wash, for 1 minute each and then rinsed 
copiously with 100% ethanol, to clean them. The cleaned gold substrates were then 
incubated in 1.0 mM alkanethiol solutions for 24 h, as per the established protocols 
described previously [181, 182].  
Prior to the protein adsorption step, the SAM surfaces were cleaned to remove any 
traces of hydrophobic contaminants on their surface [99]. The CH3 SAMs were sonicated 
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in ethanol, hexane and ethanol, and then rinsed with nanopure water. The OH SAMs 
were sonicated in ethanol, and then incubated in a 25 mM potassium phosphate buffer 
containing 0.005 volume % Triton-X-100 (Sigma; Catalog No. T-9284) in order to block 
off hydrophobic defect sites (e.g. grain boundaries), and then rinsed thoroughly with 
acetone, ethanol and nanopure water to remove loosely-bound Triton. 
 
8.2.3 Buffers 
25 mM potassium phosphate buffer (pH 7.4), prepared by combining appropriate 
amounts of the mono- and dibasic salts (Sigma-Aldrich) to maintain the pH at 7.4, was 
used for all adsorption experiments. This buffer is recommended for CD experiments to 
determine the secondary structure of proteins [79, 132, 193] as it permits measurement of 
CD spectra with minimal noise below 200 nm, especially the positive CD peaks at 193 
and 195 nm, which are critical in determining the α-helix and β-sheet content of the 
proteins, respectively. 
The platelet suspension buffer (PSB, pH 7.4) contained 137 mM NaCl, 2.7 mM KCl, 
5.5 mM Dextrose, 0.4 mM sodium phosphate monobasic, 10 mM HEPES and 0.1 U/mL 
apyrase [201]. 2.5 mM CaCl2 and 1.0 mM MgCl2 was added to the PSB to give a platelet 
suspension buffer with metal ions (PSB+MI).   
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8.2.4 Protein adsorption 
The Alb stock solution was prepared by dissolving human Alb (Sigma, Catalog No. 
A9511) in 25 mM phosphate buffer solution (pH 7.4), and protein adsorption was carried 
out as described previously in Chapters 4 and 6, at a bulk solution concentration of 10.0 
mg/mL, so as to obtain an irreversibly adsorbed, tightly packed layer(s) of adsorbed Alb.  
The cleaned SAM surfaces were incubated in 25 mM potassium phosphate buffer (pH 
7.4), and then a suitable amount of Alb stock solution was added to give the desired bulk 
protein solution concentration. Special care was taken to ensure that the tip of the pipette 
was held below the air-water interface to avoid denaturation of the protein at this 
interface. The protein adsorption step lasted for 2 h, after which an infinite dilution step 
was carried out to wash away the bulk protein solution as well as any loosely adherent 
protein.  
 
8.2.5 CD studies to quantify the adsorption-induced conformational changes and 
total surface coverage of Alb on SAM surfaces  
A Jasco J-810 spectropolarimeter (Jasco, Inc., Easton, MD) was used to determine the 
native and adsorbed secondary structures of Alb, as well as the surface coverage of 
adsorbed Alb, as described earlier in Section 4.2.6. The native solution structure of Alb 
was determined using a high-transparency quartz cuvette (Starna Cells, Inc., Atascadero, 
CA), while the adsorbed structure of Alb on the SAM surfaces was determined using a 
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special custom-designed cuvette (as seen in Fig. 4.1), which maximizes the signal-to-
noise ratio. The ellipticity of the samples (θ, in mdeg) was converted to molar ellipticity 
(designated as [θ], with standard units of deg·cm2/dmol) using the following equation 
[132, 135]:  
[θ] = (θ · M0)/(10,000 · Csoln · L),    (8.1) 
where θ is the ellipticity in mdeg, L is the path length of the cuvette in cm, Csoln is the 
solution concentration of the protein in g/mL, and M0 is the mean residue molecular 
weight of 118 g/mol. 
Since proteins exhibit an absorbance peak at 195 nm [184], a calibration curve plotting 
the height of this peak (A195) as a function of Csoln for various known concentrations of 
Alb was created, as described in Section 4.2.6. The slope of this plot is “εprotein·L” from 
Beer’s Law, which can be written as: 
A195 = εprotein · Csoln · L    (8.2) 
where εprotein is the extinction coefficient of the protein  in mL · g-1 · cm-1 (or cm2/g) and L 
is the path length of the cuvette.  
The term “Csoln · L” in eq. 8.2 has units of g/cm2, which is equivalent to the amount of 
protein adsorbed per unit area. Assuming that the absorbance is dependent on the total 
amount of protein present per unit area through which the light beam passes, irrespective 
of whether the protein is in the solution or the adsorbed state, the calibration curve of 
A195 vs. Csoln can also be used for calculating the surface coverage of adsorbed Alb on the 
SAMs (i.e., Qads). The validity of this method for measuring the amount of adsorbed 
protein has been confirmed by independent measurement of Qads from the thickness of 
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the adsorbed protein film obtained by ellipsometry (see Section 4.5.S.2) using de Feijter’s 
formula [198]. 
Hence, in the calculation for the molar ellipticity of the adsorbed Alb layer on the 
SAMs, the term “Csoln · L” in eq. 8.1 can be replaced by the term Qads to give the 
following equation: 
[θ] = (θ · M0)/(10,000 · Qads),     (8.3) 
The CD spectra (molar ellipticity vs. wavelength) thus obtained were deconvoluted 
using the SP-22X algorithm and analyzed using the CONTIN/LL software packages to 
quantify the percentage of α-helix and β-sheet content of the native/adsorbed Alb [148]. 
 
8.2.6 Platelet adhesion 
The platelet adhesion experiments were carried out using a suspension of washed 
human platelets. Briefly, 25.0 mL of blood was collected from volunteers in BD 
Vacutainer tubes (Becton-Dickinson, Catalog No. 364606) containing an acid-citrated 
dextrose (ACD) anti-coagulant, as per protocols approved by the Institutional Review 
Board (IRB) and Institutional Biosafety Committee (IBC) at Clemson University. It is 
important to note that the first few mL of blood was discarded, as it is rich in clotting 
factors and then 25 mL of blood was collected. 
The blood collected was then centrifuged (225g, 15 min, 25°C) to generate platelet 
rich plasma (PRP), and platelets were separated from the PRP via a gel separation 
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method [201], using a liquid chromatography column (Sigma-Aldrich, Catalog No. 
C4169) containing Sepharose 2B (Sigma-Aldrich, Catalog No. 2B-300). The Sepharose 
column was equilibrated with PSB, prior to layering the PRP on the column. PSB was 
then added to the column from a reservoir, with the column running. Fractions were 
collected from the bottom of the column, with the platelets being identified by their 
increased turbidity, and the platelet-rich fractions were pooled. Platelet concentration was 
measured using a Beckman Coulter Z2 Coulter Particle Count and Size Analyzer 
(Beckman Coulter, Fullerton, CA), and the platelet count was adjusted to 108 
platelets/mL with PSB. CaCl2 and MgCl2 were added to give 2.5 mM and 1.0 mM 
concentrations of these salts, respectively. The washed platelet suspension was allowed to 
rest for 30 min, and the platelet adhesion step was carried out on the protein-coated 
SAMs for 1 h at 37°C.  
At the end of the platelet adhesion step, the platelet suspension was aspirated from 
each well, and the non-adherent platelets on the Alb-coated surfaces were rinsed away by 
filling and aspirating the wells five times with PBS. The substrates were then removed to 
a fresh well-plate, for carrying out the lactate dehydrogenase (LDH) assay to quantify the 
platelet adhesion levels.  
 
8.2.7 Measurement of platelet adhesion using lactate dehydrogenase (LDH) assay 
A CytoTox96® Non-Radioactive Cytotoxicity Assay (Promega Corporation, Madison, 
WI), was used for quantification of the platelet adhesion levels on the Alb-coated SAMs 
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by measuring the lactate dehydrogenase (LDH) released when the adherent platelets were 
lysed with a Triton-PSB buffer, (2% v/v Triton-X-100 in PSB), as indicated in Section 
5.2.9. A calibration curve was constructed by concurrent measurement of the LDH 
released from a known number of platelets, and the platelet adhesion on the SAM 
surfaces was determined from this calibration curve. 
 
8.2.8 Aging studies for adsorbed Alb on SAM surfaces 
CD and platelet adhesion studies were performed to measure the conformation of the 
adsorbed Alb layers on the SAM surfaces and the platelet adhesion response to the 
adsorbed Alb at day 0. The Alb-coated SAMs were then re-immersed in fresh 25 mM 
potassium phosphate buffer, supplemented with 0.1% cellgro antibiotic/antimycotic 
solution (Mediatech Inc., Catalog No. MT30-004-CI). These substrates were then 
incubated for up to 6 months at 37°C in an incubator, with the buffer (supplemented with 
antibiotic/antimycotic solution) being replenished regularly at 2 week intervals. CD and 
platelet adhesion analyses were then performed after aging the adsorbed Alb layers at 3 
month and 6 month time points following initial Alb adsorption. Prior to conducting the 
CD and platelet adhesion studies, the protein-coated aged samples were infinitely diluted 
and rinsed copiously with nanopure water, to remove all traces of the 
antibiotic/antimycotic solution. 
 
190 
 
8.2.9 Statistical analysis 
The results we present are the mean values with 95% confidence intervals (CI). 
Statistical significance of differences between mean values for different samples and 
conditions was evaluated using a Student’s t-test, with p ≤ 0.05 considered as statistically 
significant. 
 
8.3 Results and Discussion 
8.3.1 Time-dependent conformational changes in adsorbed Alb on SAM surfaces 
The percentage α-helix and β-sheet content of Alb adsorbed on the CH3 and OH 
SAMs from 10.0 mg/mL bulk Alb solution concentration, determined using adsorbed-
state CD spectropolarimetry, is presented in Fig. 8.1. 
As seen in Fig. 8.1, there was a distinct loss in α-helix of adsorbed Alb with increasing 
residence time over the 6 month duration of the study for both the OH and CH3 SAMs, 
indicating that the adsorbed Alb layer underwent a significant degree of structural 
unfolding over the 6-month time period. This is in agreement with previous studies which 
have pointed to the fact that proteins undergo time-dependent conformational changes 
[31, 37, 38]. Additionally, the decrease in α-helix of adsorbed Alb was more pronounced 
on the CH3 SAM compared to the OH SAM, which is in agreement with observations 
from studies done by other groups [33, 35] as well as our preliminary CD results listed in 
Chapter 4. This increased extent of unfolding on the hydrophobic CH3 SAM as compared 
 to the hydrophilic OH SAM may be attributed 
on hydrophobic surfaces which induces protein unfolding in order to minimize the overall 
solvent-accessible surface area of the system. 
 
Figure 8.1.  Secondary structural changes in Alb adsorbed on OH (left) and
SAMs, from 10.0 mg/mL bulk solution concentration for time points of 0, 3, and 6 
months (n=10, mean ± 95% CI).  The native solution structure of Alb is included for 
comparison. * denotes no statistically significant difference, 
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p > 0.05.  
 
 CH3 (right) 
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Table 8.1. Amounts of Alb adsorbed on CH3 and OH SAM surfaces from 10.0 mg/mL 
bulk solution concentrations, for 3 and 6 month residence times. Initial values of surface 
coverage at day 0 are included for comparison (n= 6, mean ± 95% CI). 
Surface 
Day 0 
[µg/cm2] 
3 months 
[µg/cm2] 
6 months 
[µg/cm2] 
CH3 2.65 ± 0.24 2.63 ± 0.30 2.83 ± 0.18 
OH 1.63 ± 0.23 1.64 ± 0.19 1.73 ± 0.16 
 
8.3.2 Surface coverage of adsorbed Alb over residence times up to six months 
In addition to the percentages of α-helix and β-sheet of the adsorbed Alb, the surface 
coverages on the CH3 and OH SAMs were also calculated at day 0, 3 months, and 6 
months, with the results listed in Table 8.1. The values for the amount of Alb adsorbed 
were comparable to those obtained in our earlier studies listed in Chapter 6 (2.71 ± 0.18 
µg/cm2 for the CH3 SAM, 1.77 ± 0.49 µg/cm2 for the OH SAM). Additionally, the 
surface coverage values remained consistent over the six month residence time, 
suggesting that the adsorbed Alb layer did not desorb over this period of time. 
 
8.3.3 Effect of residence-time dependent changes in adsorbed Alb on platelet 
adhesion 
Our previous results indicated that platelet adhesion to adsorbed Alb on SAM surfaces 
was significantly reduced for preadsorption from 10.0 mg/mL bulk solution concentration 
 compared to those for preadsorption from 0.1 and 1.0 mg/mL bulk solution 
concentrations, as presented in Chapters 5 and 6. This was attributed to the relatively 
minimal conformational changes undergone by the adsorbed Alb layer u
conditions. Our primary aim was to examine whether this adsorbed Alb layer on an 
implant surface underwent any structural changes for residence times of up to six months, 
and if so, whether this would enable and enhance platelet adhesion, an iss
not been previously addressed by the biomaterials field. 
 
Figure 8.2.  Platelet adhesion to OH and CH
mg/mL bulk solution concentration, 
95% CI).  * denotes no statistically significant difference, 
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Figure 8.3. Platelet adhesion to adsorbed Alb aged on the OH and CH3 SAM surfaces for 
‘aging’ times of 0, 3, and 6 months, as a function of the degree of unfolding, as measured 
by the percentage loss in α-helix. These data points are overlaid on Fig. 6.3A for purposes 
of comparison. (Each point represents the mean of six values for each SAM surface). 
 
The platelet adhesion levels on the OH and CH3 SAMs preadsorbed with Alb from 
10.0 mg/mL bulk solutions for residence times of 0, 3, and 6 months are shown in Fig. 
8.2. Although there was no statistically significant difference in the platelet adhesion 
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levels on the OH and CH3 SAMs at day 0, the difference in the adhesion levels on the 
two SAMs became apparent after 3 and 6 months of aging, following the same general 
trend observed for the aging-induced conformational changes in the adsorbed Alb layer 
(as seen in Fig. 8.1); i.e., more pronounced on the hydrophobic CH3 SAM compared to 
the hydrophilic OH SAM for both 3 and 6 months of aging.  Additionally, the platelet 
adhesion response on the OH SAM preadsorbed with Alb and aged over 6 months 
showed a significant increase compared to the two earlier time points (which were not 
statistically significantly different from each other). Similarly, there was a strong increase 
in the platelet response at the 6 month time point compared to the values at 3 months and 
day 0 on both SAMs. Coupled with the information on the conformational state of the 
adsorbed Alb layer on the SAM surfaces from Fig. 8.1, these results suggest that platelet 
adhesion to the adsorbed Alb layers over increasing residence times is driven by the time-
dependent conformational changes in the adsorbed Alb layer.  
The platelet adhesion levels on these aged Alb layers as a function of the degree of 
time-dependent unfolding, as measured by the percentage loss of α-helix, was overlaid on 
Figure 6.3A in which we had previously plotted the platelet adhesion levels on the 
different SAM surfaces at the three different Alb preadsorption conditions as a function 
of the percentage α-helix loss. As seen in Fig. 8.3, the large increase in the platelet 
adhesion levels on the OH SAM after 6 months of residence time can be attributed to the 
fact that the degree of unfolding at this time-point was greater than the critical degree of 
unfolding (~34% loss in α-helix) required for an adsorbed Alb layer to mediate platelet 
attachment, with platelet adhesion being even greater than that which was found for the 
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same degree of unfolding without aging.  Although the CH3 SAM aged over a 3 month 
period exhibited platelet adhesion levels which were somewhat lower than anticipated as 
per Fig. 8.3, the platelet adhesion response on the same SAM surface after 6 months of 
aging was found to be significantly greater than that which occurred for the same degree 
of unfolding without aging.  
 
8.4 Conclusions 
This study is the first study to our knowledge to examine long-term, aging-induced 
conformational changes in an adsorbed plasma protein, and its potential effect on platelet 
adhesion. The results conclusively illustrate that an irreversibly adsorbed, tightly packed 
layer of Alb is structurally altered with increasing residence time, and this leads to an 
enhanced platelet adhesion response. The platelet adhesion levels on the CH3 and OH 
SAMs agree well with the results presented in Chapter 6, which suggest that Alb is 
capable of mediating platelet adhesion only beyond a critical degree of adsorption-
induced unfolding. Since Alb is the most abundant plasma protein [77], and has been 
shown to only exhibit minimal to modest desorption by more surface-active plasma 
proteins, such as Fg and IgG, these results have critical implications in the development 
of a more comprehensive understanding of the factors associated with the 
hemocompatibility of biomaterials used for cardiovascular applications. Further studies 
are needed to examine residence time-dependent conformational changes in Fg and other 
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plasma proteins, and their influence (if any) on potentially mediating platelet adhesion 
responses to biomaterial surfaces.   
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CHAPTER 9 
CONCLUSIONS AND RECOMMENDATIONS 
 
9.1 Conclusions 
The layer of adsorbed plasma proteins on the surface of a biomaterial is a critical 
determinant of its hemocompatibility due to the ability of cells such as platelets and 
leukocytes to recognize specific amino acid sequences, adhere and become activated, 
thereby triggering the deleterious thrombotic and inflammatory response(s) to the 
biomaterial. In addition to Fg, the role of which is well known in thrombosis, we also 
delineated the role of Alb in mediating platelet adhesion. Based on the results from this 
project, the following conclusions can be drawn regarding the role of plasma protein 
adsorption and the mechanisms of platelet adhesion to these adsorbed plasma proteins: 
• Using a broad range of surface chemistries and protein solution concentrations, it 
was possible to independently vary the conformation of the adsorbed Fg layers 
from its surface coverage. 
• With the ability to differentiate the adsorbed conformation from the amount of 
adsorbed Fg, we proved that the conformation of the adsorbed Fg layer plays a 
more critical role in mediating platelet adhesion than simply the amount of Fg 
adsorbed.  
• We conclusively demonstrated that platelets can adhere to adsorbed Alb, beyond a 
critical degree of adsorption-induced unfolding.  
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• Pretreatment of the platelet suspension with an Arg-Gly-Asp-Ser (RGDS) peptide 
led to a partial inhibition (~50%) of platelet adhesion due to its inhibition of 
RGD-specific platelet receptors, which are hypothesized to mediate both adhesion 
and activation. However, this pretreatment also likely led to the activation of a 
non-RGD-specific receptor set(s), which mediates adhesion with little or no 
platelet activation.  
• Anti-GPIb antibodies were found to be unable to inhibit the adhesion of RGDS-
treated platelets to adsorbed Fg and Alb, indicating that this receptor set was not 
the non-RGD-specific receptor set that mediated the amount of platelet adhesion 
that occurred with RGDS-blocking.  
• Blockade of the GPIIb/IIIa receptors by a peptidomimetic platelet antagonist 
Aggrastat led to a near complete inhibition of platelet adhesion to both adsorbed 
Fg and Alb, thus illustrating the critical role played by this receptor set in 
mediating platelet interactions with adsorbed proteins.   
• Site-specific chemical modification of amino acids represents a powerful 
technique to examine their roles in mediating platelet binding. This technique was 
used to show that platelet adhesion to adsorbed Alb is largely mediated by Arg 
amino acid residues in Alb and that Lys amino acid residues did not play a 
significant role in the platelet adhesion response to adsorbed Alb. 
• Additionally, we also showed that an irreversibly adsorbed, tightly packed layer 
of Alb undergoes residence time-dependent structural changes over a 6-month 
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time period, leading to a greater amount of platelet adhesion to the adsorbed Alb 
than that which occurs due to the unfolding process alone. 
In conclusion, although our results show that the conformation of the adsorbed 
protein is a critical determinant of its ability to adhere platelets, we have also 
conclusively demonstrated that an irreversibly adsorbed, tightly packed Alb layer with 
near native structure undergoes time-dependent structural changes which enables and 
enhances platelet adhesion. Hence, this suggests that the optimal hemocompatible 
biomaterial would be one which adsorbs plasma protein(s) reversibly, without causing 
any adsorption-induced unfolding. This would represent a significant shift from the 
current design strategy of developing protein-resistant materials for cardiovascular 
applications.  
 
9.2 Recommendations for future studies 
The studies done as part of this project were aimed at delineating the molecular-level 
mechanisms of single-component protein adsorption on biomaterial surfaces, and 
subsequent platelet adhesion on this layer of adsorbed protein. However, blood-
biomaterial interactions are highly complex, involving a variety of other proteins and 
cells including the complement system as well as leukocytes which mediates the 
inflammatory response. Additionally, the inflammatory and thrombotic responses are also 
highly interlinked. 
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Hence, the following studies are proposed for future studies to further the 
understanding of the factors underlying biomaterial-associated thrombosis: 
• The studies must be extended to include other proteins including vWf, Fn and Vn. 
Additionally, competitive protein adsorption studies involving Fg and Alb as well 
as the proteins listed above would also help build a more comprehensive 
understanding of the interplay of these proteins both in the adsorption process, 
and also in mediating platelet adhesion.  
• Although SAM surfaces are very useful in delineating the influence of specific 
surface chemistries on protein adsorption and subsequent platelet adhesion, they 
are not generally implanted in vivo. Hence, methods developed in this research 
need to be applied to study the relationships between adsorbed protein structure 
and platelet adhesion on more clinically relevant polymers, metals, and ceramic 
surfaces. 
• Carrying out the protein adsorption and platelet adhesion experiments in a flow 
system is needed to more closely simulate in vivo conditions.  
• In addition to the adhesion of platelets to adsorbed proteins on biomaterials, their 
activation and subsequent aggregation also play a critical role in biomaterial-
associated thrombosis. Hence, it would be important to address this by carrying 
out assays to examine the activation state of the adherent platelets via a suitable 
method, such as a platelet factor 4 (PF4) assay. 
• Extending our work with Alb, it would be important to examine whether the 
relationship between adsorption-induced conformational changes in proteins and 
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platelet adhesion is universal to all types of proteins.  This could be addressed by 
extending these investigations to include non-plasma proteins (e.g., hemoglobin), 
which are not known to be unable to bind platelets. 
• Since leukocytes and macrophages have been found to bind to adsorbed plasma 
proteins, understanding the mechanisms mediating the response of these cells on a 
protein layer as a function of its adsorption-induced conformational states would 
provide insights into the inflammatory response as well.  
• Chemical modification of amino acid residues in proteins represents a powerful 
technique to examine the role of specific residues in mediating cell attachment, 
and our present work can be extended to potentially include other proteins, as well 
as other amino acid targets as an investigative tool to determine the types of 
amino acid residues that are involved in cellular responses to adsorbed proteins.   
• Investigation of the GPVI and α2β1 collagen receptors, among other platelet 
receptors as the non-RGD specific receptor set would provide deeper insight into 
platelet-protein interactions. 
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CHAPTER 10 
APPENDICES 
A.  PROTOCOL FOR SAM FORMATION AND CHARACTERIZATION 
A.1. Cleaning procedures for bare substrates 
All cleaning procedures are to be carried out in the chemical hood, and all wash solutions 
must be freshly prepared. 
1. The following wash solutions were prepared first: 
a. ‘Piranha’ wash: (7:3 v/v H2SO4:H2O2). (Note: The hydrogen peroxide 
used is purchased from VWR, Catalog No.  VW3742-1).  
NOTE: It is very important to note that the sulfuric acid is added to the 
hydrogen peroxide, and not vice versa. This reaction is highly exothermic, 
with the temperature of the solution reaching up to 100°C. While handling 
this solution, suitable precautions (gloves, safety glasses and lab coat) 
must be taken, as the solution is highly corrosive. It may also be advisable 
to use a face-shield as well. 
b. RCA basic wash: (1:1:5 v/v H2O2:NH4OH:H2O). 
2. The bare substrates (quartz slides or cover glasses or silicon chips) are removed 
from their packaging and placed in a Pyrex petridish containing the ‘piranha’ 
wash, and then incubated in an oven at 50°C for at least 30 minutes.  
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3. The petridish containing the substrates in ‘piranha’ wash is kept under distilled 
water for 2 minutes. The slides are removed and rinsed thoroughly with distilled 
water. 
4. The slides/cover glasses are then transferred to another petridish containing RCA 
basic wash, and kept in the oven at 50°C for at least 30 minutes.  
5. The petridish is removed from the oven and placed under distilled water for 5 
minutes. The substrates are transferred to a petridish containing ‘piranha’ wash, 
and the process is repeated twice starting from step 2. 
6. After going through the ‘piranha’ and RCA basic washes twice, the substrates are 
rinsed with nanopure water, 100% ethanol (Pharmco-Aaper, Catalog No. 
11100200; obtained from Mr. Michael Moore in Jordan Hall at Clemson 
University) and then dried under a stream of nitrogen gas. 
Note: It is essential that 100% ethanol is used, as commercial sources of ethanol 
contain impurities which lead to the presence of undesirable contaminants on the 
surface. 
7. The cleaned, dry bare substrates are kept in a clean, dry plastic petridish and taken 
for gold coating to Dr. James Harriss at the Microstructures Laboratory in the 
Department of Electrical Engineering in 22-B Riggs Hall.  
8. Thermal vapor deposition of gold and chromium (which serves as an adhesive 
layer for the overlaying gold layer) is carried out. 
a. Substrates are generally coated with 50 Å of chromium and 1000 Å of 
gold. 
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b. For circular dichroism experiments, the quartz slides are coated with 30 Å 
of chromium and 100 Å of gold, to ensure optical transparency of these 
substrates. 
 
A.2 Cleaning protocol for gold-coated substrates 
The cleaning procedures for the gold coated substrates are similar to those used for bare 
substrates, but are less aggressive to avoid etching and pitting of the gold coating. Special 
caution must be exercised while cleaning the gold-coated quartz slides used for CD 
experiments, which have a thin layer of gold. 
1. The gold-coated substrates are dipped in a modified ‘piranha’ wash (8:2 v/v 
H2SO4:H2O2) for about 15 sec, and then rinsed thoroughly with nanopure water.  
2. The RCA basic wash is prepared and heated on a hot-plate. The substrates were 
then dipped in the RCA basic wash for about 15 sec, and then rinsed copiously 
with nanopure water. 
3. The cleaned gold substrates are rinsed with 100% ethanol and either stored in a 
petridish filled with ethanol until needed, or directly immersed in a petridish 
containing alkanethiol solution for surface modification. 
 
A.3  Formation of self-assembled monolayers (SAMs) of alkanethiols 
1. 1.0 mM solutions of the following alkanethiols were prepared in 50 mL of 100% 
ethanol: 
a. 1-dodecanethiol (CH3, Sigma #471364, 12.0 µL), 
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b. 11-(2,2,2-Trifuoroethoxy) undecane-1-thiol (CF3, custom-synthesized by 
Asemblon Inc., 5 mL of 10X CF3 solution in 45 mL of 100% ethanol) 
c. 1-mercaptoundecanylamine (NH2, Prochimia #FT 02A.11-1, 10.6 mg),  
d. 12-mercaptododecanoic acid (COOH, Prochimia #FT 01.11-1, 11.6 mg), 
and  
e. 11-mercapto-1-undecanol (OH, Sigma #447528, 10.22 mg). 
NOTE: 3% v/v triethylamine must be added to the ethanol prior to the 
addition of the 1-mercaptoundecanylamine while preparing the NH2 SAM 
solution, so as to prevent the thiol from adsorbing in an inverted fashion and 
thereby avoid a double layer formation.  
2. The gold-coated substrates are incubated in the alkanethiol solutions overnight 
(for at least 16 hours) in the dark, to avoid/reduce oxidation of the thiol groups. 
 
A.4 Cleaning the SAM surfaces 
1. The substrates are removed from the alkanethiol solutions, rinsed with ethanol 
and sonicated in ethanol for 1 minute to displace any multilayers which may have 
formed.  
2. The SAM surfaces are then cleaned to removed any traces of hydrophobic 
contaminants 
a. CH3 and CF3 SAMs are sonicated sequentially in ethanol, hexane and 
ethanol for 5 minutes each. 
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b. NH2, COOH and OH SAMs are incubated in 25 mM phosphate buffer 
containing 0.005% v/v Triton-X-100 for 5 minutes to block off any 
hydrophobic defect sites (e.g., grain boundaries). These SAMs were then 
sonicated in acetone and ethanol for 5 minutes each, to remove any traces 
of loosely-bound Triton-X-100. 
3. The cleaned SAM surfaces are then rinsed with ethanol and nanopure water, and 
stored in a petridish until further use. 
 
A.5 Contact angle measurements 
1. The slides are removed from the petridish, sonicated in ethanol for 10 minutes, 
rinsed with nanopure water and dried under a nitrogen gas stream, prior to being 
mounted on the sample stage of the CAM 200 Optical Contact Angle/Surface 
Tension Meter (KSV Instruments Ltd.).  
2. Six drops of nanopure water (volume of each drop = 3.0 µL) is pipetted on to the 
surface. (Multiple drops are pipetted onto the surface to speed up the analysis). 
3. The camera of the instruments is carefully focused on each drop individually, and 
then snapshot is captured using the CAM 200 software. The camera is then moved 
to the next drop, and the process is repeated until images of all drops have been 
captured.  
4. The slides are then rinsed with nanopure water and then ethanol, and finally 
stored in ethanol until further use. 
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A.6  Ellipsometry 
1. The cleaned SAM surface is rinsed with ethanol and dried under a stream of 
nitrogen gas, prior to being placed on the ellipsometry stage for analysis. If the 
liquid cell is being used, the sample must be placed in the cell, which is filled with 
buffer or nanopure water. 
2. The position of the slide on the stage is adjusted to ensure that the spot (from the 
laser) falls on the desired region of the surface for analysis.  
3. Start-up the computer, open the GESPACQ software, and click on “Show”. 
4. In the window which opens, set the following parameters: 
a. Wavelength = 0.45 µm,  
b. Analyzer angle = 0˚, and 
c. Incidence angle = 90˚. 
5. Then click “Run”. 
6. After a pause of about 15 seconds, the instruments will start.  
7. Lower the stage of the ellipsometer until the sample is out of the light beam.  
8. Adjust the slit using the gold knob located under the ellipsometer table-top, until 
the counts value is approximately 20,000,0000. 
9. Raise the stage until the counts value is half the original value, i.e., 10,000,000 
counts. 
10. Change the incidence angle to 70° (the general angle used for analysis of SAMs 
and protein layers). Higher incidence angles can be used for reducing noise and 
large variations in the measured thicknesses of rougher surfaces.  
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Note: The liquid cell can only be used at an incidence angle of 70°.  
11. Ensure that the laser beam is hitting the desired location for analysis. If not, then 
the slide will have to be moved, and redo steps 7-11. 
12. The sample is then leveled by adjusting two of the three screws located at the 
corners underneath the stage.  
a. The screw located on the left front side of the stage must not be touched.  
b. The back screw is adjusted until the counts are maximized, and then repeat 
with the right screw until the counts are maximized.  
c. Adjust the screws again, if necessary, until the symmetry is as close to 
zero as is possible (± 0.2). 
13. Click on “Stop” and then exit “Show” mode. 
14. Click on “Settings” and ensure that the incidence angle is set at the desired value 
for ellipsometric analysis. Then click on “Ok” to confirm the settings and close 
the “Settings” window.  
15. Now click on the “Measurement” button, and then “Run”. 
16. Once the data has been collected, save the .dat and .mse files. 
17. Close the GESPACQ program, and open the WINELLI software, which is used 
for calculating the thickness of the layer(s). 
18. Open the .dat file. 
19. In the “Analysis” tab, choose the “Regression” option. 
20. For measuring the thickness of the alkanethiol layer, set the following parameters: 
a. Layer type of Layer 1 = Dispersion Law.  
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i. Double-click on Layer 1 and set Dispersion Law Type = Standard 
Dielectric Function,  
ii. Selected Term = UV Term,  
iii. Selected Law = Cauchy (nk), and  
iv. A = 1.5. 
b. Layer 2 is the gold layer. Browse and find the required .nk file (Au.nk). 
i. Set Layer Type = Materials, 
ii. Set Layer Thickness = 0.1 µm. 
c. Layer 3 is the chromium layer. Browse and find the required .nk file 
(Cr.nk) 
i. Set Layer Type = Materials, 
ii. Set Layer Thickness = 0.005 µm. 
d. The Substrate Layer is Quartz. Browse and find the required .nk file 
(SiO2.nk) 
i. Set Layer Type = Materials. 
e. If the measurement is being carried out in air, the void.nk file is set for the 
ambient, and layer type is set as Materials. For samples analyzed under 
aqueous conditions (say, in the liquid cell), the suitable .nk file for the 
solution must be used. Usually, the measurements are generally carried out 
in buffer or nanopure water.  
21. Click “Run”, and then click “Run” again to determine the thickness of the layer.  
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B.  PROTOCOL FOR CIRCULAR DICHROISM SPECTROPOLARIMETRY 
B.1  Buffer used for circular dichroism spectropolarimetry 
1. Stock solutions of 25 mM monobasic and dibasic potassium phosphate are 
prepared. 
2. Equal amounts of the two buffers mixed together yield a 25 mM potassium 
phosphate buffer with a pH close to 7.4, which generally needs minimal 
adjustment. 
B.2 Circular dichroism measurements 
1. The nitrogen gas flow rate is set to between 6-7 liters/min, and the nitrogen gas is 
allowed to flow for about 1 minute before the CD spectropolarimeter is switched 
on.  
2. The instrument is left on for about 10 minutes, and then the Spectra Manager 
program is opened on the computer.  
3. Open the “Spectrum Measurement” tool. A timer will count down for 5 minutes 
before the lamp gets turned on.  
4. At the end of this, diagnostics will run. Errors may occur under the Amp and HT 
checks, and the “Ignore” box should be clicked, should they occur. The 
instrument will now be ready for use. 
5. It is important to calibrate the instrument using the standard CD calibration 
solution of (1S)-(+)-10-camphorsulfonic acid (Sigma-Aldrich, Catalog No. 
C2107-5G), to ensure that the instrument does not have any true errors. 
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a. A 0.06% aqueous solution of this salt (30 mg of salt in 50 mL nanopure 
water) in a 1.0 cm quartz cuvette is used for calibration.  
b. The CD value at a wavelength of 350 nm should be 0 mdeg. If this value 
is off, then it can be adjusted using the CD offset screw located on the 
back of the instrumentation circuit board observed when you take the top 
panel off the instrument.   
c. Similarly, the CD value at a wavelength of 291 nm should be adjusted to 
190.4 mdeg.  
6. Before carrying out a CD scan, it is important to ensure that the scan parameters 
are set. 
a. The normal parameters used for CD scans on protein in solution are: 
i. Sensitivity = Standard (100 mdeg) 
ii. Starting wavelength = 300 nm 
iii. End wavelength = 190 nm 
iv. Data Pitch = 0.1 nm 
v. Scan mode = Continuous 
vi. Scan speed = 50 nm/min 
vii. Response = 0.25 sec 
viii. Bandwidth = 1.0 nm 
ix. Accumulations = 6 
b. The parameters used for high resolution scans (i.e., for adsorption studies) 
are: 
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i. Sensitivity = Standard (100 mdeg) 
ii. Starting wavelength = 300 nm 
iii. End wavelength = 190 nm 
iv. Data Pitch = 0.1 nm 
v. Scan mode = Continuous 
vi. Scan speed = 5 nm/min 
vii. Response = 16 sec 
viii. Bandwidth = 1.0 nm 
ix. Accumulations = 3 
7. Background spectra are collected first. For protein solution studies this will be of 
the buffer in the cuvette, while for adsorption studies this will be of the buffer 
plus the alkanethiol-modified gold substrates in the custom-designed cuvette (see 
Fig. 4.1). 
8. The 0.1 mm quartz cuvette (with removable windows) is typically used for CD 
studies on the native/solution structure of proteins.  
a. The protein solutions analyzed in these cuvettes typically have a 
concentration of approximately 2.0 mg/mL. 
b. The CD response is a function of both the concentration of the protein 
solution and the path-length of the cuvette, and the signal is based on the 
total number of molecules in the path of the light beam. Hence, a 0.2 
mg/mL protein solution in a 1 mm cuvette would give an identical 
spectrum as a 2.0 mg/mL protein solution in a 0.1 mm cuvette. 
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c. If the protein concentration is too high in a cuvette with a given path-
length, the absorbance may spike at wavelengths below 200 nm and yield 
a very noisy CD spectrum. In this case, it would be advisable to dilute the 
protein solution and then re-run the CD scan.  
Note: It is very important to ensure that the absorbance of the samples 
does not exceed a value of ~4.0, as the high tension (HT) voltage at this 
absorbance would be in the range of 800 V, and voltages above this can 
potentially damage the instrument.  
d. If the characteristic CD minima for proteins do not appear in the 208-225 
nm range, this likely implies that the concentration of protein is too low. 
This issue can be overcome by using a cuvette with longer path-length or 
using a more concentrated protein solution.  
9. The custom-designed cuvette (shown in Fig. 4.1) was used for CD studies on the 
structure of adsorbed proteins on the SAM surfaces. 
a. The cleaned SAM surfaces were incubated in a petridish filled with 25 
mM potassium phosphate buffer.  
b. Stock solutions of proteins were prepared in 25 mM phosphate buffer, and 
a suitable amount of stock protein was added to the SAM surfaces in the 
petridish to give the desired bulk solution concentration, taking care to 
ensure that the tip of the pipette is held below the air-water interface to 
avoid protein denaturation at this interface.   
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c. The protein adsorption step was carried out for the required duration (2 
hours, in our case). For smaller proteins, the protein adsorption step may 
last even as long as 24 hours. 
d. At the completion of protein adsorption, the petridish containing the 
protein-coated SAM surfaces in protein solution was infinitely diluted 
with buffer (or nanopure water) to wash away the protein solution as well 
as any loosely adherent protein.  
e. This infinite dilution step gets rid of the layer the denatured protein which 
would have been present at the air-water interface and potentially 
contaminated the adsorbed protein layer, thereby permitting the removal 
of the SAM surfaces from the petridish without dragging it through this 
layer.  
f. The custom-designed cuvette is filled with 1.0 mL of phosphate buffer, 
and then protein-coated SAM surfaces are then loaded into this cuvette. 
Any buffer overflowing from the cuvette is wiped off with a KimWipe, 
and once the cuvette has been wiped dry, it is loaded into the CD 
spectropolarimeter and scanned.   
10. The spectrum obtained from the CD scans consists of the CD (in mdeg) and the 
absorbance values over the wavelength range scanned, and the .jws file is saved. 
11. The CD spectra obtained are analyzed using the “Spectrum Analysis” program, 
which is part of the Spectrum Manager software package, and the percentage 
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composition of the secondary structural components of the native/adsorbed 
protein is calculated using the CDPro software package. 
a. The .jws file is opened, to load the CD and absorbance spectra. 
b. The spectra can be smoothed by using the “Data Cut” function (Processing 
 Correction  Data Cut), and adjusting the data pitch from 0.1 nm to 
either 0.5 nm or 1.0 nm. Further smoothing can also be done using the 
Savitzky-Golay algorithm under the curve smoothing option (Processing 
 Correction  Smoothing). 
c. The data dump option (Processing  Common Options Data Dump) is 
then used to copy the raw CD and absorbance data as a function of 
wavelength to a Microsoft Excel spreadsheet for further data analysis, 
taking care to ensure that the “thin out” (i.e., data pitch) is set to 1.0 nm. 
Additionally, the data dump option can also be used to choose CD and 
absorbance values for the wavelength range of 190 nm – 240 nm. 
d. The ellipticity (θ, in mdeg) is converted to molar ellipticity ([θ], in 
deg·cm2/dmol) using the following formulae: 
[θ] = (θ · M0) / (10,000 · Csoln · L)  (A.1) 
[θ] = (θ · M0) / (10,000 · Qads)   (A.2) 
where M0 is the mean residue molecular weight (118 g/mol), Csoln is the 
protein solution concentration (g/mL), Qads is the protein surface 
concentration (g/cm2), and L is the path-length of the cuvette (cm). 
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e. The concentrations of the protein in solution (Csoln) and adsorbed on the 
SAM surfaces (Qads) is determined from the height of the peptide 
absorbance peak at 195 nm (A195).  
i. Using a reference wavelength of 300 nm, the height of the 
absorbance peaks (A195 = Abs195nm - Abs300nm) for serial dilutions 
of 2.0 mg/mL protein stock solutions are determined at 195 nm, 
with the actual concentrations of these solutions being determined 
using a bicinchoninic acid assay (BCA, Pierce Biotechnology).  
ii. Calibration curves of A195 vs. Csoln were plotted for both Fg and 
Alb, with the slope of these plots representing the term “εprotein · L” 
from Beer’s Law, which can be written as: 
A195 = εprotein · Csoln · L   (A.3) 
where εprotein is the extinction coefficient of the protein (which has 
units of mL · g-1 · cm-1 or cm2/g) 
iii. The terms “Csoln · L” in equation A.3 has units of g/cm2, which is 
equivalent to the units of surface coverage of the adsorbed protein. 
Hence this explains the equivalency of the “Csoln · L” term in 
equation A.1 being replaced by Qads in equation A.2. 
f. The wavelength and molar ellipticity values are copied to a text document 
“s.txt” in the CDPro folder. 
g. Double-click/run the crdata.exe file in the CDPro folder, and enter the 
following parameters: 
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i. Type ‘0” for a new input file and hit the enter key. 
ii. Enter a suitable name for the data and hit the enter key. 
iii. Since the data has wavelength intervals (i.e., data pitch) of 1.0 nm, 
choose number 1. 
iv. Input the initial and final wavelengths of 240 nm and 190 nm. 
v. When prompted, enter the number 1 to indicate that the data is in 
units of molar ellipticity. 
vi. Enter s.txt as the name of the file which contains the CD data. 
vii. The next screen will ask the user to choose a reference set of 
proteins for deconvolution of the CD spectra. Choose option 2 (i.e., 
SP-22X algorithm), which generally has been found to be suitable 
for fibrinogen and albumin.  
viii. Now go to the CDPro folder and run the CONTINLL.exe and 
SELCON3.exe files to get the values of the various secondary 
structural components in the native/adsorbed protein.  
ix. It is advisable to note these values in the research lab notebook 
immediately, although they are stored the file protss.out, and may 
be accessed later if required. However, the data in this file does not 
have any date/time stamp, but has the name entered for the data in 
step (ii) above. 
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C. PROTOCOL FOR PLATELET ADHESION ASSAYS 
C.1 Buffers used in platelet adhesion assays 
1. The platelet suspension buffer (PSB, pH 7.4) contained 137 mM NaCl, 2.7 mM 
KCl, 5.5 mM Dextrose, 0.4 mM sodium phosphate (monobasic), 10 mM HEPES 
and 0.1 U/mL apyrase. 
2. PSB was supplemented with 2.5 mM CaCl2 and 1.0 mM MgCl2 to give a platelet 
suspension with metal ions (PSB + MI). 
3. Phosphate buffered saline (PBS) was made by dissolving 9.9 g of PBS powder 
(Fisher, Catalog No. BP661-10)  in 1.0 L of nanopure water.  
C.2 Protocol for obtaining whole blood from human volunteers  
1. The use of human blood for research projects requires approval of the Institutional 
Review Board (IRB) and the Institutional Biosafety Committee (IBC) at Clemson 
University. The following protocols were approved by the IRB and IBC: 
IRB#2007-140 and IBC# 2009-39. 
2. In addition to the main IRB and IBC protocol forms, two keys documents are the 
IRB-approved consent form and the IRB-approved questionnaire, for volunteers 
who consent to donate blood. 
a. The consent form, which is renewed annually by the IRB, will be filled in 
by the donor and signed at any time, indicating their consent to donate 
blood for our research project. It also outlines the risks associated with the 
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blood-draw process and suggests suitable steps, should a medical 
emergency arise due to the blood donation process. 
b. The questionnaire on the other hand, is filled in by the donor on the day of 
the blood draw process, and is renewed annually by the IRB. It asks the 
donor some simple questions to assess whether (s)he is fit for donating 
blood on that day. 
3. The blood is drawn from the volunteers by trained nurses at the Redfern Health 
Center in Clemson University. The student in charge of the project always 
accompanies the volunteer to and from the Redfern Health Center. 
a. The student generally picks up the ice chest, which is used to transport the 
blood samples from Redfern to the laboratory in Rhodes, from 202 Rhodes 
and fills the chest with 2-3 scoops of ice from the ice-making machine in 
the Histology Lab in 418 Rhodes.  
b. Approximately 30.0 mL of blood is collected per draw per donor into four 
BD Vacutainer tubes (Becton-Dickinson, Catalog No. 364606) containing 
an acid-citrated dextrose (ACD) anticoagulant. Note: These Vacutainer 
tubes are purchased by our laboratory and are generally kept in the 
laboratory at Redfern. 
c. Since the first few mL of blood is rich in coagulation factors, the first tube 
is always discarded, and remaining three Vacutainer tubes are put into a 
biohazard Ziploc bag, and transported back to the BSL-2 laboratory in 202 
Rhodes on ice in an ice chest. 
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C.3 Protocol for processing whole blood to obtain washed platelets 
While handling blood and platelets, it is essential to observe all safety precautions and 
wear a lab coat and safety glasses. A face mask may also be used, if the student deems it 
necessary. 
1. The Vacutainer tubes are carefully removed from the Ziploc bag and the blood is 
transferred into 15.0 mL centrifuge tubes. The blood is centrifuged at 225g (i.e., 
1190 rpm) for 15 minutes at 20°C in a Beckman Coulter Allegra 6R centrifuge 
located in 202 Rhodes to generate a yellowish supernatant which is platelet rich 
plasma (PRP). 
2. The PRP is carefully aspirated out of each centrifuge tube and transferred to a 
fresh centrifuge tube using a transfer pipette, taking care not to disturb/touch the 
layer below the supernatant. 
3. The used centrifuge and Vacutainer tubes are closed tightly and carefully put into 
the biohazard Ziploc bag, for disposal at the end of the experiment. 
4. Washed platelets are separated from PRP by a gel separation method. 
a. Sepharose 2B (Sigma, Catalog No. 2B-300) is poured into a measuring 
cylinder and allowed to stand for about 2 hours, after which the 
supernatant is discarded and replaced with PSB. This process is repeated 
thrice, and the Sepharose suspension is finally poured into a liquid 
chromatography column (Sigma, Catalog No. C4169).  
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b. The Sepharose suspension is allowed to settle in the column for about 1 
hour, with additional Sepharose added, if necessary. The level of 
Sepharose in the column should be visible, and should ideally be around 
the “Sigma” etching near the top of the column. The column can be kept 
running, with the addition of a suitable amount of PSB, to speed up the 
settling process, ensuring that the column does not run dry.  
c. The remainder of the liquid column above the Sepharose layer is filled 
with PSB using a Pasteur pipette or transfer pipette and the column is 
connected to the reservoir containing PSB. 
d. The system is allowed to run until about 100 mL of PSB has flowed 
through the column, to ensure optimal settling of the column.  
e. The column is now ready for use. 
Note: It is ideal to complete steps (a-e) before going to Redfern to collect 
blood, so that the washed platelets can be separated from the PRP as soon 
as possible. 
f. Once the PRP is ready, the flow of PSB from the reservoir to the column 
is stopped, and the PSB in the column is allowed to drain until its level is 
just above the top edge of the Sepharose. At this point, the bottom outlet 
of the column is closed. 
g. The top of the column is then opened and the PRP is carefully layered on 
to the Sepharose using a transfer pipette, and allowed to pass into the main 
column. The remainder of the column is then filled carefully with PSB, 
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and the top of the column is closed and the flow of PSB from the reservoir 
to the column is restarted after re-opening the bottom outlet of the column.  
h. Fractions are collected from the column in 1.7 or 2.0 mL centrifuge tubes. 
Buffer from the column elutes first, followed by the platelets and then the 
plasma proteins.  
i. About 2 minutes after restarting flow from the column, the platelets will 
start exiting the column and are identified by their increased turbidity 
(compared to the buffer). The platelet-rich fractions with maximum 
turbidity are pooled and their concentration is measured using a Beckman 
Coulter Z2 Particle Counter and Size Analyzer (in the common cell 
culture laboratory in 416 Rhodes).  
j. After the platelets have been collected from the column, the plasma 
proteins are collected (for disposal) in a 15 mL centrifuge tube, and the 
column is allowed to run until all the proteins have eluted from the 
column.  
k. All biohazard waste from the blood collection and processing steps are 
packed in the biohazard Ziploc bag, sealed and disposed in the red 
biohazard bucket in 202 Rhodes.   
C.3 Platelet adhesion experiments 
1. The typical platelet count we generally get in the washed platelet suspension is 2-
3 x 108 platelets/mL, which is adjusted to 108 platelets/mL with PSB, and then 
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supplemented with CaCl2 and MgCl2 to give final salt concentrations of 2.5 mM 
and 1.0 mM, respectively.  
2. The platelet suspension is allowed to rest for 30 min at 37°C, after which it is 
added to the protein-coated SAMs in the 6- or 24-well plate and allowed to adhere 
for 1 hour at 37°C. 
3. Six serial dilutions of the platelet suspension are made in PSB + MI in 1.7 mL 
centrifuge tubes, which are used for constructing the calibration curve used for 
quantifying the platelet adhesion levels. A seventh (control) centrifuge tube 
containing only PSB + MI is also used as part of the calibration curve samples. 
The samples for the calibration curve are incubated for 1 hour at 37°C, along with 
platelet-SAM samples.  
5. At the end of the platelet adhesion step, the platelet suspension is aspirated from 
the wells into a centrifuge tube (which is later disposed in the biohazard disposal 
bin), and the SAM surfaces are rinsed five times with PBS to remove any non-
adherent platelets.  
6. The samples for SEM are processed via the following steps:  
a. A special buffer (3% glutaraldehyde + 0.1 M sodium cacodylate, pH 7.4) 
was used for fixing the samples for SEM for 30 minutes at room 
temperature, after which the fixed samples are rinsed with PBS thrice. 
b. The fixed samples are then incubated in ascending ethanol:water mixtures 
(50%, 60%, 70%, 80%, 90% and 99%) for 10 minutes each, to dehydrate 
them. 
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c. Finally, the samples are treated with 0.02 mL of hexamethyldisilazane 
(Sigma; obtained from Dr. Ken Webb’s laboratory) and allowed to dry 
overnight in a laminar flow hood. 
d. The next day, the samples are taken to the Microscopy Facility at the 
Advanced Materials Research Laboratory (AMRL, Clemson University, 
Pendleton, SC) to examine the morphology of the adherent platelets. 
7. The platelet adhesion was quantified using a lactate dehydrogenase (LDH) assay. 
The kit we used as a Cytotox96® non-radioactive cytotoxicity assay (Promega). 
a. After the rinsing step (step 5), the samples are transferred to a fresh well-
plate filled with PSB+MI, and the adherent platelets as well as the 
platelets for the calibration curve are lysed with a Triton-PSB buffer (2% 
v/v Triton-x-100 in PSB). 100 µL lysing buffer is used per 1 mL of 
PSB+MI in well-plate/centrifuge tube. The samples are then incubated at 
37°C for 45 minutes (in 502 Rhodes). 
b. While this lysing step is running, we prepare the chromogenic substrate 
mix for the assay. 
i. Assay buffer from the kit is warmed to room temperature taking 
precautions to protect it from light), and 12 mL of this buffer is 
added to a bottle of the substrate mix (part of the kit).  
ii. Invert the bottle and shake gently until the substrate mix has 
dissolved in the assay buffer. One bottle of the reconstituted 
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substrate mix generally supplies enough chromogenic substrate for 
two 96-well plates, as per the suppliers instructions.  
iii. It is important to always protect the reconstituted substrate mix 
from strong direct light. The unused portion of this mix can be 
stored for ≤ 6-8 weeks at -20°C. 
c. After the cell lysis step is complete, 50 µL aliquots from all wells and 
tubes are transferred to a 96-well plate.  
d. 50 µL of the reconstituted substrate mix is then added to each well of the 
96-well plate. The plate is covered with foil/opaque box to protect it from 
direct light, and is incubated at room temperature for 30 minutes. 
e. At the end of this incubation step, 50 µL of stop solution from the kit is 
added to each well, and the plate should be read within one hour of 
addition of the stop solution. 
f. Prior to reading the plate, a syringe is used to pop any bubbles in the 
wells. 
g. The plate is read at 492 nm and 600 nm (reference wavelength) and the 
values of the difference in absorbance at the two wavelengths for the 
samples are used to quantify the platelet adhesion. 
h. A calibration curve of absorbance vs. platelet number is constructed, and 
the number of platelets adherent on the SAM surfaces can be read off this 
curve. This number is then divided by the surface area of the substrate to 
give the platelet adhesion per unit area.  
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D.  PROTOCOL FOR MODIFICATION OF ARGININE RESIDUES IN 
ALBUMIN 
D.1. Chemical modification of Arg and Lys in Alb solution 
1. Prepare about 5.0 mL of 2.0 mg/mL Alb solution in 25 mM potassium phosphate 
buffer. 
2. 2, 3-butanedione was used for the site-specific modification of Arg residues in 
Alb, while acetic anhydride was used for the acetylation of Alb. 
a. Prepare a 50 mM borate buffer, and add a suitable amount of 2, 3-
butanedione to give a 50 mM final concentration of the butanedione.  
b. Prepare a 10% acetic anhydride solution in 25 mM phosphate buffer.  
3. The modification reaction was carried out by mixing the protein and the 
modifying agents using the appropriate reaction conditions. 
a. Mix the Alb solution and the butanedione solution, and allow the 
modification reaction to proceed for 2 h at room temperature.  
b. For acetylation of the Alb solution, 100 µL aliquots of the acetic 
anhydride is added to the protein solution at 15 min intervals, over a 2 h 
period, with the reaction being carried out on ice.  
4. At the end of the modification reaction, the modified protein solution was 
dialyzed against 25 mM phosphate buffer for at least 12 h, with the buffer being 
changed every 4 h.  
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5. The modified protein samples are then taken to the Clemson University Genomics 
Institute to analyze for Arg and Lys modification via electrospray ionization mass 
spectrometry (ESI-MS).   
 
D.2. Chemical modification of Arg and Lys in adsorbed Alb on SAM surfaces 
1. All substrates are cleaned with the wash solutions, coated with chromium and 
gold, and surface functionalized with alkanethiols, as described earlier in Section 
A of this appendix. 
2. These cleaned SAM surfaces are incubated in the 25 mM phosphate buffer, and 
the Alb adsorption experiments are carried out on the SAM surfaces, as described 
in Section B.9  (a-e) of this appendix. 
3. After the infinite dilution step is carried out, the Alb-coated SAM surfaces are 
incubated in 25 mM phosphate buffer, and the chemical modification of the 
adsorbed Alb on the SAM surfaces is carried out by the addition of the 
butanedione or acetic anhydride, as described in Section D.3 of this appendix.  
4. At the end of the chemical modification step, an infinite dilution step is carried 
out to remove all traces of the modifying agent, and the surfaces are rinsed with 
nanopure water. 
5. Further experimental analyses are carried out on the surfaces with adsorbed, 
modified Alb. 
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a. CD analysis was performed as described in Section B of this appendix, to 
examine the conformation of the modified protein layer. 
b. The protein-coated SAMs are incubated with a washed platelet 
suspension, and the platelet adhesion levels are quantified by an LDH 
assay, as listed in Section C.3. 
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E.  PROTOCOL FOR RESIDENCE TIME DEPENDENT STUDIES ON 
ADSORBED ALB ON SAM SURFACES 
1. CH3 and OH SAMs are prepared, as described in Section A of this appendix.  
a. 18 mm cover glasses are used for the platelet adhesion experiments. 
b.  Standard quartz slides designed to fit our customized cuvette are used for 
CD studies. 
2. These SAM surfaces are preadsorbed with 10.0 mg/mL bulk Alb solution 
concentration for 2 h, as described in Section B.9, so as to obtain an irreversibly 
adsorbed, tightly packed Alb layer. 
3. These Alb-coated SAMs are analyzed via CD spectropolarimetry to evaluate the 
adsorbed conformation of the Alb layer, as listed in Section B of the appendix. 
4. These surfaces are then immersed in 25 mM potassium phosphate buffer 
supplemented with 0.1% cellgro antibiotic/antimycotic solution (Mediatech Inc., 
Catalog No. MT30-004-CI), and incubated for 6 months at 37°C in an incubator 
(located in Room 416 Rhodes). 
5. The buffer (with 0.1% antibiotic/antimycotic agent) is replenished every 2 weeks. 
6. The samples are withdrawn at the 3 month and 6 month time-points for CD and 
platelet adhesion experiments. 
a. CD analysis is performed as described in Section B of this appendix, to 
examine the conformation of the modified protein layer, as well 
quantifying the surface coverage of the adsorbed Alb. 
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b. The protein-coated SAMs are incubated with a washed platelet 
suspension, and the platelet adhesion levels are quantified by an LDH 
assay, as listed in Section C.3. 
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